Document:

Share Purchase Agreement

 Exhibit 10.46 
  
  
  
 SHARE PURCHASE AGREEMENT 
 among

 MULTI-FINELINE ELECTRONIX SINGAPORE PTE. LTD.

 a private company of Singapore limited by shares; 
 PELIKON LIMITED 
 a private limited company of England and Wales;

 MULTI-FINELINE ELECTRONIX, INC. 
 a Delaware corporation; 
 THE
SELLING SHAREHOLDERS; 
 and 
 MICHAEL POWELL, as the Shareholders’ Representative 
  
  
 Dated as of November 18,
2008 
  
  
  
  
  

 EXHIBITS AND SCHEDULES 
  

					
	Exhibit A	  	-	  	Certain Definitions
		  		  	
	Exhibit B	  	-	  	Form of Lender Promissory Notes
		  		  	
	Exhibit C	  	-	  	Form of Remaining Shareholder Promissory Note
		  		  	
	Exhibit D	  	-	  	Form of Selling Shareholder Promissory Notes
		  		  	
	Exhibit E	  	-	  	Form of Contingent Consideration Note
		  		  	
	Exhibit F	  	-	  	List of Key Employees

  

 -1- 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	PAGE
	ARTICLE 1.	  	DESCRIPTION OF TRANSACTION	  	2
			
	1.1    	  	Purchase and Sale of the Shares	  	2
			
	1.2    	  	Closing	  	3
			
	1.3    	  	Treatment of Company Rights	  	3
			
	1.4    	  	Estimated Balance Sheet and Estimated Closing Indebtedness	  	3
			
	1.5    	  	Assumption of Closing Indebtedness	  	3
			
	1.6    	  	Delivery of Sellers Promissory Notes	  	4
			
	1.7    	  	Contingent Consideration	  	5
			
	ARTICLE 2.	  	WARRANTIES OF THE COMPANY	  	9
			
	2.1    	  	Organization; Standing and Power; Subsidiaries	  	9
			
	2.2    	  	Company Constituent Documents; Records	  	10
			
	2.3    	  	Capitalization, Etc	  	11
			
	2.4    	  	Authority; Binding Nature of Agreement	  	12
			
	2.5    	  	Non-Contravention; Consents	  	12
			
	2.6    	  	Financial Statements	  	13
			
	2.7    	  	Absence of Certain Changes	  	14
			
	2.8    	  	Title to and Sufficiency of Assets	  	16
			
	2.9    	  	Bank Accounts; Accounts Receivable; Inventory	  	17
			
	2.10  	  	Equipment	  	17
			
	2.11  	  	Real Property	  	18
			
	2.12  	  	Intellectual Property	  	18
			
	2.13  	  	Contracts	  	20
			
	2.14  	  	Customers; Accounts Payable	  	23
			
	2.15  	  	Liabilities	  	23
			
	2.16  	  	Compliance with Legal Requirements; Governmental Authorizations	  	24
			
	2.17  	  	Tax Matters	  	24
			
	2.18  	  	Benefit Plans; Employees and Agents	  	31
			
	2.19  	  	Environmental Matters	  	33
			
	2.20  	  	Insurance	  	34
			
	2.21  	  	Related Party Transactions	  	35

  

 -i- 

 TABLE OF CONTENTS 
 (CONTINUED) 
  

					
	 	  	 	  	PAGE
	2.22  	  	Legal Proceedings; Orders	  	35
			
	2.23  	  	Company and Shareholder Action	  	36
			
	2.24  	  	Finder’s Fee; Transaction Costs	  	36
			
	2.25  	  	Certain Payments	  	36
			
	2.26  	  	Full Disclosure	  	37
			
	ARTICLE 3.	  	WARRANTIES OF THE SELLING SHAREHOLDERS	  	37
			
	3.1    	  	Organization; Standing and Power	  	37
			
	3.2    	  	Authority; Binding Nature of Agreement	  	37
			
	3.3    	  	Ownership and Transfer of the Shares	  	38
			
	3.4    	  	Non-Contravention; Consents	  	38
			
	3.5    	  	No Other Agreements	  	38
			
	3.6    	  	Litigation	  	39
			
	3.7    	  	Finder’s Fees	  	39
			
	ARTICLE 4.	  	WARRANTIES OF PURCHASER AND PARENT	  	39
			
	4.1    	  	Corporate Existence and Power	  	39
			
	4.2    	  	Authority; Binding Nature of Agreement	  	39
			
	4.3    	  	Non-Contravention; Consents	  	40
			
	4.4    	  	Compliance with Legal Requirements	  	40
			
	ARTICLE 5.	  	PARENT GUARANTEE OF PURCHASER OBLIGATIONS	  	40
			
	5.1    	  	Guarantee of Purchaser Obligations	  	40
			
	ARTICLE 6.	  	COVENANTS OF THE PARTIES	  	41
			
	6.1    	  	Access to Information	  	41
			
	6.2    	  	Operation of the Company’s Business	  	42
			
	6.3    	  	No Solicitation	  	45
			
	6.4    	  	Termination of Company Rights	  	45
			
	6.5    	  	Exercise of Drag-Along Right	  	45
			
	6.6    	  	Third Party Notices	  	46
			
	6.7    	  	Notification of Certain Matters; Updated Company Disclosure Schedule	  	46
			
	6.8    	  	Confidentiality	  	46
			
	6.9    	  	Public Disclosure	  	46
			
	6.10  	  	Payment of Stamp Duty	  	46

  

 -ii- 

 TABLE OF CONTENTS 
 (CONTINUED) 
  

					
	 	  	 	  	PAGE
	6.11  	  	Corporation Tax Returns	  	47
			
	6.12  	  	Minority Shareholder SPA	  	47
			
	ARTICLE 7.	  	CLOSING CONDITIONS	  	47
			
	7.1    	  	Conditions to Obligation of Each Party to Effect the Transactions	  	47
			
	7.2    	  	Additional Conditions to Obligations of Purchaser	  	47
			
	7.3    	  	Additional Conditions to Obligation of the Selling Shareholders and the Company	  	50
			
	ARTICLE 8.	  	TERMINATION	  	50
			
	8.1    	  	Termination	  	50
			
	8.2    	  	Procedure and Effect of Termination	  	51
			
	ARTICLE 9.	  	RECOURSE FOR DAMAGES	  	51
			
	9.1    	  	Survival	  	51
			
	9.2    	  	Recovery by Purchaser Parties	  	52
			
	9.3    	  	Basket; Limitation on Liability	  	53
			
	9.4    	  	Offset Against Sellers Promissory Notes and Contingent Consideration	  	54
			
	9.5    	  	Procedure for Recovery of Damages	  	55
			
	9.6    	  	Third Party Claims	  	57
			
	9.7    	  	Characterization of Recovery	  	58
			
	9.8    	  	No Contribution	  	58
			
	ARTICLE 10.	  	MISCELLANEOUS PROVISIONS	  	58
			
	10.1    	  	Shareholders’ Representative	  	58
			
	10.2    	  	Further Assurances	  	59
			
	10.3    	  	Fees and Expenses	  	60
			
	10.4    	  	Amendment	  	60
			
	10.5    	  	Attorneys’ Fees	  	60
			
	10.6    	  	Waiver; Remedies Cumulative	  	60
			
	10.7    	  	Entire Agreement	  	61
			
	10.8    	  	Execution of Agreement; Counterparts; Electronic Signatures	  	61
			
	10.9    	  	Governing Law and Submission to Jurisdiction; Appointment of Process Agent	  	61
			
	10.10  	  	Assignment and Successors	  	62

  

 -iii- 

 TABLE OF CONTENTS 
 (CONTINUED) 
  

					
	 	  	 	  	PAGE
			
	10.11    	  	Parties in Interest	  	62
			
	10.12    	  	Notices	  	62
			
	10.13    	  	Construction; Usage	  	63
			
	10.14    	  	Enforcement of Agreement	  	64
			
	10.15    	  	Severability	  	65

  

 -iv- 

 EXECUTION COPY 
  

 SHARE PURCHASE AGREEMENT 
 This SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as a deed
as of November 18, 2008 (the “Agreement Date”), by and among Multi-Fineline Electronix Singapore Pte. Ltd., a private company of Singapore limited by shares (“Purchaser”), Pelikon Limited, a private limited
company of England and Wales (the “Company”), Multi-Fineline Electronix, Inc., a Delaware corporation (“Parent”), the members of the Company set forth on the signature pages hereto (each a “Selling
Shareholder” and together, the “Selling Shareholders”), and Michael Powell, an individual serving as and entering into this Agreement in the capacity of the Shareholders’ Representative (the “Shareholders’
Representative,” as replaced or substituted from time to time in accordance with Section 10.1(b) hereof). Capitalized terms used in this Agreement and not otherwise defined shall have the meanings set forth in
Exhibit A hereto. 
 RECITALS 
 WHEREAS, the Purchaser has made a bona fide offer on an arm’s length basis to purchase all of the issued ordinary shares of £0.001 each in the capital of the Company (the “Company Ordinary
Shares”) for aggregate consideration as described in Article 1 hereof; 
 WHEREAS, the Selling Shareholders collectively own
92.7% of the issued Company Ordinary Shares; 
 WHEREAS, the Selling Shareholders desire to sell to the Purchaser all of the Company Ordinary
Shares held by them (the “Selling Shareholder Shares”), and the Purchaser desires to purchase from the Selling Shareholders all of the Selling Shareholder Shares, on the terms and subject to the conditions contained in this
Agreement; 
 WHEREAS, the Articles of Association of the Company provide that if holders of at least 75% of the issued Company Ordinary
Shares intend to sell all of their holdings of Company Ordinary Shares to a proposed purchaser who has made a bona fide offer on an arm’s length basis for all of the issued Company Ordinary Shares, such selling holders can compel the remaining
holders of Company Ordinary Shares (the “Remaining Shareholders” and, together with the Selling Shareholders, the “Sellers”) to sell all Company Ordinary Shares held by them (the “Remaining Shareholder
Shares” and, together with the Selling Shareholder Shares, the “Shares”) to such purchaser on the same terms and conditions offered to the Selling Shareholders (such right to compel the sale of the Remaining Shareholder
Shares being referred to herein as the “Drag-Along Right”); and 
 WHEREAS, the Selling Shareholders desire to exercise the
Drag-Along Right such that upon the consummation of the transactions contemplated by this Agreement, the Purchaser will own 100% of the total issued share capital of the Company, on a fully-diluted basis. 
 NOW, THEREFORE, in consideration of the foregoing and the respective covenants, agreements and warranties set forth herein, the parties to this
Agreement, intending to be legally bound, agree as follows: 
  

 1 

 EXECUTION COPY 
  

 AGREEMENT 
 ARTICLE 1. 
 DESCRIPTION OF TRANSACTION 
 1.1 Purchase and Sale of the Shares. 
 (a) On the terms and subject to the conditions set forth in this Agreement and in accordance with the Drag-Along Right and Minority Shareholder SPA, at the Closing, each Seller shall sell, assign, transfer, convey and deliver to the
Purchaser (or to the Purchaser’s designee), free and clear of all Encumbrances, and in the case of the Selling Shareholders, with full title guarantee, and the Purchaser (or Purchaser’s designee, if applicable) shall purchase from each
Seller, all the Shares owned by such Seller in consideration of payment of any: 
 (i) amounts to the Sellers, on the dates and under the
terms set forth in this Agreement and in the Sellers Promissory Notes (as defined in Section 1.6(a)), with each Seller being entitled to receive an amount in cash equal to the product of (1) the Per Share Note Payment Amount,
multiplied by (2) the number of Shares owned by such Seller, and 
 (ii) amounts of Contingent Consideration to the Sellers on the
dates and under the terms set forth in this Agreement and in the Contingent Consideration Note (as defined in Section 1.7(a)), with each Seller being entitled to receive an amount in cash, without interest, equal to the product of
(1) the Per Share Contingent Consideration, multiplied by (2) the number of Shares owned by such Seller. 
 (b) For purposes of
this Agreement: 
 (i) “Financial Advisor Commission” shall mean five percent (5%) of any Contingent Consideration
earned by and payable to the Sellers pursuant to Section 1.7(b) of this Agreement, subject to the limitations set forth in Section 1.7(d) of this Agreement. 
 (ii) “Fully Diluted Company Ordinary Shares” shall mean the aggregate number of Company Ordinary Shares that are issued immediately
prior to the Closing. 
 (iii) “Per Share Contingent Consideration” shall mean the quotient (rounded to the nearest cent)
obtained by dividing (A) any Contingent Consideration earned by and payable to the Sellers pursuant to Section 1.7(b) of this Agreement, subject to the limitations set forth in Section 1.7(d) of this Agreement, less the
Financial Advisor Commission, by (B) the Fully Diluted Company Ordinary Shares. 
 (iv) “Per Share Note Payment
Amount” shall mean the quotient (rounded to the nearest cent) obtained by dividing (A) the Note Payment Amount (as defined in Section 1.6(a)) paid to the Sellers under the terms of the Sellers Promissory Notes, if any, by
(B) the Fully Diluted Company Ordinary Shares. 
  

 2 

 EXECUTION COPY 
  

 1.2 Closing. Subject to the terms and conditions of this Agreement, the purchase and sale of
the Shares and the consummation of the other transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of Burges Salmon LLP, Narrow Quay House, Narrow Quay, Bristol BS1 4AH, at 10:00 a.m., local
time, on the last day of the month in which the last of the conditions set forth in Article 7 of this Agreement is satisfied or waived (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the
satisfaction or waiver of such conditions), or on such other date as may be mutually agreed upon by the Selling Shareholders, on the one hand, and the Purchaser, on the other hand. The date on which the Closing actually takes place is referred to in
this Agreement as the “Closing Date”. 
 1.3 Treatment of Company Rights. As of the Closing Date, all rights under
any provision of any scheme, plan, program, agreement or arrangement providing for the issuance or grant of any interest in respect of the share capital of the Company shall be cancelled and terminated. Neither Purchaser nor any of its Affiliates
shall be responsible for or otherwise assume any obligations with respect to any outstanding options, warrants or other rights to purchase share capital of the Company. The Company shall effectuate the foregoing and the Sellers and the Company shall
ensure that, from and following the Closing Date, no Person shall have any right under any scheme, plan, program, agreement or arrangement with respect to share capital of the Company. 
 1.4 Estimated Balance Sheet and Estimated Closing Indebtedness. No later than five Business Days prior to the Closing Date, the Company shall
deliver to the Purchaser (a) an estimated balance sheet of the Company, which estimated balance sheet reflects estimated balances as of the Closing Date (the “Estimated Balance Sheet”), (b) an itemized schedule of the
estimated amount of Closing Indebtedness (separately listing each item of Indebtedness and the related creditor) (“Estimated Closing Indebtedness”), (c) an itemized schedule of the Transaction Costs paid or owed by the Company
(separately listing each Transaction Cost and the related creditor), in each case as of the Closing Date (the “Schedule of Company Transaction Costs”), and (d) a certificate of the Company, executed by the Chief Executive
Officer and the Chief Financial Officer of the Company, certifying that each of the Estimated Balance Sheet, Estimated Closing Indebtedness and Schedule of Company Transaction Costs were prepared by the Company in good faith in accordance with this
Agreement, and, in the case of the Estimated Balance Sheet, in accordance with the Company’s accounting policies and generally accepted accounting practice in the United Kingdom (“GAAP”) applied in a manner consistent with the
preparation of the Company Audited Financial Statements, except as otherwise specifically contemplated by this Agreement (the “Closing Certificate”). 
 1.5 Assumption of Closing Indebtedness. At the Closing, the Purchaser shall deliver to each creditor listed on the schedule of Estimated Closing Indebtedness attached to the Closing Certificate (other than
creditors under Capital Lease Obligations) a promissory note, in substantially the form attached hereto as Exhibit B, in a principal amount equal to the amount of Indebtedness outstanding to such creditor immediately prior to the Closing, as
reflected on the schedule of Estimated Closing Indebtedness (collectively, the “Lender Promissory Notes”); provided, that the aggregate principal amount of the Lender Promissory Notes shall not exceed an amount equal to US$4.857
million. As of the date hereof, the Purchaser and each creditor listed on the schedule of Estimated Closing Indebtedness (other than creditors under Capital 

  

 3 

 EXECUTION COPY 
  

 
Lease Obligations) have entered into an assignment agreement pursuant to which each such creditor has agreed, effective as of the Closing Date, to
(a) assign all Indebtedness outstanding to such creditor immediately prior to the Closing, as reflected on the schedule of Estimated Closing Indebtedness, to the Purchaser and (b) provide the Purchaser with recordable form lien releases,
note, trademark and patent assignments and other documents reasonably requested by the Purchaser, in exchange for delivery by the Purchaser of the Lender Promissory Note. 
 1.6 Delivery of Sellers Promissory Notes. 
 (a) At the Closing, the Purchaser shall deliver
(i) to the Shareholders’ Representative, on behalf of the Remaining Shareholders, a promissory note in substantially the form attached hereto as Exhibit C (the “Remaining Shareholder Promissory Note”) and
(ii) to each of the Selling Shareholders, a promissory note in substantially the form attached hereto as Exhibit D (each, a “Selling Shareholder Promissory Note” and, together with the Remaining Shareholder Promissory
Note, the “Sellers Promissory Notes”). The aggregate principal amount of the Sellers Promissory Notes shall be calculated as follows (the “Aggregate Principal Amount”): (i) US$5.85 million, minus
(ii) any unpaid Transaction Costs at Closing, minus (iii) any past due real property lease obligations reflected on the schedule of Estimated Closing Indebtedness, minus (iv) any other accounts payable or accrued
liabilities reflected on the Estimated Balance Sheet (excluding those accounts payable and accrued liabilities reflected on Part 1.6(a) of the Company Disclosure Schedule, up to an aggregate amount of £219,000), minus
(v) 50% of the Stamp Duty payable in connection with the transactions effected pursuant to this Agreement, plus (vi) any cash held by the Company at the Closing (taking into account any outstanding cheques), plus
(vii) to the extent actually received by the Company on or before March 31, 2009, the 2008 R&D Tax Credit; provided, that the increase to the Aggregate Principal Amount, if any, pursuant to this subsection (vii) shall not
exceed the reduction to the Aggregate Principal Amount, if any, pursuant to subsection (iv) above, without duplication and, in the case of (ii), (iii), (iv), (v), (vi) and (vii), converted into U.S. dollars, if necessary, based upon the
Agreed Rate. The principal amount of each Selling Shareholder Promissory Note shall be equal to the result of (A)(1) the Aggregate Principal Amount, divided by (2) the Fully Diluted Company Ordinary Shares, multiplied by
(B) the aggregate number of Company Ordinary Shares that are issued to the Selling Shareholder holding such Selling Shareholder Promissory Note immediately prior to the Closing. The principal amount of the Remaining Shareholder Promissory Note
shall be equal to (1) the Aggregate Principal Amount, minus (2) the aggregate principal amount of the Selling Shareholder Promissory Notes, calculated in accordance with the foregoing sentence. The Sellers Promissory Notes shall be
issued by the Purchaser or an Affiliate of the Purchaser and guaranteed by Parent as described with particularity in Article 5 hereof. The Remaining Shareholder Promissory Note shall be issued in the name of the Shareholders’
Representative who shall hold as nominee for the Remaining Shareholders, on behalf of the Remaining Shareholders, and is hereby authorized to propose, negotiate and agree (as applicable) to any variation to the terms of the Remaining Shareholder
Promissory Note on behalf of the Remaining Shareholders, provided that any such variation shall not be to the detriment of any one or more of the Remaining Shareholders, diminish the value of the Remaining Shareholder Promissory Note nor deprive any
one or more of the Remaining Shareholders of his, her or its entitlement to benefit under the terms of the Remaining Shareholder Promissory Note. The principal amount of each Sellers Promissory Note and any accrued interest earned thereon shall be
subject to reduction to satisfy any rights of the Purchaser Parties to recover for Damages 

  

 4 

 EXECUTION COPY 
  

 
suffered by them in accordance with Section 1.6(b) and Article 9 of this Agreement. The aggregate amount of principal and accrued interest
paid to the Sellers under the Seller Promissory Notes, as reduced to satisfy any rights of the Purchaser Parties to recover for Damages suffered by them in accordance with Section 1.6(b) and Article 9 of this Agreement (the
“Note Payment Amount”), shall be for the benefit of the Sellers and for distribution in accordance with Section 1.1(a)(i) of this Agreement. 
 (b) In the event that any Purchaser Party shall incur any Damages for which it is entitled to recovery under this Agreement, the Purchaser shall be entitled to offset the aggregate amount of such Damages (converted
into U.S. dollars in accordance with Section 9.4, if necessary) against the principal amounts of the Sellers Promissory Notes and all accrued interest thereon in accordance with Section 9.4 hereof. In addition, if any
Purchaser Party has any pending claim for recovery of Damages under this Agreement on the date on which final payment under the Sellers Promissory Notes is due, the Purchaser shall be entitled to withhold from the final payments due to the Sellers
an amount equal to 100% of any Claimed Amount or Contested Amount, as applicable (converted into U.S. dollars, if necessary, in accordance with Section 9.4), in accordance with Section 9.4 hereof and the Purchaser shall not
be obligated to deliver any of such withheld amount to the Sellers until the related claim for recovery of Damages is finally resolved in accordance with the terms set forth in this Agreement, at which time such amount shall be delivered to the
Sellers together with any accrued interest thereon less any setoff in accordance with Section 9.4 of this Agreement. 
 1.7
Contingent Consideration. 
 (a) Delivery of Contingent Consideration Note. At the Closing, the Purchaser shall deliver to the
Shareholders’ Representative a promissory note, in substantially the form attached hereto as Exhibit E (the “Contingent Consideration Note”), in a principal amount of up to US$9.426 million. For the avoidance of doubt,
no amounts shall be payable pursuant to the Contingent Consideration Note unless and until such time as the Sellers have earned and are entitled to receive Contingent Consideration pursuant to this Section 1.7, and then, only to the
extent of the Contingent Consideration earned by and payable to the Sellers. The Contingent Consideration Note shall be issued by the Purchaser or an Affiliate of the Purchaser and guaranteed by Parent as described with particularity in Article
5 hereof and shall be issued in the name of the Shareholders’ Representative who shall hold as nominee for the Sellers, on behalf of the Sellers, and is hereby authorized to propose, negotiate and agree (as applicable) to any variation to
the terms of the Contingent Consideration Note on behalf of the Sellers, provided that any such variation shall not be to the detriment of any one or more of the Sellers, diminish the value of the Contingent Consideration Note nor deprive any one or
more of the Sellers of his, her or its entitlement to benefit under the terms of the Contingent Consideration Note. 
 (b) Calculation of
Contingent Consideration. The Sellers shall be entitled to receive additional earn-out consideration equal to US$0.30, for each pSel Hybrid Display sold and delivered to any third party by the Purchaser, the Company or any of their respective
Affiliates or licensees (collectively, the “Selling Parties”), without duplication and net of applicable returns (including returns for warranty claims), during calendar years 2009 and 2010, which shall be paid to the Sellers
pursuant to the terms of the Contingent Consideration Note, subject to reduction, if any, to satisfy the rights of the Purchaser Parties to recover for Damages 

  

 5 

 EXECUTION COPY 
  

 
suffered by them in accordance with the terms of Section 1.7(d) and Article 9 of this Agreement (the “Contingent
Consideration”), subject to the following: 
 (i) the Sellers shall not be entitled to receive any payments of Contingent
Consideration pursuant the Contingent Consideration Note with respect to sales made during calendar year 2009 until such time as the Selling Parties have sold and delivered in excess of 3.65 million pSel Hybrid Display units to third parties,
net of any applicable returns (including returns for warranty claims), in such year (in which case and at such time, the Sellers shall be deemed to have earned and shall be entitled to receive, on the next Installment Due Date, subject to the terms
and conditions set forth in Section 1.7(d), Contingent Consideration pursuant to the Contingent Consideration Note with respect to all units sold and delivered to third parties by the Selling Parties during such year, net of any
applicable returns (including returns for warranty claims), and not merely the units in excess of 3.65 million units); provided, that the aggregate Contingent Consideration to be paid by the Purchaser pursuant to the Contingent
Consideration Note shall not exceed US$2.19 million with respect to units sold and delivered to third parties by the Selling Parties during calendar year 2009; 
 (ii) the Sellers shall not be entitled to receive any payments of Contingent Consideration pursuant to the Contingent Consideration Note with respect to sales made during calendar year 2010 until such time as the
Selling Parties have sold and delivered in excess of 12.9 million pSel Hybrid Display units to third parties, net of any applicable returns (including returns for warranty claims), in such year (in which case and at such time, the Sellers shall
be deemed to have earned and shall be entitled to receive, on the next Installment Due Date, subject to the terms and conditions set forth in Section 1.7(d), Contingent Consideration pursuant to the Contingent Consideration Note with
respect to all units sold and delivered to third parties by the Selling Parties during such year, net of any applicable returns (including returns for warranty claims), and not merely the units in excess of 12.9 million units); provided,
that the aggregate Contingent Consideration to be paid by the Purchaser pursuant to the Contingent Consideration Note shall not exceed US$7.236 million with respect to units sold and delivered to third parties by the Selling Parties during calendar
year 2010; provided, further, that under no circumstances shall sales made during calendar year 2009 (regardless of whether any Contingent Consideration was payable) be taken into account in determining whether the 12.9 million
unit threshold for 2010 has been achieved; and 
 (iii) notwithstanding the foregoing provisions of this Section 1.7(b), if any
Company Contract existing immediately prior to the Closing permits a Person (other than ELK Corporation, the Purchaser and their respective Affiliates) to manufacture and sell pSel Hybrid Display units following the Closing, the Contingent
Consideration to be paid by the Purchaser pursuant to the Contingent Consideration Note with respect to each unit sold and delivered to a third party by such Person shall be equal to the lesser of (A) US$0.30 or (B) 50% of the amount
actually paid by such Person to the Purchaser or an Affiliate of the Purchaser as a royalty, per unit or other license or similar payment on such units sold, and shall be subject to all of the limitations set forth in the foregoing clauses
(i) and (ii). 
 (c) Sale of Company Products. Following the Closing, Purchaser shall not take any action that is specifically
intended to affect the timing and delivery of Company Products in an effort to prevent the payment or decrease the amount of Contingent Consideration that may become payable under this Section 1.7. 
  

 6 

 EXECUTION COPY 
  

 (d) Payment of Contingent Consideration. Any Contingent Consideration earned pursuant to
Section 1.7(b) shall be paid by the Purchaser to the Sellers in five installments under the terms of the Contingent Consideration Note. Installment payments under the Contingent Consideration Note shall be made on or before
August 31, 2009, February 28, 2010, August 31, 2010, February 28, 2011 and August 31, 2011, or such later date with respect to all or any portion of the Contingent Consideration payable on each such date as
necessary to resolve any disputes with respect to the calculation of Contingent Consideration pursuant to Section 1.7(e) and to resolve any pending claims for recovery of Damages pursuant to Article 9 (each, an
“Installment Due Date”). On each of the first four Installment Due Dates, the Sellers shall be entitled to receive an amount equal to any Contingent Consideration earned by the Sellers pursuant to Section 1.7(b) during
the relevant measurement period set forth in the Contingent Consideration Note (each, a “Measurement Period”) (subject to the limitations set forth in this Section 1.7(d)). All calculations of the number of pSel Hybrid
Display units sold and delivered at any time and the related calculation of any Contingent Consideration due pursuant to the Contingent Consideration Note shall be net of any applicable returns (including returns for warranty claims) without
duplication; provided, that Purchaser shall be entitled to withhold an amount from the installment payment to be made on February 28, 2011 equal to the Estimated Remaining Return Amount. Purchaser shall pay the Excess Warranty Holdback
Amount (to the extent such amount is a positive number) pursuant to the terms of the Contingent Consideration Note on the August 31, 2011 Installment Due Date. If the Excess Warranty Holdback Amount is zero or a negative number, Purchaser shall
have no obligation to pay the Sellers any portion of the Estimated Remaining Return Amount. In the event that any Purchaser Party shall incur any Damages for which it is entitled to recovery under this Agreement, the Purchaser shall be entitled to
offset in the manner described in Article 9 the aggregate amount of such Damages (converted into U.S. dollars in accordance with Section 9.4, if necessary) against any Contingent Consideration otherwise payable to the Sellers
under the Contingent Consideration Note pursuant to this Section 1.7 to the extent such Damages exceed the then-outstanding balance under the Sellers Promissory Notes (including accrued interest). In addition, if any Purchaser Party has
any pending claim pursuant to Article 9 of this Agreement for the recovery of Damages under this Agreement on an Installment Due Date in excess of the then-outstanding balance under the Sellers Promissory Notes (including accrued interest),
then the Purchaser shall be entitled to withhold from the Contingent Consideration otherwise payable to the Sellers under the Contingent Consideration Note an amount equal to the amount by which the Claimed Amount or Contested Amount, as applicable
(converted into U.S. dollars in accordance with Section 9.4, if necessary), exceeds the then-outstanding balance under the Sellers Promissory Notes (including accrued interest), and the Purchaser shall not be obligated to deliver any of
such withheld Contingent Consideration to the Sellers pursuant to the Contingent Consideration Note until the related claim for recovery of Damages is finally resolved in accordance with the terms of this Agreement, at which time such Contingent
Consideration shall be delivered to the Sellers together with any accrued interest thereon, less any setoff in accordance with Section 9.4 of this Agreement. For the avoidance of doubt, however, Purchaser’s withholding of amounts
from payment on the February 28, 2011 Installment Due Date with respect to the Estimated Remaining Return Amount shall not extend the period for which Purchaser’s recourse for Damages is available pursuant to Article 9 or increase
the amount available for recovery of Damages. Any payment of Contingent Consideration to the Sellers under the Contingent Consideration Note pursuant to this Section 1.7(d) shall be distributed in accordance with
Section 1.1(a)(ii) of this Agreement. 
  

 7 

 EXECUTION COPY 
  

 (e) Administration and Calculation of Contingent Consideration. 
 (i) Fifteen (15) Business Days prior to each of the first four Installment Due Dates, Purchaser shall: (A) prepare or cause to be prepared a
statement (the “Sales Statement”) setting forth the number of pSel Hybrid Display units sold and delivered to third parties by the Selling Parties during the relevant Measurement Period, net of applicable returns (including returns
for warranty claims), together with supporting documentation, and a calculation of the Contingent Consideration payable to the Sellers pursuant to the Contingent Consideration Note at such Installment Due Date and (B) deliver or cause to be
delivered such Sales Statement to the Shareholders’ Representative. 
 (ii) In the event that the Shareholders’ Representative
objects to Purchaser’s calculation of the number of pSel Hybrid Display units sold or the calculation of Contingent Consideration set forth in such Sales Statement or requires further information in order to perform and confirm such
calculations or determine such amounts, then within ten (10) Business Days after receipt by the Shareholders’ Representative of the Sales Statement (the “Initial Response Period”), the Shareholders’ Representative
shall deliver to Purchaser a written notice (an “Initial Objection Notice”): (A) describing in reasonable detail the Shareholders’ Representative’s objections to Purchaser’s calculation of the amounts set forth
in the Sales Statement and containing a statement setting forth the actual number of pSel Hybrid Display units sold net of applicable returns (including returns for warranty claims), or the amount of any such Contingent Consideration, determined by
the Shareholders’ Representative to be correct; or (B) requesting additional information from Purchaser that the Shareholders’ Representative reasonably requires in order to perform such calculations or determine such amounts (which
information, to the extent reasonably necessary in order to perform such calculations, shall be provided by Purchaser within fifteen (15) Business Days after Purchaser’s receipt of such request). If the Shareholders’ Representative
does not deliver an Initial Objection Notice to Purchaser during the Initial Response Period, then Purchaser’s calculation of the amounts set forth in the Sales Statement shall be final, binding and conclusive on Purchaser, Sellers and the
Shareholders’ Representative. If the Shareholders’ Representative delivers an Initial Objection Notice to Purchaser accompanied by a request for additional information from Purchaser as described above during the Initial Response Period,
then the Shareholders’ Representative shall have an additional ten (10) Business Days after receiving from Purchaser all of the information reasonably requested by Shareholders’ Representative and required in order for
Shareholders’ Representative to perform its calculation of the Sales Statement (the “Final Response Period”) to deliver to Purchaser a written notice (a “Final Objection Notice”) describing in reasonable detail
the Shareholders’ Representative’s objections to Purchaser’s calculations of the amounts set forth in the Sales Statement accompanied by a statement setting forth the number of pSel Hybrid Display units sold net of applicable returns
(including returns for warranty claims), or the dollar amount of any such Contingent Consideration, determined by the Shareholders’ Representative to be correct. If the Shareholders’ Representative has requested additional information
during the Initial Response Period and does not deliver a Final Objection Notice to Purchaser during the Final Response Period, then Purchaser’s calculation of the amounts set forth in the Sales 

  

 8 

 EXECUTION COPY 
  

 
Statement shall be final, binding and conclusive on Purchaser, the Sellers and the Shareholders’ Representative. If the Shareholders’
Representative delivers an Initial Objection Notice or Final Objection Notice, as the case may be, accompanied by a statement setting forth the number of pSel Hybrid Display units sold net of applicable returns (including returns for warranty
claims), or the amount of any such Contingent Consideration, determined by the Shareholders’ Representative to be correct to Purchaser during either the Initial Response Period or the Final Response Period in accordance with this
Section 1.7(e)(ii), and if the Shareholders’ Representative and Purchaser are unable to agree upon the calculation of the amounts set forth in the Sales Statement within thirty (30) calendar days after such Initial Objection
Notice or Final Objection Notice, as the case may be, is delivered to Purchaser, the dispute shall be finally settled by a U.S. nationally recognized independent accounting firm jointly selected by Purchaser and the Shareholders’
Representative; provided, that such independent accounting firm shall have had no material relationship with Seller or Purchaser or their respective Affiliates (the “Accounting Referee”). The determination by the Accounting
Referee of the disputed amounts, number of pSel Hybrid Display units sold net of applicable returns (including returns for warranty claims) and/or the Contingent Consideration, if any, shall be final, conclusive and binding on Purchaser, the Sellers
and the Shareholders’ Representative. The fees and other expenses of such independent accounting firm shall be paid by the party whose determination of Contingent Consideration payable most diverges (on an absolute dollar basis) from the
determination of the Accounting Referee. For the avoidance of doubt, the Shareholders’ Representative shall be the sole party authorized, on behalf of the Sellers, to object to the calculations set forth in the Sales Statement, request
additional information from the Purchaser related to such calculations and negotiate, adjudicate and enter into settlements and compromises of objections and claims made pursuant to this Section 1.7(e)(ii). 
 (f) Payment of the Financial Advisor. To the extent that any Contingent Consideration has been earned by and is payable to the Sellers pursuant
to this Section 1.7 and the Contingent Consideration Note, the Purchaser shall pay the Financial Advisor an amount in cash equal to the Financial Advisor Commission. 
 ARTICLE 2. 
 WARRANTIES OF THE COMPANY 
 Except as set forth on the Company Disclosure Schedule, which shall qualify the warranties of the Company set forth in this Article 2, the
Company warrants, on a dollar for dollar basis and in accordance with Article 9, as of the date of this Agreement and as of the Closing Date, to and for the benefit of the Purchaser Parties, as follows (an exception or disclosure made in the
Company Disclosure Schedule with regard to a warranty of the Company shall be deemed made with respect to any other warranty to which the applicability of such exception or disclosure is reasonably apparent): 
 2.1 Organization; Standing and Power; Subsidiaries. 
 (a) The Company is a private limited company duly incorporated and validly existing under the laws of England and Wales, has all necessary power and authority to (i) own, lease and use its properties and assets
in the manner in which its properties and assets are currently owned, leased and used; (ii) carry on its business in the manner in which its business is currently being conducted and (iii) perform its obligations under all Company
Contracts. 
  

 9 

 EXECUTION COPY 
  

 (b) The Company has not conducted any business under or otherwise used, for any purpose or in any
jurisdiction, any fictitious name, assumed name, trade name or other name, other than the name Pelikon Limited or Elumin Limited. 
 (c) The
Company is not, and within the last two (2) years has not been, required to be qualified, authorized, registered or licensed to do business as a foreign corporation in any jurisdiction other than the jurisdictions identified in
Part 2.1(c) of the Company Disclosure Schedule. 
 (d) Part 2.1(d) of the Company Disclosure Schedule accurately
sets forth (i) the names of the members of the board of directors of the Company (the “Board”), (ii) the names of the members of each committee of the Board (if any) and (iii) the names and titles of the officers of
the Company. 
 (e) The Company has no Subsidiary. The Company does not own any controlling interest in any Entity and, except for the
financial interests identified in Part 2.1(e) of the Company Disclosure Schedule, the Company has never owned, beneficially or otherwise, any shares or other securities of, or any direct or indirect equity or other financial interest in,
any Entity. The Company has not agreed nor is it obligated to make any future investment in or capital contribution to any Entity. The Company has not guaranteed nor is it responsible or liable for any obligation of any of the Entities in which it
owns or has owned any equity or other financial interest. Neither the Company nor any of its members has ever approved, or commenced any proceeding or made any election contemplating, the dissolution or liquidation of the business or affairs of the
Company. 
 2.2 Company Constituent Documents; Records. The Company has delivered to Purchaser accurate and complete copies of
(a) the Certificate of Incorporation of the Company, Memorandum of Association of the Company and the Articles of Association of the Company, in each case including all amendments thereto; (b) its statutory registers and (c) the
minutes and other records of the meetings and other proceedings (including any actions taken by written consent or otherwise without a meeting) of its members in their capacity as such, the Board and all committees of the Board, in each case since
January 1, 2001 (the items described in (a), (b) and (c) above, collectively, the “Company Constituent Documents”). There have been no formal meetings of or material actions taken by the Company’s members, the
Board or any committee of the Board that are not fully reflected in the Company Constituent Documents. There has not been any violation of the Company Constituent Documents, and the Company has not taken any action that is inconsistent in any
material respect with the Company Constituent Documents. The books of account, statutory registers (including the register of members and register of directors and register of charges) and other records of the Company are accurate, up-to-date and
complete in all material respects, and have been maintained materially in accordance with applicable Legal Requirements and prudent business practices. 
  

 10 

 EXECUTION COPY 
  

 2.3 Capitalization, Etc. 
 (a) The authorized share capital of the Company consists of 4,648,936,483 Company Ordinary Shares, of which 3,150,752,088 shares have been issued as of
the date of this Agreement. None of the issued share capital of the Company is held by the Company in treasury. All the issued Company Ordinary Shares have been duly authorized and validly issued, are fully paid and were not issued in violation of
any preemptive or other similar rights. All issued Company Ordinary Shares have been issued in compliance with (i) all applicable securities laws and other applicable Legal Requirements, and (ii) all requirements set forth in the Company
Constituent Documents and applicable Contracts. Each of the Remaining Shareholders is the record and beneficial owner of the Shares as set forth opposite such Remaining Shareholder’s name on Part 2.3(a) of the Company Disclosure
Schedule, and such Shares are free and clear of all Encumbrances. None of the Remaining Shareholders are organized or incorporated in or residents or citizens of the United States or Singapore. Upon execution and delivery by Purchaser of the Lender
Promissory Notes, the Sellers Promissory Notes and the Contingent Consideration Note at the Closing, each Remaining Shareholder will convey good and marketable title to the Shares held by it set forth opposite its name on Part 2.3(a) of the
Company Disclosure Schedule to Purchaser, free and clear of all Encumbrances. The assignments, endorsements, powers and other instruments of transfer delivered by each of the Remaining Shareholders (or their respective authorized agents) at the
Closing will be sufficient to transfer to the Purchaser such Remaining Shareholder’s entire right, title and interest, legal and beneficial, in such Shares. 
 (b) As of the date of this Agreement, there are issued warrants to purchase 466,250,000 Company Ordinary Shares and stock options to purchase 1,031,934,395 Company Ordinary Shares. As of the Closing, there are no
issued warrants, options or other rights to purchase Company Ordinary Shares. 
 (c) Except as set forth above in this
Section 2.3, as of the date of this Agreement, there is no (i) issued share capital or other voting securities of the Company; (ii) outstanding securities, instruments or obligations that are or may become convertible into or
exchangeable or exercisable for any share capital or other securities of the Company; (iii) outstanding subscriptions, options, calls, warrants or rights (whether or not currently exercisable) to acquire any share capital or other securities of
the Company; or (iv) commitments or agreements to which the Company is a party or by which it is bound, in any case obligating the Company to issue, deliver, sell, purchase, redeem or acquire, or cause to be issued, delivered, sold, purchased,
redeemed or acquired, any share capital or other securities of the Company, or obligating the Company to enter into any such commitment or agreement or grant or extend any subscription, option, warrant, call or right to acquire any share capital of,
or any securities that are convertible into or exchangeable or exercisable for any share capital of, or other securities of the Company (clauses (i) through (iv) of this Section 2.3(c) above, collectively “Company
Rights”). The Company has not issued any debt securities which grant the holder thereof any right to vote on, or veto (except in the context of negative covenants over the Company’s ability to incur indebtedness and grant security
interests in the assets or property of the Company), any actions by the Company (or which are convertible into, or exercisable or exchangeable for, securities having the right to vote on, or veto, any actions by the Company). 
  

 11 

 EXECUTION COPY 
  

 (d) The Company has never repurchased, redeemed or otherwise reacquired any share capital or other
securities of the Company other than pursuant to share purchase agreements or option agreements providing for the repurchase of such securities at the original issuance price of such securities. All securities so reacquired by the Company were
reacquired in compliance with (i) the applicable provisions of the Companies Act 1985 and all other applicable Legal Requirements, and (ii) all requirements set forth in applicable subscription and shareholders’ agreements and other
applicable Contracts. 
 2.4 Authority; Binding Nature of Agreement. The Company has all right, power and authority to execute and
deliver this Agreement and any Related Agreement to which it is a party, to consummate the transactions contemplated hereby and thereby and to take all other actions required to be taken by it pursuant to the provisions hereof and thereof. The
execution, delivery and performance of this Agreement and any Related Agreement to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the
Company, and no other action on the part of the Company is necessary to authorize the execution, delivery and performance by the Company of this Agreement and any Related Agreement to which the Company is a party and to consummate the transactions
contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Company. This Agreement constitutes and, upon execution and delivery thereof by the Company, any Related Agreement to which it is a party will constitute
(assuming due and valid authorization, execution and delivery hereof and thereof by the other parties hereto and thereto, if any) the valid and binding obligation of the Company, enforceable against the Company in accordance with their respective
terms, except as such enforcement may be limited by any insolvency, fraudulent conveyance, reorganization, moratorium or similar laws affecting creditors’ rights and remedies generally and by general principles of equity, regardless of whether
enforcement is sought in a proceeding at law or in equity. 
 2.5 Non-Contravention; Consents. Except as set forth in
Part 2.5 of the Company Disclosure Schedule, the execution, delivery and performance of this Agreement and the Related Agreements and the consummation of the transactions contemplated hereby and thereby do not, directly or indirectly
(with or without notice or lapse of time): 
 (a) contravene, conflict with or result in a violation of any of the terms, conditions or
provisions of the Company Constituent Documents; 
 (b) contravene, conflict with or result in a violation of any Legal Requirement or any
Order, writ, injunction, judgment or decree to which the Company or any of the assets owned, used or controlled by the Company is subject or, to the Knowledge of the Company, give any Governmental Body or other Person the right to challenge any of
the transactions contemplated by this Agreement or any of the Related Agreements or to exercise any remedy or obtain any relief under, any such Legal Requirement or Order, writ, injunction, judgment or decree to which the Company or any of the
assets owned, used or controlled by the Company is subject; 
 (c) contravene, conflict with or result in a violation of any of the terms or
requirements of any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company or to any of the assets owned, used or controlled by the 
  

 12 

 EXECUTION COPY 
  

 Company, including in such a manner as would, pursuant to the terms of such Governmental Authorization, give any
Governmental Body the right to revoke, withdraw, suspend, cancel, terminate or modify such Governmental Authorization; 
 (d) contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any Material Contract to which the Company or any of the assets owned, used or controlled by the Company is subject, or give any Person the right to
(i) declare a default or exercise any remedy under any such Material Contract, (ii) accelerate the maturity or performance of any such Material Contract or (iii) cancel, terminate or modify any such Material Contract; or 

(e) result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for minor liens
that will not, in any case or in the aggregate, materially detract from the value of the assets subject thereto or materially impair the operations of the Company). 
 The Company has complied, in all material respects, with all applicable Legal Requirements and Orders in connection with the execution, delivery and performance of this Agreement and any Related Agreements to which it
is a party and the consummation of the transactions contemplated hereby and thereby. No filing with, notice to or consent from any Person (other than the parties hereto) is required in connection with the execution, delivery or performance of this
Agreement or any of the Related Agreements by the Company, the consummation of the transactions contemplated hereby and thereby by the Company or the conduct of the business of the Company in the same manner immediately after the Closing Date as
before the Closing Date. 
 2.6 Financial Statements. 
 (a) Part 2.6 of the Company Disclosure Schedule includes the following financial statements (collectively, the “Company Financial Statements”): 
 (i) The audited consolidated balance sheet of the Company as of December 31, 2007 and 2006 (the “Balance Sheet”) and the related
audited profit and loss account of the Company for the periods then ended together with the notes thereto and the unqualified report and opinion of Deloitte & Touche LLP relating thereto (collectively, the “Company Audited Financial
Statements”); and 
 (ii) the unaudited consolidated balance sheets of the Company as of September 30, 2008 (the
“Balance Sheet Date”) and the related unaudited profit and loss account of the Company for the period from January 1, 2008 through the Balance Sheet Date (the “Unaudited Interim Financial Statements”).

 (b) The Company Audited Financial Statements give a true and fair view of the financial position of the Company as of the dates thereof
and the results of operations and cash flows of the Company for the periods covered thereby. The Company Audited Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the periods covered. The
Company Audited Financial Statements were prepared from the books and records of the Company, which books and records have been maintained in accordance with sound business practices and all applicable Legal Requirements and reflect all financial
transactions of the Company that are required to be reflected in accordance with GAAP. 
  

 13 

 EXECUTION COPY 
  

 (c) The Unaudited Interim Financial Statements have been prepared with due care and attention, on a
basis consistent with the Company Audited Financial Statements, and give a fair and reasonable view of the assets and liabilities of the Company as at their date and of the profits and losses for the period in respect of which they have been
prepared, subject to year-end adjustments. 
 (d) The Company maintains accurate books and records reflecting its assets and liabilities and
maintains proper and adequate internal accounting controls which provide assurance that (i) transactions are executed with management’s authorization; (ii) transactions are recorded as necessary to permit preparation of the financial
statements of the Company in accordance with GAAP and to maintain accountability for the Company’s assets; (iii) access to the Company’s assets is permitted only in accordance with management’s authorization; (iv) the
reporting of the Company’s assets is compared with existing assets at regular intervals and (v) accounts and other receivables and inventory are recorded in good faith and reserves established against them based upon actual prior
experience and in accordance with GAAP, and proper procedures are implemented for the collection thereof on a commercially reasonable basis. The Company does not have any Knowledge of any significant deficiencies or material weaknesses in the design
or operation of the Company’s internal control structure and procedures over financial reporting. The Company has heretofore made available to Purchaser a true, complete and correct copy of any disclosure (or, if unwritten, a summary thereof)
by any Representative of the Company to the Company’s independent auditors relating to (A) any significant deficiencies in the design or operation of internal controls that could adversely affect the ability of the Company to record,
process, summarize and report financial data and any material weaknesses in internal controls and (B) any fraud, whether or not material, that involves management or other Employees who have a significant role in the internal control over
financial reporting of the Company. 
 (e) The Company possesses books and records which contain all financial and other information from
the date of its incorporation through the date hereof necessary for the preparation of financial statements. 
 2.7 Absence of Certain
Changes. Except as set forth in Part 2.7 of the Company Disclosure Schedule, since the Balance Sheet Date, the Company has conducted its business only in the ordinary course of business consistent with past practice. Except as set
forth in Part 2.7 of the Company Disclosure Schedule, since the Balance Sheet Date: 
 (a) there has not been any Company Material
Adverse Effect, and, to the Knowledge of the Company, no event has occurred that will, or could reasonably be expected to, have a Company Material Adverse Effect; 
 (b) the Company has not (i) suffered any damage, destruction or loss, or any interruption in the use of, any of its assets with a value in excess of US$50,000 in the aggregate (whether or not covered by
insurance) or (ii) suffered any repeated, recurring or prolonged shortage, cessation or interruption of supplies or services required to conduct its business; 
  

 14 

 EXECUTION COPY 
  

 (c) the Company has not declared, accrued, set aside or paid any dividend or made any other
distribution in respect of any capital shares or other equity securities, and, other than repurchases at cost of shares or other equity securities subject to repurchase options, has not repurchased, redeemed or otherwise reacquired any of its
capital shares or other securities; 
 (d) the Company has not sold, issued or authorized the issuance of (i) any of its capital shares
or other securities or (ii) any Company Rights; 
 (e) there has been no amendment to any of the Company Constituent Documents, and the
Company has not effected or been a party to any Acquisition Transaction, recapitalization, reclassification of shares or similar transaction; 
 (f) the Company has not formed any Subsidiary or acquired any equity interest or other interest in any other Entity; 
 (g) the
Company has not made any capital expenditure which, when added to all other capital expenditures made on behalf of the Company since the Balance Sheet Date, exceeds US$50,000; 
 (h) the Company has not written off as uncollectible, or established any extraordinary reserve with respect to, any billed or unbilled account
receivable or other indebtedness outside existing reserves; 
 (i) the Company has not incurred any liabilities in excess of US$50,000 in
the aggregate, other than in the ordinary course of business consistent with past practice, or failed to pay or discharge when due any liabilities of which the failure to pay or discharge has caused or will cause any material damage or risk of
material loss to it or relating to any of its assets or properties; 
 (j) the Company has not (i) acquired, leased or licensed any
right or other asset from any other Person, (ii) sold, assigned, transferred or otherwise disposed of, or leased or licensed, any right or other asset to any other Person or (iii) waived or relinquished any right, except, in each case, for
(A) immaterial rights or other immaterial assets acquired, leased, licensed or disposed of, (B) non-exclusive licenses of Intellectual Property in connection with sales of Company Products or services to customers and (C) sales of
Company Products, in each case in the ordinary course of business and consistent with past practice; 
 (k) the Company has not
(i) loaned any sum of money to any Person (other than pursuant to advances for ordinary and necessary business expenses made to employees in the ordinary course of business consistent with past practice), (ii) created, incurred, assumed or
guaranteed any indebtedness for money borrowed or (iii) mortgaged, pledged or otherwise permitted any of its assets or properties to become subject to any Encumbrance, except for Permitted Encumbrances made in the ordinary course of business
consistent with past practice; 
 (l) the Company has not (i) made or suffered any amendment or termination of any Contract to which it
is a party or by which it is bound and under which it is entitled to receive or obligated to pay US$25,000 or more in the aggregate or (ii) cancelled, modified or waived any debts or claims in excess of US$25,000 in the aggregate held by it,
whether or not in the ordinary course of business; 
  

 15 

 EXECUTION COPY 
  

 (m) the Company has not (i) established, adopted or materially amended any employee benefit
plan, (ii) paid or committed to pay any bonus or made any profit-sharing or similar payment to, or increased the amount of wages, salary commissions, fringe benefits, pension or welfare benefits, severance benefits, stock-based benefits or
other compensation or remuneration payable to, any of its current or former directors, consultants, officers or employees, or (iii) hired any new director, consultant, officer or any other employee; 
 (n) the Company has not changed any of its methods of accounting or accounting practices in any respect, except as may be required by GAAP; 

(o) the Company has not made any Tax election; 
 (p) the Company has not threatened, commenced or settled any Legal Proceeding; 
 (q) the Company has not entered into any
transaction involving US$25,000 or more other than in the ordinary course of business consistent with past practice; 
 (r) the Company has
not entered into, or agreed to enter into, any agreements granting any Person a license to any Company Intellectual Property, other than non-exclusive licenses of Intellectual Property in connection with sales of Company Products or services to
customers in the ordinary course of business and consistent with past practice; 
 (s) the Company has not terminated the employment of any
Employees; 
 (t) the Company has not hired any executive officer of the Company; 
 (u) the Company has not terminated or reduced any development activities; and 
 (v) the Company has not agreed to take, or committed to take, any of the actions referred to in clauses (c) through (u) above. 
 2.8 Title to and Sufficiency of Assets. 
 (a) Except as set forth in Part 2.8(a) of the Company Disclosure Schedule and save for any Real Property, the Company is the sole legal and beneficial owner of all the assets that it purports to own, including, without limitation,
(i) all assets referred to in Sections 2.9 and 2.11 of this Agreement, and (ii) all other assets reflected in the Company’s books and records as being owned by the Company. All such assets are owned by the Company free
and clear of any Encumbrances, except for (A) Permitted Encumbrances and (B) Encumbrances specifically described in the notes to the Company Audited Financial Statements. 
  

 16 

 EXECUTION COPY 
  

 (b) The assets of the Company constitute all the assets used in or necessary to carry on its
business as such business is being conducted as of the date hereof and as of immediately prior to the Closing. 
 (c) Except for this
Agreement, the Company does not have any Contract, absolute or contingent, (i) to effect any Acquisition Transaction or (ii) to sell or otherwise transfer any assets of the Company, except for sales of Company Products or services to be
made in the ordinary course of business consistent with past practice. 
 2.9 Bank Accounts; Accounts Receivable; Inventory.

 (a) Part 2.9(a) of the Company Disclosure Schedule provides accurate information with respect to each account maintained by or
for the benefit of the Company at any bank or other financial institution, including the name of the bank or financial institution, the account number, the balance as of the date hereof and the names of all individuals authorized to draw on or make
withdrawals from such accounts. 
 (b) Part 2.9(b) of the Company Disclosure Schedule provides an accurate and complete
breakdown and aging of all billed and unbilled accounts receivable and other receivables of the Company as of the Balance Sheet Date. All existing accounts receivable of the Company (including those accounts receivable that have not yet been billed
or that have not yet been collected and those accounts receivable that have arisen since the Balance Sheet Date and have not yet been collected) are (i) valid, genuine and subsisting obligations of customers of the Company, arising from bona
fide sales and deliveries of goods, performance of services or other business transactions in the ordinary course of business and (ii) are fully collectible (except to the extent reserved against in the Company Financial Statements, which such
reserves have been determined based upon actual prior experience and are consistent with GAAP, consistently applied) and are not presently, other than as set forth in Part 2.9(b) of the Company Disclosure Schedule, subject to defences,
set-offs or counterclaims. 
 (c) Part 2.9(c) of the Company Disclosure Schedule sets forth a true, correct and complete list of all
of the inventory of the Company. All of the inventory of the Company (i) was acquired for the operation of its business in the ordinary course consistent with past practice, (ii) is of a quality and quantity usable or saleable in the
ordinary course of business (except as reserved against in the Company Financial Statements), and (iii) is valued on the books and records of the Company at the lower of cost or market value with the cost determined under the first-in-first-out
inventory valuation method consistent with past practice. 
 2.10 Equipment. Part 2.10 of the Company Disclosure Schedule sets
forth a true, correct and complete list of all equipment and other tangible assets owned by the Company having an original cost in excess of US$10,000 and regularly or customarily used by the Company in the operation of its business. All equipment
and other tangible assets that are owned, leased or used by the Company (i) are free of material defects and deficiencies and in good operating condition and repair, subject to normal wear and tear and continued repair and replacement in
accordance with past practice, and (ii) comply in all material respects with, and are being operating and otherwise used in material compliance with, all applicable Legal Requirements. During the past twelve (12) months there has not been
any significant interruption of the operations of the Company due to inadequate maintenance of such assets. 
  

 17 

 EXECUTION COPY 
  

 2.11 Real Property. 
 (a) The Company does not own, nor has it ever owned, any real property or any interest in any real property, except for the leasehold interests created
under the real property leases identified in Part 2.13(a)(viii) of the Company Disclosure Schedule (each, a “Lease”). 
 (b) Part 2.11(b) of the Company Disclosure Schedule includes a complete list of all real property leased, subleased or licensed by the Company (the “Real Property”). No material damage or destruction has occurred
with respect to any of the Real Property for which the Company corporation may be liable. 
 (c) The premises leased pursuant to each Lease
are supplied with utilities and other services necessary for the operation of such premises. 
 2.12 Intellectual Property.

 (a) Part 2.12(a) of the Company Disclosure Schedule sets forth a complete and accurate list of all Registered IP owned, in whole or
in part, by, under an obligation to be assigned to, or filed in the name of the Company. 
 (b) Part 2.12(b) of the Company
Disclosure Schedule sets forth all Intellectual Property (including software programs) and Intellectual Property Rights (other than Registered IP) owned, in whole or in part, by or under an obligation to be assigned to the Company that are material
to the conduct of its business as presently being conducted. 
 (c) Part 2.12(c) of the Company Disclosure Schedule sets forth all
In-Licenses, other than software that is generally commercially available for a cost of not more than US$5,000 for a perpetual license for a single user or work station (or US$25,000 in the aggregate for all users and work stations), and excluding
“open source” materials described in Section 2.12(p) below. 
 (d) Part 2.12(d) of the Company Disclosure
Schedule sets forth all Out-Licenses, other than non-exclusive licenses and related agreements of Company Products granted to end user customers in the ordinary course of business pursuant to the standard form of end user license agreement used by
the Company and other than written non-disclosure agreements. 
 (e) Except as set forth in Part 2.12(e) of the Company Disclosure
Schedule, the Company exclusively owns all Company Intellectual Property and all Company Intellectual Property is free and clear of any Encumbrances other than Permitted Encumbrances and nonexclusive licenses granted to end user customers in the
ordinary course of business. The Intellectual Property and the Intellectual Property Rights owned or used by the Company are not subject to any restriction or limitation of any kind (including geographic restrictions or limitations) that would
materially adversely affect the right by the Company to use or exploit thereof, or the right to manufacture, market, distribute, or sell any Company Products currently being developed, offered, manufactured, distributed or sold by the Company.

  

 18 

 EXECUTION COPY 
  

 (f) The Company owns or otherwise has sufficient rights to all Intellectual Property and
Intellectual Property Rights necessary to conduct its businesses as currently conducted. 
 (g) The Company does not jointly own any
Intellectual Property or Intellectual Property Rights with any of its directors, officers, employees, consultants or any other Person pursuant to any non-disclosure, collaboration, license or other agreement or otherwise. 
 (h) The Company is no longer subject to the exclusivity provision set forth in Section 6.3(a) of that certain Development and Engineering Services
Agreement, dated October 23, 2006, between the Company and Motorola related to wireless communications voice devices. 
 (i) The
Registered IP owned by the Company (i) has not been adjudged invalid or unenforceable, (ii) to the Knowledge of the Company, is valid, subsisting, and enforceable, (iii) is not the subject of any pending or threatened proceeding in
which the scope, validity, or enforceability of any Registered IP is being or has been contested or challenged and (iv) is in compliance with all formal legal requirements, and all filings, payments, and other actions required to be made or
taken to maintain such Registered IP in full force and effect have been made by the applicable deadline. 
 (j) The Company has not, within
the last six years, infringed, misappropriated, or otherwise violated the Intellectual Property Rights of any third party. There are no pending or, to the Knowledge of the Company, threatened infringement, misappropriation, or similar claims or
proceedings against the Company. The Company has not received any written notice or other written communication of any alleged infringement or misappropriation of any third party’s Intellectual Property Rights by the Company. 
 (k) To the Knowledge of the Company, no person or entity is infringing, misappropriating, or otherwise violating any Intellectual Property Rights owned
by the Company. 
 (l) The Company has taken all reasonable steps to maintain the confidentiality of or otherwise protect and enforce its
rights in its confidential information, in particular the trade secrets owned by the Company. 
 (m) None of the software distributed,
licensed, or sold by the Company (“Company Software”) fails to comply in any material respect with any applicable warranty or other contractual commitment by the Company relating to the use, functionality, or performance of such
software. 
 (n) Except as set forth in Part 2.12(n) of the Company Disclosure Schedule, no portion of any Company Software has been
delivered, made available, or licensed to any third party, nor is the Company obligated to deliver, make available, or license such software in source code form to any third party under any circumstance, other than to the Company’s contractors
or consultants who have been hired to develop, manage, and/or modify such Company Software and are obligated to maintain the confidentiality of such source code. 
  

 19 

 EXECUTION COPY 
  

 (o) To the Knowledge of the Company, no Company Software contains any “back door,”
“drop dead device,” “time bomb,” “Trojan horse,” “virus,” or “worm” (as such terms are commonly understood in the software industry) or any other code designed to (i) disrupt, disable, harm, or
otherwise impede in any manner the operation of, or provide unauthorized access to, a computer system or network or other device on which such code is stored or installed or (ii) damage or destroy any data or files without the user’s
consent. 
 (p) No Company Software is subject to any “copyleft” or other obligation or condition (including any obligation or
condition under any “open source” license such as the GNU Public License, Lesser GNU Public License, the wxWindows Library License, or Mozilla Public License) that would require the disclosure, licensing or distribution of any source code
for the Company Software owned by the Company. 
 (q) All Employees of the Company who have created or developed any Intellectual Property
or Intellectual Property Rights for the Company have signed written agreements that are valid and enforceable, containing a confidentiality provision protecting the Company’s confidential information and assigning to the Company his or her
Intellectual Property Rights developed within the scope of his or her employment or engagement (as applicable) with the Company. 
 (r)
Other than IP Contracts with third parties set forth in Part 2.12(c) and Part 2.12(d) of the Company Disclosure Schedule and agreements with the Company’s customers entered into in the ordinary course of business, the Company is
not bound by any agreement to indemnify any other person or entity for intellectual property infringement, misappropriation, or similar claims. 
 (s) Neither the execution, delivery, or performance of this Agreement (or any of the Related Agreements) nor the consummation by the Company of any of the transactions contemplated by this Agreement (or any of the Related Agreements) will,
with or without notice or lapse of time, directly or indirectly result in (i) a loss of, or encumbrance or restriction on any Intellectual Property or Intellectual Property Rights owned by or used by the Company that are material to the conduct
of its business as presently being conducted, (ii) a breach of any In-License, (iii) the grant, assignment, or transfer to any third party of any license or other right or interest under, to, or in any of the Company Intellectual Property.

 2.13 Contracts. 
 (a)
Except as set forth in Part 2.13(a) of the Company Disclosure Schedule, the Company is not a party to nor is it bound by any written or oral: 
 (i) Contract with any present or former shareholder, partner, member other equity holder, director, officer, employee or consultant or for the employment of, performance of services by or payment of commissions to any
Person, including any consultant; 
 (ii) Contract with any labor union or other representative of employees; 
  

 20 

 EXECUTION COPY 
  

 (iii) Contract relating to the acquisition, transfer, use, development, sharing or license of any
Company Intellectual Property other than (A) licenses of Intellectual Property in connection with the sales of Company Products or services in the ordinary course of business consistent with past practice, (B) end user software licenses
that are generally available on standard terms for less than US$5,000; and (C) contracts relating to technology and proprietary assets immaterial to the Company’s business as presently conducted; 
 (iv) Contract relating to any material acquisition, issuance or transfer of any securities (other than issuances of Company securities in connection
with connection with the Company’s share option scheme and employee equity arrangements); 
 (v) Contract for the purchase of, or
payment for, supplies, products or services (A) from a Related Party or (B) involving (1) in any one case, US$25,000 or more or (2) in the aggregate, US$50,000 or more; 
 (vi) Contract to sell or supply products or to perform services, (A) to or for a Related Party or (B) involving (1) in any one case,
US$25,000 or more or (2) in the aggregate, US$50,000 or more; 
 (vii) Contract creating or involving any agency relationship,
distribution arrangement or franchise relationship; 
 (viii) Contract relating to the lease of or license to enter any Real Property;

 (ix) Contract relating to the lease of any equipment used by the Company; 
 (x) note, debenture, bond, conditional sale agreement, equipment trust agreement, loan agreement or other contract or commitment for the borrowing or
lending of money (including, without limitation, loans to or from present or former shareholders, partners, members, other equity holders, officers, directors, employees or any member of their immediate families); 
 (xi) Contract relating to the creation of an Encumbrance (other than a Permitted Encumbrance) with respect to any asset of the Company or involving or
incorporating any indemnity or surety arrangement, guaranty, security agreement, pledge, performance or completion bond or pursuant to which the Company otherwise undertakes the indebtedness of any other Person; 
 (xii) Contract creating or relating to any partnership or joint venture or any sharing of revenues, profits, losses, costs or liabilities; 

(xiii) Contract involving Tax sharing; 
 (xiv) Contract relating to a charitable or political contribution; 
  

 21 

 EXECUTION COPY 
  

 (xv) Contract for any individual capital expenditure in excess of US$25,000, or US$50,000 in the
aggregate; 
 (xvi) Contract imposing any restriction on the Company’s right or ability (A) to compete with any other Person,
(B) to acquire any product or other assets or any services from any other Person, to sell any amount of product or other assets to, or perform any services for any other Person, or (C) to develop or distribute any technology, nor, to the
Knowledge of the Company, is any officer or employee of the Company subject to any such Contract, other than with the Company; 
 (xvii)
Contract not made in the ordinary course of business; or 
 (xviii) Contract not otherwise listed in Part 2.13(a) of the Company
Disclosure Schedule that (A) continues over a period of more than twelve (12) months from the date hereof, (B) exceeds US$25,000 in value and (C) may not be terminated by the Company (without penalty) within 30 days after the
delivery of a termination notice by the Company. 
 Contracts in the respective categories described in clauses (i) through
(xviii) of this Section 2.13 are referred to in this Agreement as “Material Contracts”. 
 (b) The Company
has provided Purchaser with true, correct and complete copies of all written Material Contracts. Part 2.13(b) of the Company Disclosure Schedule provides an accurate description of the terms of each Material Contract that is not in written
form. Each Material Contract is valid and in full force and effect and is enforceable in accordance with its terms. 
 (c) Except as set
forth in Part 2.13(c) of the Company Disclosure Schedule: 
 (i) The Company has not violated or breached, or committed any
default under, any provision of any Material Contract, and, to the Knowledge of the Company, no other Person has violated or breached, or committed any default under, any provision of any Material Contract; 
 (ii) No event has occurred, and no circumstance or condition exists, that (with or without notice or lapse of time) will, or could reasonably be
expected to, (A) result in a violation or breach of any provision of any Material Contract, (B) give any Person the right to declare a default or exercise any remedy under any Material Contract, (C) give any Person the right to
accelerate the maturity or performance of any Material Contract, or (D) give any Person the right to cancel, terminate or modify any Material Contract; 
 (iii) The Company has not received any notice or other communication regarding any actual or possible violation or breach of, or default under, any Material Contract that has not been resolved; and 
 (iv) The Company has not waived any of its rights under any Material Contract. 
  

 22 

 EXECUTION COPY 
  

 (d) No Person is renegotiating, or has a right (absent any default or breach of a Material Contract)
pursuant to the terms of any Material Contract to renegotiate, any amount paid or payable to the Company under any Material Contract or any other material term or provision of any Material Contract. 
 (e) The Company Contracts collectively constitute all of the Contracts necessary to enable the Company to conduct its business substantially in the
manner in which its business is being conducted as of the date hereof and as of immediately prior to the Closing. 
 (f) Except as disclosed
in Part 2.13(f) of the Company Disclosure Schedule, with respect to each Material Contract, the Material Contract will continue to be valid, binding, enforceable, and in full force and effect on identical terms immediately following the
consummation of the transactions contemplated by this Agreement and the Related Agreements, and the consummation of the transactions contemplated hereby and thereby shall not result in any payment or payments becoming due from the Company to any
Person or give any Person the right to terminate or alter the provisions of such Material Contract. The consummation of the transactions described herein will not affect any of the Material Contracts in a manner that could reasonably be expected to
result in a Company Material Adverse Effect. 
 2.14 Customers; Accounts Payable. 
 (a) Part 2.14(a) of the Company Disclosure Schedule identifies each Person that has committed (whether oral or written and whether pursuant to an
agreement or purchase order or otherwise) to purchase products or services with a dollar value of US$25,000 or more from the Company, and sets forth for each such Person the quantities or amounts of such products or services that such Person has
committed to purchase (the “Purchase Commitments”) and whether such commitment is oral or written. The Company has provided to Purchaser true and complete copies of all documents evidencing such Purchase Commitments. All such
Purchase Commitments are in full force and effect, have not been withdrawn, amended, modified or terminated and, if accepted and performed by the Company prior to any such withdrawal, amendment, modification or termination, are enforceable by the
Company and, upon consummation of the Transactions, will be enforceable by Purchaser, against the other party to such Purchase Commitments. No fact, condition or circumstance exists that would give any party the right to withdraw, amend, modify or
terminate any Purchase Commitment and no Person has given any notice to the Company, and the Company has no knowledge, that any Person intends to withdraw, amend, modify or terminate any Purchase Commitment. 
 (b) Part 2.14(b) of the Company Disclosure Schedule provides an accurate and complete breakdown and aging of the Company’s accounts payable
as of the Balance Sheet Date. Part 2.14(b) of the Company Disclosure Schedule accurately identifies, and provides an accurate and complete breakdown of the amounts paid to, each supplier or other Person (other than Employees) that received
more than $50,000 from the Company during 2006, 2007 or 2008. 
 2.15 Liabilities. Except (i) as not required in accordance with
GAAP to be reflected or reserved against in the Company Financial Statements, (ii) as and to the extent reflected or reserved against in the Company Financial Statements (including the notes thereto), (iii) as set forth in
Part 2.15 of the Company Disclosure Schedule or (iv) as incurred in the 

  

 23 

 EXECUTION COPY 
  

 
ordinary course of business since the Balance Sheet Date, the Company does not have any material direct or indirect debts, liabilities, claims, losses,
damages, deficiencies, costs, expenses or obligations (whether absolute, accrued, known or unknown, contingent or otherwise) of any nature whatsoever (including, without limitation, obligations under capital leases or any unfunded obligations as
required for funding on an ongoing basis under any Plan or arrangement or any uninsured liabilities resulting from failure to comply with any applicable Legal Requirement). The Company does not have any off-balance sheet liabilities. 
 2.16 Compliance with Legal Requirements; Governmental Authorizations. 
 (a) The Company is, and has at all times been, in material compliance with all applicable Legal Requirements. The Company has not received any notice or
other communication from any Governmental Body regarding any actual or possible violation of, or failure to comply with, any material Legal Requirement. To the Knowledge of the Company, no Governmental Body has proposed or is considering any Legal
Requirement that, if adopted or otherwise put into effect, would reasonably be expected to have an adverse effect on the Company’s business, condition, assets, liabilities, operations, financial performance, net income or prospects. 

(b) Part 2.16(b) of the Company Disclosure Schedule identifies each Governmental Authorization held by the Company and the Company has
delivered to Purchaser accurate and complete copies of all Governmental Authorizations identified in Part 2.16(b) of the Company Disclosure Schedule. The Governmental Authorizations identified in Part 2.16(b) of the Company
Disclosure Schedule are valid and in full force and effect, collectively constitute all Governmental Authorizations necessary to enable the Company to conduct its business in the manner in which its business is currently being conducted and will
continue in full force and effect immediately following the Closing. The Company is in substantial compliance with the terms and requirements of the respective Governmental Authorizations identified in Part 2.16(b) of the Company
Disclosure Schedule. The Company has not received any notice or other communication from any Governmental Body regarding (i) any actual or possible violation of or failure to comply with any material term or requirement of any Governmental
Authorization or (ii) any actual or possible revocation, withdrawal, suspension, cancellation, termination or modification of any material Governmental Authorization. 
 2.17 Tax Matters. 
 (a)
General. 
 (i) All notices, returns (including any land transaction returns), reports, accounts, computations, statements,
assessments and registrations and any other necessary information submitted by the Company to any Taxation Authority for the purpose of Taxation have been made on a proper basis, were submitted within applicable time limits, were accurate and
complete in all material respects when supplied and remain, to the Knowledge of the Company, accurate and complete in all material respects. None of the above is, or, to the Knowledge of the Company, is likely to be, the subject of any material
dispute with any Taxation Authority. 
  

 24 

 EXECUTION COPY 
  

 (ii) All Taxation (whether of the UK or elsewhere), for which the Company has been liable or is
liable to account for, has been duly paid (insofar as such Taxation ought to have been paid) and the Company will not become liable to pay any Taxation as a result of any event occurring before Closing or income profits or gains arising to or earned
by the Company before Closing. 
 (iii) The Company has, within applicable time limits, maintained all records in relation to Taxation as
they are required by law to maintain. 
 (iv) The Company has complied within applicable time limits with all notices served on them and any
other requirements lawfully made of them by any Taxation Authority. 
 (v) The Company has not made any payments representing installments
of corporation tax pursuant to the Corporation Tax (Installment Payments) Regulations 1998 in respect of any current or preceding accounting periods and is not under any obligation to do so. 
 (vi) The Company has not paid, within the past seven years ending on the Agreement Date, any penalty, fine, surcharge or interest charged by virtue of
the TMA 1970 or any other Tax Statute. 
 (vii) All Taxation and national insurance deductible and payable under the Pay-As-You-Earn system
and/or any other Taxation Statute has, so far as is required to be deducted, been deducted from all payments made (or treated as made) by the Company. All amounts due to be paid to the relevant Taxation Authority prior to the date of this Agreement
have been so paid, including without limitation all Tax chargeable on benefits provided for directors, employees or former employees of the Company or any persons required to be treated as such. 
 (viii) Proper records have been maintained in respect of all such deductions and payments, and all applicable regulations have been complied with.

 (ix) The Company is not involved in any dispute with any Taxation Authority and has not, within the past 12 months, been subject to any
visit, audit, investigation, discovery or access order by any Taxation Authority. The Company is not aware of any circumstances existing which make it likely that a non-routine visit, audit, investigation, discovery or access order will be made in
the next 12 months. 
 (x) The Company Disclosure Schedule contains details of any concession, agreement or other formal or informal
arrangement (that is, an arrangement which is not based on a strict interpretation of all relevant Taxation Statutes, published extra-statutory concessions and published statements of practice) with any Taxation Authority. 
 (xi) The Company Disclosure Schedule contains details of all transactions, schemes or arrangements in respect of which the Company has been a party or
has otherwise been involved for which a statutory clearance application was made. The Company Disclosure Schedule also contains copies of all relevant applications for clearances and copies of 

  

 25 

 EXECUTION COPY 
  

 
all clearances obtained in connection with such transactions, schemes or arrangements. All such clearances have been obtained on the basis of full and
accurate disclosure of all material facts and considerations relating thereto. All such transactions, schemes or arrangements have been implemented strictly in accordance with the terms of such clearances. 
 (xii) The Company is not, or will not become, liable to make to any Person (including any Taxation Authority) any payment in respect of any liability to
Taxation which is primarily or directly chargeable against, or attributable to, any other Person (other than the Company). 
 (xiii) The
Company Financial Statements make full provision or reserve within GAAP for any period ended on or before the date to which they were drawn up for all Taxation assessed or liable to be assessed on the Company, or for which the Company is accountable
at that date, whether or not the Company has (or may have) any right of reimbursement against any other person. Proper provision has been made and shown in the Company Financial Statements for deferred taxation in accordance with GAAP. 

(b) Chargeable Gains. The book value shown in, or adopted for the purposes of, the Company Financial Statements as the aggregate value of the
assets of the Company, on the disposal of which a chargeable gain or allowable loss could arise, does not exceed the amount which on a disposal of the assets at the date of this Agreement would be deductible, in each case, disregarding any statutory
right to claim any allowance or relief other than amounts deductible under Section 38 of TCGA 1992. 
 (c) Capital Allowances.

 (i) If the assets of the Company were disposed of at the Closing Date for their book value as shown in, or adopted for the purpose of, the
Company Financial Statements, or for the value of consideration actually given for them on their acquisition (if such assets were acquired since the Balance Sheet Date), no balancing charge under CAA 2001 would be made on the Company. 
 (d) Distributions and Other Payments. 
 (i) No distribution or deemed distribution, within the meaning of Sections 209, 210 or 211 of ICTA 1988, has been made (or will be deemed to have been made) by the Company, except dividends shown in the Company Audited Financial Statements,
and the Company is not bound to make any such distribution. 
 (ii) No rents, interest, annual payments or other sums of an income nature,
paid or payable by the Company or which the Company is under an existing obligation to pay in the future, are or will be wholly or partially disallowable as deductions, management expenses or charges in computing taxable profits for Taxation
purposes. 
 (iii) The Company has not, within the period of seven years preceding the Closing Date, been engaged in, or been a party to,
any of the transactions set out in Sections 213 to 218 (inclusive) of ICTA 1988, nor has it made or received a chargeable payment as defined in Section 218(1) of ICTA 1988. 
  

 26 

 EXECUTION COPY 
  

 (e) Loan Relationships. 
 (i) All interests, discounts and premiums payable by the Company in respect of its loan relationships (within the meaning of Section 81 of the
Finance Act 1996) are eligible to be brought into account by the Company as a debit for the purposes of Chapter II of Part IV of the Finance Act 1996 at the time, and to the extent that such debits are recognized in the statutory accounts of the
Company. 
 (ii) The Company is not a party to a debtor relationship (within the meaning of Section 103 of the Finance Act 1996) to
which paragraph 2 of Schedule 9 to the Finance Act 1996 applies or may apply. 
 (iii) The Company is not a party to a loan relationship
made other than on arm’s length terms. There are no circumstances in which paragraphs 11 and 11A of Schedule 9 to the Finance Act 1996 could apply to require an adjustment of debits and/or credits brought into account by the Company.

 (iv) The Company has not been a party to a loan relationship which had an unallowable purpose (within the meaning of paragraph 13 of
Schedule 9 to the Finance Act 1996). 
 (f) Close Companies. The Company is not, nor has it ever been a close company within the
meaning of Sections 414 and 415 of ICTA 1988. 
 (g) Intangible Assets. For the purposes of this paragraph (g), references to
intangible fixed assets means intangible fixed assets and goodwill within the meaning of Schedule 29 to the Finance Act 2002 to which that Schedule applies. References to an intangible fixed asset shall be
construed accordingly. 
 (i) Part 2.17(g)(i) of the Company Disclosure Schedule sets out the amount of expenditure on each of the
intangible fixed assets of the Company and provides the basis on which any debit relating to that expenditure has been taken into account in the Company Financial Statements. 
 (ii) No claims or elections have been made by the Company under Part 7 of, or paragraph 86 of Schedule 29 to, the Finance Act 2002 in respect of any
intangible fixed asset of the Company. 
 (iii) Since the Balance Sheet Date: 
 (1) the Company has not owned an asset which has ceased to be a chargeable intangible asset in the circumstances described in paragraph 108 of Schedule
29 to the Finance Act 2002; 
 (2) the Company has not realized or acquired an intangible fixed asset for the purposes of Schedule 29 to the
Finance Act 2002; and 
  

 27 

 EXECUTION COPY 
  

 (3) no circumstances have arisen which have required, or will require, a credit to be brought into
account by the Company on a revaluation of an intangible fixed asset. 
 (h) Company Residence, Treasury Consents and Overseas
Interests. 
 (i) The Company has, throughout the past seven years, been resident in the UK for corporation tax purposes and has not, to
the Knowledge of the Company, at any time in the past seven years, been treated as resident in any other jurisdiction for the purposes of any double taxation arrangements having effect under Section 249 of the Finance Act 1994, Section 788
of ICTA 1988 or for any other tax purpose. 
 (ii) The Company has not caused, permitted or entered into any of the transactions specified
in Section 765 of ICTA 1988 (migration of companies) without the prior written consent of HM Treasury, or without having duly provided the required information to HM Revenue & Customs (as appropriate). 
 (iii) The Company does not hold shares in a company which is not resident in the UK and which would be a close company if it were resident in the UK in
circumstances such that a chargeable gain accruing to the company not resident in the UK could be apportioned to the Company pursuant to Section 13 of TCGA 1992. 
 (iv) The Company is not holding, or has not held in the past seven years, any interest in a controlled foreign company within Section 747 of ICTA 1988. The Company does not have any material interest in an
offshore fund as defined in Section 759 of ICTA 1988. 
 (v) The Company has not had, nor within the last seven years has it had, a
permanent establishment outside the UK. 
 (vi) The Company is not an agent or permanent establishment of another company, Person, business
or enterprise for the purpose of assessing the company, Person, business or enterprise to Taxation in the country of residence of the Company. 
 (i) Anti-Avoidance. All transactions or arrangements made by the Company have been made on fully arm’s length terms. There are no circumstances in which Section 770A of, or Schedule 28AA to, ICTA 1988 or any other rule or
provision could apply allowing any Taxation Authority to make an adjustment to the terms on which such transaction or arrangement is treated as being made for Taxation purposes, and no notice or enquiry has been made by any Taxation Authority in
connection with any such transactions or arrangements. 
 (j) Inheritance Tax. 
 (i) The Company has not: 
 (1) made any
transfer of value within Sections 94 and 202 of IHTA 1984; or 
  

 28 

 EXECUTION COPY 
  

 (2) received any value such that liability might arise under Section 199 of IHTA 1984; or

 (3) been a party to associated operations in relation to a transfer of value as defined by Section 268 of IHTA 1984. 
 (ii) There is no unsatisfied liability to inheritance tax attached to, or attributable to, the Shares or any asset of the Company. None of them are
subject to any HM Revenue & Customs charge as mentioned in Section 237 and 238 of IHTA 1984. 
 (iii) No asset owned by the
Company, nor the Shares, are liable to be subject to any sale, mortgage or charge by virtue of Section 212(1) of IHTA 1984. 
 (k)
Value Added Tax. 
 (i) The Company is a taxable Person and is registered for the purposes of VAT. The Company is not, nor has it been
in the period of six years ending with the Closing Date, a member of a group of companies for VAT purposes. 
 (ii) The Company is
registered, for the purposes of VAT, with monthly prescribed accounting periods. Such registration, as is referred to this Section 2.17(k)(ii) is not subject to any conditions imposed by or agreed with HM Revenue & Customs. The Company
is not (nor are there any circumstances by virtue of which it may become) under a duty to make monthly payments on account under the Value Added Tax (Payments on Account) Order 1993. The Company has complied with all statutory provisions, rules,
regulations, orders and directions in respect of VAT. 
 (iii) All supplies made by the Company are taxable supplies. The Company has not
been, nor, to the Company’s Knowledge, will it be, denied full credit for all input tax paid or suffered by it. All VAT paid or payable by the Company is input tax as defined in Section 24 of the VATA 1994 and regulations made under it.

 (iv) No act or transaction has been effected in consequence of which the Company is liable for any VAT arising from supplies made by
another company. No direction has been given by HM Revenue & Customs under Schedule 9A to the VATA 1994 as a result of which the Company would be treated for the purposes of VAT as a member of a group. 
 (v) The Company does not own, or has at any time within the period of ten years preceding the date of this Agreement owned, any assets which are capital
items subject to the capital goods scheme under Part XV of the VAT Regulations 1995. 
 (vi) The Company has not made any claim for any bad
debt relief under Section 36 of the VATA 1994. 
  

 29 

 EXECUTION COPY 
  

 (l) Stamp Duty, Stamp Duty Land Tax and Stamp Duty Reserve Tax. 
 (i) Any document that is necessary in proving the title of the Company to any asset which is owned by the Company at the Closing Date, and each document
which the Company may wish to enforce or produce in evidence is, so far as required by law, duly stamped for stamp duty purposes. No such documents which are outside the UK would attract stamp duty if they were brought into the UK. 
 (ii) Neither entering into this Agreement nor Closing will result in the withdrawal of any stamp duty or stamp duty land tax relief granted on or before
Closing Date which will affect the Company. 
 (iii) The Company Disclosure Schedule sets out full and accurate details of any chargeable
interest (as defined under Section 48 of the Finance Act 2003) acquired or held by the Company before the Closing Date in respect of which the Company is aware, or ought reasonably to be aware, that an additional land transaction return will be
required to be filed with a Taxation Authority and/or a payment of stamp duty land tax made on or after the Closing Date. 
 (iv) The
Company has complied in all material respects with the provisions of Part IV of Finance Act 1986 (Stamp Duty Reserve Tax) and any regulations made under such legislation. 
 (m) Tax Sharing. The Company is not bound by or party to any Taxation indemnity, Taxation sharing or any Taxation allocation agreement in respect
of which claims against the Company would not be time barred. 
 (n) Capital Losses. No capital loss has accrued to the Company that
is a loss within the meaning of Section 8 or 16A of the Taxation of Capital Gain Act 1992. 
 (o) Exclusions. The Tax Warranties
shall not apply to the extent that in respect of any liability to Taxation of the Company: 
 (i) a provision or reserve in respect thereof
is made in the Accounts; or 
 (ii) it would not have arisen but for a change after Closing in the accounting bases upon which the Company
values its assets (other than a change made in order to comply with GAAP or any applicable Tax Statute); or 
 (iii) the Purchaser is
compensated for any such matter under any other provision of this Agreement; or 
 (iv) it would not have arisen but for a voluntary act or
transaction carried out by Purchaser or the Company after Closing being an act which: 
 (1) is not in the ordinary course of business; or

 (2) could reasonably have been avoided; or 
 (3) the Company was not legally committed to do under a commitment that existed on or before Closing; or 
  

 30 

 EXECUTION COPY 
  

 (v) such liability arises or is increased as a result of a change in the law or published
administrative or revenue practice or interpretation announced and coming into force on or after Closing or any subsequent increase in the rates of Taxation in force at today’s date; or 
 (vi) such liability arises or is increased as a result of a failure or omission of the Company or Purchaser to make any claim, election, surrender or
disclaimer or give any notice or consent after Closing the making, giving, or doing of which was taken into account or assumed in the provision or reserve for Tax or deferred Tax in the Accounts; or 
 (vii) such liability arises or is increased as a result of the winding up or a change after Closing in the nature or conduct of a trade carried on by
the Company before Closing or a reduction or cessation of trade after Closing; or 
 (viii) such liability is stamp duty in respect of the
purchase of the Shares pursuant to this Agreement (except if and to the extent the Sellers’ portion of any such Taxes, as set forth in Section 6.10, was not offset in calculating the Aggregate Principal Amount of the Sellers
Promissory Notes on the Closing Date); or 
 (ix) such liability would not have arisen or been increased but for any claim, election,
surrender or disclaimer made or notice or consent made or given after Closing by Purchaser or the Company other than any claim, election, surrender, disclaimer, notice or consent assumed to have been made, given or done in computing the amount of
any allowance, provision or reserve in the Accounts. 
 2.18 Benefit Plans; Employees and Agents. 
 (a) Part 2.18(a) of the Company Disclosure Schedule identifies each employee benefit plan and all salary, bonus, deferred compensation,
incentive scheme, stock purchase, stock option, restricted stock, severance pay, termination pay, hospitalization, medical, life or other insurance, supplemental unemployment benefits, welfare, profit-sharing, pension or retirement plan, program or
agreement (whether qualified or non-qualified, currently effective or terminated, written or unwritten) (collectively, the “Plans”) currently sponsored, maintained, contributed to or required to be contributed to by the Company for
the benefit of any current or former employee, director or consultant of the Company (collectively, “Employee”). 
 (b)
Since the Balance Sheet Date, no material changes have been made or promised to the terms of employment, benefits or conditions of service of any Employee or to benefits provided to any person engaged to any extent in the Company’s business
(now or in the past) or any dependants of such person or to the terms of any agreement or arrangement (whether written or unwritten and whether binding or not) with any trade union, employee representative or body of employees or their
representatives. 
 (c) No person is employed or engaged in the Company’s business (whether temporarily or permanently and whether
under a contract of service or contract for services) other than the Employees, and the Employees are all employed by the Company and work wholly or mainly in the Company’s business. 
  

 31 

 EXECUTION COPY 
  

 (d) The Company has disclosed full and accurate particulars of the current terms of employment or
engagement and benefits of all Employees whether or not recorded in writing, or implied by custom or practice or otherwise; and details of all remuneration and benefits which the Employees or their dependants receive or are entitled to receive (now
or in the future). 
 (e) In respect of each of the Employees, the Company has: materially performed all obligations and duties required to
be performed by it, whether arising under contract, statute, at common law or in equity; maintained adequate, suitable and up to date records relating to the Employees; and paid to HM Revenue & Customs and any other appropriate authority
all taxes, National Insurance contributions and other levies due in respect of the Employees on account of their employment by the Company up to and including the Closing Date. 
 (f) With the exception of the Enterprise Management Incentive Scheme adopted by the Board on 23 October 2001 (the “EMI Scheme”),
the Company has established no employee share or other incentive plans or arrangements, and nothing has been done to undermine the tax-favored status of the EMI Scheme. 
 (g) All contracts of service or for services with any of the Employees or agents of the Company are terminable by the Company at any time on three months’ notice or less without compensation (other than for
unfair dismissal or a statutory redundancy payment). The Company has no liability other than for salary, wages, commission or pension to or for the benefit of any person who is an Employee or agent of the Company. 
 (h) There are no terms under which the Employees are employed and, to the Knowledge of the Company, no event has occurred and no condition or
circumstance exists that could give rise to any claim for unlawful discrimination or unequal pay. 
 (i) No Employee: has given or received
notice to terminate employment or engagement and, to the Knowledge of the Company, no Employee is entitled or intends or is likely to terminate such employment or engagement as a result of the parties entering into this Agreement or the consummation
of the transactions contemplated by this Agreement; has been off sick for a period of 21 working days or more in any six-month period within the three years ending on the date of this Agreement (whether or not consecutive), or is receiving or is due
to receive payment under any sickness or disability or permanent health insurance scheme and, so far as the Company is aware, there are no such claims pending or threatened; is on secondment, maternity or other statutory leave or otherwise absent
from work other than on normal annual leave or continuous sickness or incapacity absence of less than 21 working days; or is subject to a current disciplinary warning or procedure. 
 (j) The Company is not a party to any arrangements or promise to make or in the habit of making ex gratia or voluntary payments on redundancies or
payments by way of bonus, pension, allowance or similar payments to any such persons. 
  

 32 

 EXECUTION COPY 
  

 (k) There are no schemes or arrangements (whether legally enforceable or not) for payment of
pension, disability, or death benefit or similar schemes or arrangements in operation or contemplated in respect of any of the Employees or their dependants, or persons formerly employed or engaged in the Company’s business or their dependants,
under which the Purchaser or any of the owners for the time being of the Company’s business or the assets or any part of them may become liable to make payments or to provide equivalent benefits. 
 (l) The Company is not engaged or involved in any dispute, claim or legal proceedings (whether arising under contract, common law, statute or in equity)
with any of the Employees or any other person currently or previously employed by or engaged in the Company’s business or their dependants and, so far as the Company is aware, there is no event which could give rise to such dispute, claim or
proceeding. 
 (m) The Company has not recognized any trade union or any other organization of employees or their representatives in respect
of any of the Employees.
 2.19 Environmental Matters. 
 (a) The Company is in compliance in all material respects with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required
under applicable Environmental Laws and compliance with the terms and conditions thereof. All material Governmental Authorizations currently held by the Company pursuant to Environmental Laws are identified in Part 2.19(a) of the Company
Disclosure Schedule. All applications required to have been filed by the Company for the renewal or transfer of the Governmental Authorizations identified or required to be identified in Part 2.19(a) of the Company Disclosure Schedule
have been duly filed on a timely basis with the appropriate Governmental Bodies, and each other notice or filing required to have been given or made with respect to such Governmental Authorizations has been duly given or made on a timely basis with
the appropriate Governmental Body. 
 (b) The Company has not received, at any time, any notice or other communication (in writing), whether
from a Governmental Body, citizens group, Employee or otherwise, (i) that alleges that it is not in compliance with any Environmental Law, (ii) regarding any actual, alleged, possible or potential obligation on the part of the Company to
undertake, or to bear all or any portion of the cost of, any investigation, cleanup or remedial, corrective or response action of any nature arising as a result of a breach of Environmental Law, (iii) that alleges environmental claims, damages,
penalties or losses, including bodily injury and property damage claims. 
 (c) Part 2.19(c) of the Company Disclosure Schedule sets
forth a list of all documents (whether in hard copy or electronic form) that contain any environmental reports, investigations and audits relating to premises currently or previously owned or operated by the Company (whether conducted by or on
behalf of the Company or a third party, and whether done at the initiative of the Company or directed by a Governmental Body or other third party) which were issued or conducted during the past five years and which the Company has possession of or
access to. A complete and accurate copy of each such document has been provided to the Purchaser. 
  

 33 

 EXECUTION COPY 
  

 (d) To the Knowledge of the Company, no Materials of Environmental Concern have been used,
manufactured, generated, sold, handled, treated, transported, stored or disposed by the Company, in breach of applicable Environmental Laws. 
 (e) To the Knowledge of the Company no Materials of Environmental Concern are present at or have been released on or at any property owned, leased or controlled by the Company in quantities that will trigger an environmental claim by a
Governmental Authority or third party, and to the knowledge of the Company no underground storage tanks, above-ground storage tanks, asbestos-containing materials, landfills or disposal areas are present on any such property. 
 2.20 Insurance. 
 (a)
Part 2.20(a) of the Company Disclosure Schedule identifies all insurance contracts or policies maintained by, at the expense of or for the benefit of the Company, including the name of the insurer and the types and amounts of coverage
(collectively, the “Policies”), and the Company has delivered to Purchaser accurate and complete copies of the Policies identified or required to be identified on Part 2.20(a) of the Company Disclosure Schedule. All the
Policies are in full force and effect, all premiums with respect thereto covering all periods up to the Closing Date have been paid or accrued, and the Company has not received any notice or other communication regarding any actual or possible
(i) cancellation, invalidation or termination of any Policy or (ii) material adjustment in the amount of premiums payable with respect to any Policy. The coverage provided by the Policies complies with (i) applicable Legal
Requirements and (ii) the requirements that the Company maintain insurance under all Material Contracts. The Company has not breached or otherwise failed to perform in any material respect its obligations under any of the Policies nor has the
Company received any adverse notice from any of the insurers party to the Policies with respect to any alleged breach or failure in connection with any of the Policies which remains outstanding at Closing. Since January 1, 2006, the Company has
not been refused any insurance with respect to its assets or operations, nor has coverage ever been limited by any insurance carrier to which the Company has applied for any Policy or with which the Company has carried a Policy. The Company is, and
has at all times been, in compliance with all surety bond requirements of Governmental Authorizations held by the Company or otherwise set forth in applicable Legal Requirements or Contracts. 
 (b) Set forth in Part 2.20(b) of the Company Disclosure Schedule is a list of all claims which have been made by the Company since
January 1, 2005 under any worker’s compensation, general liability, property or other insurance policy applicable to the Company or any of its properties. Such claim information includes the following information with respect to each
accident, loss or other event: (i) the identity of the claimant; (ii) the date of the occurrence; (iii) the status as of the date hereof and (iv) the amounts paid or recovered to date. Except as set forth in
Part 2.20(b) of the Company Disclosure Schedule, there are no pending or, to the Knowledge of the Company, threatened claims under any insurance policy, and the Company has not received any notice or other communication regarding any
actual or possible rejection of any pending claim under any insurance policy. 
  

 34 

 EXECUTION COPY 
  

 2.21 Related Party Transactions. 
 (a) No Related Party has, and no Related Party has had at any time since January 1, 2005, any direct or indirect interest in any material asset used
in or otherwise relating to the business of the Company; 
 (b) no Related Party is, or has been at any time since January 1, 2005,
indebted to the Company; 
 (c) since January 1, 2005, no Related Party has entered into, or has had any direct or indirect financial
interest in, any Material Contract, transaction or business dealing involving the Company; 
 (d) to the Knowledge of the Company, no
Related Party is competing, or has competed at any time since January 1, 2006, directly or indirectly, with the Company; and 
 (e) no
Related Party has any claim or right against the Company (other than rights to receive compensation for services performed as an Employee). 
 2.22 Legal Proceedings; Orders. 
 (a) Except as set forth in Part 2.22(a) of the Company Disclosure Schedule,
there is (i) no pending Legal Proceeding, and to the Knowledge of the Company, no Person has threatened to commence any Legal Proceeding (A) against, affecting or which involves the Company or any of the assets owned by the Company, any
Person whose liability the Company has or may have retained or assumed, either contractually or by operation of law or any of the directors, officers, employees or equity holders of the Company with respect to their activities as such, any Plan or
the assets of any Plan; or (B) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Transactions or (ii) to the Knowledge of the Company, no pending or threatened Legal
Proceeding against, affecting or which involves any assets used or controlled by the Company. To the Knowledge of the Company, no event has occurred and no claim or dispute exists that will, or that would reasonably be expected to, give rise to or
serve as a basis for the commencement of any such Legal Proceeding. 
 (b) Except as set forth in Part 2.22(a) of the Company
Disclosure Schedule, no Legal Proceeding has ever been commenced by or has ever been pending against the Company that has not been fully adjudicated or settled prior to the date of this Agreement without liability to the Company that is likely to be
incurred after the date of this Agreement. The Company has delivered to Purchaser accurate and complete copies of all pleadings, correspondence and other written materials to which the Company has access and that relate to any Legal Proceeding
identified in the Company Disclosure Schedule. 
 (c) There is no Order to which the Company, or any of the assets owned or used by it, is
subject. To the Knowledge of the Company, no officer or other employee of the Company is subject to any Order that prohibits such officer or other employee from engaging in or continuing any conduct, activity or practice relating to the
Company’s business. To the Knowledge of the Company, there is no proposed Order that, if issued or otherwise put into 

  

 35 

 EXECUTION COPY 
  

 
effect, (i) could have a Company Material Adverse Effect or an adverse effect on the ability of the Company or any of its Representatives or
shareholders to comply with or perform any covenant or obligation under any of the Related Agreements or (ii) could have the effect of preventing, delaying, making illegal or otherwise interfering with the Transactions. 
 2.23 Company and Shareholder Action. 
 (a) The Board (at a meeting duly called and held in accordance with the Company Constituent Documents) has (i) unanimously determined that the Transactions are advisable and in the best interests of the Company and its members,
(ii) unanimously approved and adopted the Transactions and this Agreement, (iii) unanimously recommended the adoption and approval of the Transactions and this Agreement by the members of the Company and (iv) directed that this
Agreement be submitted for a vote by the members of the Company. The Company has provided Purchaser with a certified copy of the Board resolutions adopting and approving the Transactions and this Agreement. 
 (b) This Agreement and the Transactions were approved and ratified by the affirmative vote of members of the Company holding at least 75% of the Company
Ordinary Shares issued and outstanding on the date of such vote (which such vote was taken in compliance with all notice and other requirements contained in the Company Constituent Documents). The affirmative vote of members of the Company holding
50% of the Company Ordinary Shares issued and outstanding on the date of such vote was the only vote of the members of the Company needed to approve the Transactions and the principal terms of this Agreement. The Company has provided Purchaser with
a certified copy of the resolutions of the members of the Company approving the Transactions and this Agreement. 
 2.24 Finder’s
Fee; Transaction Costs. Other than as set forth in Part 2.24 of the Company Disclosure Schedule, no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the
Transactions based upon arrangements made by or on behalf of the Company or any of the Sellers. All Transaction Costs which were not paid by the Company at or prior to the Closing Date have been taken into account in calculating the Aggregate
Principal Amount of the Sellers Promissory Notes. 
 2.25 Certain Payments. Neither the Company, nor, to the Company’s Knowledge,
any Representative or other Person associated with or acting for or on behalf of the Company, has at any time, directly or indirectly: 
 (a) used any corporate funds (i) to make any unlawful political contribution or gift or for any other unlawful purpose relating to any political activity, (ii) to make any unlawful payment to any governmental official or employee
or (iii) to establish or maintain any unlawful or unrecorded fund or account of any nature; 
 (b) made any false or fictitious entry,
or failed to make any entry that should have been made, in any of the books of account or other records of the Company; 
 (c) made any
payoff, influence payment, bribe, rebate, kickback or unlawful payment to any Person; 
  

 36 

 EXECUTION COPY 
  

 (d) performed any favor or used corporate funds in giving any gift which was not deductible for
federal income tax purposes; 
 (e) made any payment (whether or not lawful) to any Person, or provided (whether lawfully or unlawfully) any
favor or anything of value (whether in the form of property or services, or in any other form) to any Person, for the purpose of obtaining or paying for (i) favorable treatment in securing business, or (ii) any other special concession; or

 (f) agreed, committed, offered or attempted to take any of the actions described in clauses (a) through (e) of this
Section 2.25. 
 2.26 Full Disclosure. To the Knowledge of the Company, this Agreement and the Company Disclosure Schedule
do not (a) contain any warranty or information that is false or misleading with respect to any material fact or (b) omit to state any material fact necessary in order to make the warranties and information contained herein and therein, in
light of the circumstances under which such warranties and information were or will be made or provided, not false or misleading. 
 ARTICLE 3. 
 WARRANTIES OF THE SELLING SHAREHOLDERS 
 Each Selling Shareholder, severally (but not jointly) warrants on its own behalf only, as of the date of this Agreement and as of the Closing Date, to
and for the benefit of the Purchaser, as follows: 
 3.1 Organization; Standing and Power. If a Selling Shareholder is an Entity, such
Selling Shareholder is duly organized (or incorporated as the case may be), validly existing and in good standing under the laws of the jurisdiction of its incorporation, has all necessary power and authority to enter into and perform its
obligations under this Agreement. Such Selling Shareholder is not organized or incorporated in or a resident or citizen of the United States or Singapore. 
 3.2 Authority; Binding Nature of Agreement. Such Selling Shareholder has all requisite corporate or other power and authority and the capacity to execute and deliver (or procure the delivery of) this
Agreement and any Related Agreement to which it is a party, to consummate the transactions contemplated hereby and thereby and to take all other actions required to be taken by it pursuant to the provisions hereof and thereof. The execution,
delivery and performance of this Agreement and any Related Agreement to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary corporate or other action on the part of
the Selling Shareholder, and no other corporate or other action on the part of the Selling Shareholder is necessary to authorize the execution, delivery and performance by the Selling Shareholder of this Agreement and any Related Agreement to which
the Selling Shareholder is a party and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Selling Shareholder. This Agreement and any Related Agreement to which the Selling
Shareholder is a party constitutes (assuming due and valid authorization, execution and 

  

 37 

 EXECUTION COPY 
  

 
delivery hereof and thereof by the other parties hereto and thereto, if any) the valid and binding obligation of the Selling Shareholder, enforceable against
the Selling Shareholder in accordance with their respective terms, except as such enforcement may be limited by any bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or similar laws affecting creditors’ rights and
remedies generally and by general principles of equity, regardless of whether enforcement is sought in a proceeding at law or in equity. 
 3.3 Ownership and Transfer of the Shares. Each Selling Shareholder is, in respect of the Shares as set forth opposite such Selling Shareholder’s name on Part 2.3(a) of the Company Disclosure Schedule, (a) the legal
and beneficial owner of those shares with full authority to transfer the legal and beneficial interest in the Shares or (b) the beneficial owner of those Shares and has the power to procure the transfer of those Shares by the legal owner, in
each case, free and clear of any and all Encumbrances. The Selling Shareholder has the power, authority and capacity to sell, transfer, assign and deliver (or to procure such sale, transfer, assignment and delivery of) such Shares as provided in
this Agreement, and such delivery will convey to Purchaser good and marketable title to such Shares, free and clear of any and all Encumbrances. 
 3.4 Non-Contravention; Consents. The execution, delivery and performance of this Agreement and the Related Agreements and the consummation of the transactions contemplated hereby and thereby do not, directly or indirectly (with or
without notice or lapse of time): 
 (a) contravene, conflict with or result in a violation of any of the terms, conditions or provisions of
the organizational documents of such Selling Shareholder if such Selling Shareholder is an Entity; or 
 (b) contravene, conflict with or
result in a material violation of any Legal Requirement or any Order, writ, injunction, judgment or decree to which such Selling Shareholder or any of the assets owned, used or controlled by such Selling Shareholder (including the Shares held by
such Selling Shareholder) is subject. 
 (c) Other than in connection with the Selling Shareholders’ exercise of the Drag-Along Right,
the Selling Shareholder is not required to obtain the Consent of, make any filing with or provide any notification to, any Person or Governmental Body in connection with the execution and delivery by such Selling Shareholder of this Agreement, the
performance by such Selling Shareholder of its covenants and agreements under this Agreement and the consummation by such Selling Shareholder of the transactions contemplated hereby. 
 3.5 No Other Agreements. Such Selling Shareholder does not have any legal obligation, absolute or contingent, to any other Person to sell or
otherwise transfer the Shares held by such Selling Shareholder (other than pursuant to this Agreement). Such Selling Shareholder is not subject to any voting agreement with respect to a change of control of the Company or a right of first refusal
related to the Shares held by such Selling Shareholder. 
  

 38 

 EXECUTION COPY 
  

 3.6 Litigation. There is no action, claim, suit, proceeding or investigation pending or, to
Selling Shareholder’s Knowledge, threatened against or affecting the Selling Shareholder or the Shares held by such Selling Shareholder, in each case before any court or Governmental Body, that would reasonably be expected to affect the ability
of the Selling Shareholder to sell and transfer the Selling Shareholder’s Shares or otherwise to consummate the transactions contemplated by this Agreement at the Closing. 
 3.7 Finder’s Fees. Except as set forth on the Schedule of Company Transaction Costs, no broker, finder, or investment banker is entitled to
any brokerage, finder’s or other fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Selling Shareholder. 
 ARTICLE 4. 
 WARRANTIES OF PURCHASER AND PARENT 
 Purchaser and Parent, jointly and severally, warrant to the Company and each of the Sellers, as of the date of this Agreement and as of the Closing Date,
as follows: 
 4.1 Corporate Existence and Power. Purchaser is a private company limited by shares duly organized and validly existing
under the laws of Singapore. Parent is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. Each of Purchaser and Parent has all necessary power and authority to carry on its business in the
manner in which its business is currently being conducted and is duly qualified to do business and is in good standing in each jurisdiction in which the conduct of its business or the ownership or leasing of its properties requires such
qualification, except where the failure to be so qualified would not have a material adverse effect on Purchaser’s or Parent’s ability to complete the Transactions. 
 4.2 Authority; Binding Nature of Agreement. Each of Purchaser and Parent has all right, power and authority to execute and deliver this Agreement
and any Related Agreements to which it is a party, to consummate the transactions contemplated hereby and thereby and to take all other actions required to be taken by it pursuant to the provisions hereof and thereof. The execution, delivery and
performance by each of Purchaser and Parent of this Agreement and each Related Agreement to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of
Purchaser and Parent, as applicable, and no other action on the part of Purchaser or Parent is necessary to authorize the execution, delivery and performance by Purchaser or Parent of this Agreement or any Related Agreement to which it is a party
and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by each of Purchaser and Parent. This Agreement constitutes and, upon execution and delivery thereof by Purchaser and Parent,
each Related Agreement to which either or both or them is a party will constitute (assuming due and valid authorization, execution and delivery hereof and thereof by the other parties hereto and thereto, if any) the legal, valid and binding
obligation of Purchaser and/or Parent, as applicable, enforceable against Purchaser and/or Parent, as applicable, in accordance with its terms, except as such enforcement may be limited by any bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or similar laws affecting creditors’ rights and remedies generally and by general principles of equity, regardless of whether enforcement is sought in a proceeding at law or in equity. 
  

 39 

 EXECUTION COPY 
  

 4.3 Non-Contravention; Consents. The execution, delivery and performance by Purchaser and
Parent of this Agreement and of each Related Agreement to which either is a party or both of them are parties and the consummation of the transactions contemplated hereby and thereby by Purchaser and Parent do not, directly or indirectly (without
notice or lapse of time): 
 (a) contravene, conflict with or result in a violation of any of the terms, conditions or provisions of their
respective organizational documents; 
 (b) contravene, conflict with or result in a violation of any Order, writ, injunction, judgment or
decree to which Purchaser or any of the assets owned, used or controlled by Purchaser or Parent is subject or, to the Knowledge of Purchaser and/or Parent, as applicable, give any Governmental Body or other Person the right to challenge any of the
transactions contemplated by this Agreement or any of the Related Agreements or to exercise any remedy or obtain any relief under, any Legal Requirement; or 
 (c) contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any material Contract to which Purchaser or Parent or any of the assets owned, used or controlled by
them is subject, or give any Person the right to (i) declare a default or exercise any remedy under any such Contract, (ii) accelerate the maturity or performance of any such Contract or (iii) cancel, terminate or modify any such
Contract, in each case solely to the extent that such contravention, violation or breach would reasonably be expected to prevent, enjoin, alter or delay the transactions contemplated by this Agreement or any of the Related Agreements. 
 4.4 Compliance with Legal Requirements. Purchaser and Parent each has complied with all applicable Legal Requirements and Orders in connection
with the execution, delivery and performance of this Agreement and any Related Agreements to which it is a party and the consummation of the transactions contemplated hereby and thereby. No filing with, notice to or consent from any Person (other
than the parties hereto) is required in connection with the execution, delivery or performance of this Agreement or any of the Related Agreements by Purchaser and Parent or either of them or the consummation of the transactions contemplated hereby
and thereby by Purchaser and Parent or either of them. 
 ARTICLE 5. 
 PARENT GUARANTEE OF PURCHASER OBLIGATIONS 
 5.1 Guarantee of Purchaser
Obligations. Purchaser is a direct subsidiary of Parent, and Parent acknowledges that it will derive substantial benefit from the Transactions. As consideration for the Selling Shareholders entering into this Agreement and the Related Agreements
and for the Selling Shareholders consummation of the Transactions, Parent irrevocably and unconditionally guarantees the due and punctual payment as, when and if due, of all sums payable under (a) the Sellers Promissory Notes, on the terms and
subject to the conditions set forth in Section 1.6 hereof and such Sellers Promissory Notes, and (b) the Contingent Consideration Note, on the terms and subject to the conditions set forth in Section 1.7 hereof and such
Contingent Consideration Note, and the performance of Purchaser’s obligations pursuant to this Agreement (collectively, the “Guaranteed Obligations”); provided, that the 

  

 40 

 EXECUTION COPY 
  

 
holders of the Sellers Promissory Notes and the Contingent Consideration Note to whose benefit the guarantee pursuant to this Article 5 inures (each,
a “Guaranteed Party”) shall be required first to demand payment of the Guaranteed Obligations from the Purchaser, and only if the Guaranteed Obligations are not satisfied by the Purchaser within ten (10) Business Days shall the
Guaranteed Party demand payment of or assert a claim against Parent under this Article 5. The guarantee set forth in this Article 5 may only be enforced on the terms set forth herein and nothing set forth in this Article 5 shall
confer or give or shall be construed to confer or give to any Person other than the Guaranteed Parties any rights or remedies against any Person other than the rights of the Guaranteed Parties against Parent as expressly set forth herein. For the
avoidance of doubt, the Shareholders’ Representative shall be the sole party authorized, on behalf of the Sellers, to enforce the guarantee set forth in this Article 5 with respect to the Remaining Shareholder Promissory Note and the
Contingent Consideration Note. Notwithstanding anything to the contrary contained in this Agreement, (y) to the extent the Purchaser is relieved of all or any portion of the Guaranteed Obligations (i) pursuant to the terms of this
Agreement, the Sellers Promissory Notes or the Contingent Consideration Note, (ii) by the satisfaction thereof, or (iii) in connection with any agreement between the Purchaser or Parent, on the one hand, and a Guaranteed Party, on the
other hand, or (z) in the event the Purchaser or any Affiliate of the Purchaser shall incur any Damages for which it is entitled to recovery under this Agreement, then the Guaranteed Obligations shall be reduced by an amount equal to the amount
of any such reduction or claim. 
 ARTICLE 6. 
 COVENANTS OF THE PARTIES 
 6.1 Access to Information. 
 (a) During the period from the Agreement Date until the earlier to occur of (i) the Closing Date or (ii) the termination of this Agreement
pursuant to Article 8 (the “Pre-Closing Period”), subject to compliance with applicable Legal Requirements (including antitrust, anti-competition and similar fair trade laws), the Company shall, and shall cause its
Representatives to, provide Purchaser and Purchaser’s Representatives with (i) reasonable access during normal business hours to personnel and assets and to all existing books, records, Tax Returns, contracts, work papers and other
documents and information relating to the Company; and (ii) copies of such existing books, records, Tax Returns, work papers and other documents and information relating to the Company, and with such additional financial, operating and other
data and information regarding the Company, as Purchaser may reasonably request. 
 (b) No information or knowledge obtained in any
investigation in accordance with this Section 6.1 or otherwise shall affect or be deemed to modify any warranty contained herein, the conditions to the obligations of the parties hereto to consummate the transactions contemplated by this
Agreement or any party’s rights hereunder (including rights under Article 9). 
  

 41 

 EXECUTION COPY 
  

 6.2 Operation of the Company’s Business. 
 (a) During the Pre-Closing Period, the Company shall: (i) conduct its business and operations (A) in the ordinary course and in accordance with
past practices, and (B) in compliance with all applicable Legal Requirements and the requirements of all Company Contracts; (ii) use reasonable efforts to maintain and preserve intact its current business organization, keep available the
services of its current officers and employees and maintain its business relations with all suppliers, customers, landlords, creditors, licensors, licensees, employees and other Persons having business relationships with the Company;
(iii) provide all notices, assurances and support required by any Contract relating to any Intellectual Property in order to ensure that no condition under such Contract occurs which could result in, or could increase the likelihood of, any
transfer or disclosure by the Company of any Intellectual Property; (iv) keep in full force and effect (with the same scope and limits of coverage) all insurance policies in effect as of the Agreement Date covering material assets of the
Company; and (v) take no action that would adversely affect or materially delay the ability of the parties to obtain any necessary approvals of any Governmental Body required for the Transactions or to perform its covenants and agreements under
this Agreement or to complete the Transactions. 
 (b) During the Pre-Closing Period, except as set forth in Part 6.2(b) of the
Company Disclosure Schedule, the Company shall not (without the prior written consent of Purchaser): 
 (i)        (A) declare, accrue, set aside or pay any dividends on, or make any other distributions (whether in cash, stock or property) in respect of, any of its share capital or other equity or
voting interests; (B) split, combine or reclassify any of its share capital or other equity or voting interests, or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for any of its share
capital or other equity or voting interests, (C) purchase, redeem or otherwise acquire any of its share capital, equity interests or any other securities of any Entity or any options, warrants, calls or rights to acquire any such shares, equity
interests or other securities (including any options or shares of restricted stock except pursuant to forfeiture conditions of such restricted stock), or (D) take any action that would result in any change of any term (including any conversion
price thereof) of any debt security of the Company; 
 (ii) issue or sell any additional share capital of the Company or securities
convertible into or exercisable for such share capital, or issue or grant any options, warrants, calls, subscription rights or other rights of any kind to acquire additional share capital of the Company; 
 (iii) amend or permit the adoption of any amendment to the Company Constituent Documents, or effect, become a party to or authorize any
recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction; 
 (iv) except as required by
applicable Legal Requirements, adopt or enter into any collective bargaining agreement or other labor union Contract applicable to the employees; 
 (v) adopt a plan of complete or partial liquidation or dissolution or resolutions providing for or authorizing such a liquidation or a dissolution; 
  

 42 

 EXECUTION COPY 
  

 (vi) form any Subsidiary or acquire any equity interest or other interest in any other Entity;

 (vii) make any capital expenditure outside the ordinary course of business consistent with past practices or make any single capital
expenditure in excess of US$10,000; provided, however, that the maximum amount of all capital expenditures made on behalf of the Company during the Pre-Closing Period shall not exceed US$25,000 in the aggregate; 
 (viii) enter into or become bound by, or permit any of the assets owned or used by it to become bound by, any Contract which, if entered into prior to
the date of this Agreement, would have been a Material Contract, or amend or terminate, or waive or exercise any material right or remedy under, any Material Contract; 
 (ix) acquire, lease or license any right or other asset from any other Person or sell or otherwise dispose of, or lease or encumber, any right or other asset to any other Person (except in each case for assets
acquired, leased, licensed, encumbered or disposed of by the Company in the ordinary course of business consistent with past practices and not having a value, or not requiring payments to be made or received, in excess of US$10,000 individually, or
US$25,000 in the aggregate), or waive or relinquish any material right; 
 (x) repurchase, prepay or incur any indebtedness or guarantee any
indebtedness of another Person, guarantee any debt securities of another Person, enter into any “keep well” or other agreement to maintain any financial statement condition of another Person or enter into any arrangement having the
economic effect of any of the foregoing; 
 (xi) make any loans, advances or capital contributions to, or investments in, any other Person,
except for customary travel advances to employees; 
 (xii) increase in any manner the compensation or benefits of, or pay any bonus to, any
employee, officer, director or independent contractor of the Company, except for increases, or bonuses made, in the ordinary course of business consistent with past practices for any employee or independent contractor of the Company (other than
executive officers or members of the boards of directors of the Company) that were communicated to such employee or independent contractor prior to the Agreement Date; 
 (xiii) except as required to comply with applicable Legal Requirements or a Company Employee Plan in effect on the Agreement Date, (A) pay to any employee, officer, director or independent contractor of the
Company any benefit not provided for under any Company Employee Plan in effect on the Agreement Date, (B) grant any awards under any Company Employee Plan (including the grant of options, stock appreciation rights, stock based or stock related
awards, performance units or restricted stock or the removal of existing restrictions in any Company Employee Plan or awards made thereunder), (C) take any action to fund or in any other way secure the payment of compensation or benefits under
any Company Employee Plan, (D) take any action to accelerate the vesting or payment of any compensation or benefit under any Company Employee Plan, (E) adopt, enter into or amend any employment agreement other than offer letters entered
into with new employees in the ordinary course of 

  

 43 

 EXECUTION COPY 
  

 
business consistent with past practices that provide, except as required by applicable Legal Requirements, for “at will employment” with no
severance benefits, or (F) make any material determination under any Company Employee Plan that is inconsistent with the ordinary course of business consistent with past practices; 
 (xiv) hire any new employee, dismiss any employee, promote any employee, or engage any independent contractor whose relationship may not be terminated
by the Company on thirty (30) days’ notice or less; 
 (xv) except as required by GAAP or applicable Legal Requirements, change
its fiscal year, revalue any of its material assets or make any changes in financial or Tax accounting methods, principles or practices; 
 (xvi)      (A) fail to accrue a reserve in its books and records and financial statements in accordance with past practices for Taxes payable by the Company, (B) settle or compromise any Legal
Proceeding relating to any material Tax, or (C) revoke any material Tax election; 
 (xvii)    (A) pay,
discharge, settle or satisfy any material claims, liabilities or obligations (whether absolute, accrued, asserted or unasserted, contingent or otherwise), other than the payment, discharge, settlement or satisfaction in the ordinary course of
business consistent with past practices or as required by their terms as in effect on the Agreement Date of claims, liabilities or obligations (i) reflected or reserved against in the Unaudited Interim Financial Statements (or the notes
thereto), (ii) incurred since the date of such financial statements in the ordinary course of business consistent with past practices or (iii) Transaction Costs or (B) commence any Legal Proceeding; provided, that prior to the
Closing the Company shall pay, discharge, settle or satisfy those liabilities reflected on Part 1.6(a) of the Company Disclosure Schedule to the extent possible in order to deliver the Company on a zero-cash basis at the Closing; 

(xviii) enter into any material transaction or take any other material action outside the ordinary course of business and inconsistent with past
practices; 
 (xix) enter into any new line of business that is material to the Company or change its operating policies that are material
to the Company, except as required by applicable Legal Requirements, regulations or policies imposed by any Governmental Body; 
 (xx)
transfer or license to any Person any Intellectual Property other than non-exclusive licenses of Intellectual Property granted in connection with sales of Company Products or services to customers in the ordinary course of business consistent with
past practice; 
 (xxi) enter into any operating lease requiring lease payments in excess of US$10,000; or 
 (xxii) acquire or agree to acquire by merging or consolidating with, or by purchasing the assets of, or by any other manner, any business or any
company, partnership, association or other business organization or division thereof, or otherwise acquire or agree to acquire any assets which are material, individually or in the aggregate, to the Company. 
  

 44 

 EXECUTION COPY 
  

 6.3 No Solicitation. 
 (a) During the Pre-Closing Period, the Company and the Selling Shareholders each shall not, directly or indirectly, through any officer, director,
employee, representative or agent of the Company or such Selling Shareholder or otherwise, (i) solicit, initiate, or encourage any inquiries or proposals that constitute, or would reasonably be expected to lead to, a proposal or offer for an
Acquisition Transaction involving the Company other than the Transactions (any of the foregoing inquiries or proposals an “Acquisition Proposal”); (ii) engage or participate in negotiations or discussions concerning, or provide
any non-public information to any Person or entity relating to, any Acquisition Proposal; or (iii) agree to, enter into, accept, approve or recommend any Acquisition Proposal. The Company and each of the Selling Shareholders have terminated any
pending discussions or negotiations relating to an Acquisition Proposal and each warrants that the Company and such Selling Shareholder, as applicable, had the legal right to terminate such discussions without payment of any fee or other penalty.

 (b) The Company shall notify Purchaser immediately (and no later than 48 hours) after receipt by the Company or a Selling
Shareholder (or their respective advisors) of any Acquisition Proposal or any request for nonpublic information in connection with an Acquisition Proposal or for access to the properties, books or records of the Company by any Person or entity that
informs the Company that it intends to make, or has made, an Acquisition Proposal. Such notice shall be made in writing and shall indicate in reasonable detail the identity of the offeror and the material terms and conditions of such proposal,
inquiry or contact. 
 6.4 Termination of Company Rights. The Company shall cause all options, warrants or other rights to purchase
share capital of the Company to be cancelled and terminated prior to the Closing in compliance with the underlying instrument or plan, all other applicable Company Contracts, the Company Constituent Documents, and all applicable Legal Requirements
and without liability to the Company, the Purchaser or any of their respective Affiliates after the Closing. The Company shall provide the Purchaser with a reasonable and timely opportunity to review and comment on any documentation or
correspondence related to the termination and cancellation of Company Rights. Purchaser’s review and approval of such documentation shall not alter its right to recover for Damages suffered by it under Article 9 of this Agreement or any
of the warranties of the Company or the Selling Shareholders set forth in this Agreement. 
 6.5 Exercise of Drag-Along Right. Within
one (1) Business Day following the date of this Agreement (the “Notice Date”), the Selling Shareholders shall exercise their Drag-Along Right, and the Company shall send a notice to each of the Remaining Shareholders notifying
them of such exercise, in each case, in accordance with Sections 7.5 through 7.8 of the Company’s New Articles of Association. In the event that any Remaining Shareholder does not comply with the terms of the notice sent by the Company and
agree to sell his, her or its Shares (such shares, the “Defaulting Shares”) to the Purchaser pursuant to the terms of this Agreement, the Board shall authorize some person to execute and deliver to the Purchaser, on behalf of each
holder of Defaulting Shares, the necessary Stock Transfer Form on the terms set forth in the Company’s Articles of Association. 
  

 45 

 EXECUTION COPY 
  

 6.6 Third Party Notices. On or before the Notice Date, the Company shall send a notice to
Noble Venture Finance I Limited (“NVF I”) and Noble Venture Finance II Limited (“NVF II”), pursuant to that certain Facility Agreement, dated August 8, 2005, between the Company and NVF I and that certain
Facility Agreement, dated May 30, 2008, between the Company and NVF II, respectively, regarding the conditionality of the Transactions, in each case in accordance with the terms of the applicable agreement and in such form as may be reasonably
acceptable to the Purchaser. 
 6.7 Notification of Certain Matters; Updated Company Disclosure Schedule. During the Pre-Closing
Period, each of the Purchaser, the Company and the Selling Shareholders agree to give prompt notice to each other, of (i) the occurrence or non-occurrence of any event the occurrence or non-occurrence of which could reasonably be expected to
cause any of such party’s warranties contained in this Agreement to be untrue or inaccurate in all material respects after the date hereof and (ii) any failure on its part to comply with or satisfy in all material respects any covenant,
condition, or agreement to be complied with or satisfied by it hereunder. The Company also shall be entitled to deliver at Closing an updated version of the Company Disclosure Schedule setting forth any matter described in clause (i) of the
preceding sentence. It is expressly understood that the delivery of any notice or of an updated version of the Company Disclosure Schedule pursuant to this Section 6.7 shall not limit or otherwise affect the remedies available hereunder
to the party receiving such notice or such updated version of the Company Disclosure Schedule, and such notice or updated version of the Company Disclosure Schedule shall not be considered for purposes of determining whether the condition set forth
in Section 7.2(a)(i) has been satisfied or in determining whether any warranty has been breached or is inaccurate for purposes of Section 9.2(a)(i), and such determinations shall be made based solely on the Company Disclosure
Schedule delivered to Purchaser on the date of this Agreement. 
 6.8 Confidentiality. The parties acknowledge that the Company and
the Purchaser have previously executed a Confidentiality Agreement, dated May 17, 2008 (the “Confidentiality Agreement”), which Confidentiality Agreement is hereby incorporated herein by reference and shall continue in full
force and effect in accordance with its terms. 
 6.9 Public Disclosure. Unless otherwise permitted by this Agreement, the Company and
the Selling Shareholders shall consult with the Purchaser before issuing any press release or otherwise making any public statement or making any other public (or non-confidential) disclosure (whether or not in response to an inquiry) regarding the
terms of this Agreement and the Transactions, and neither the Company nor the Selling Shareholders shall issue any such press release or make any such statement or disclosure without the prior approval of the Purchaser (which approval shall not be
unreasonably withheld), except as may be required by law or by any regulatory or governmental body to which a party is subject, including the London Stock Exchange, the Takeover Panel or the UK Listing Authority. 
 6.10 Payment of Stamp Duty. The Sellers, on the one hand, and Purchaser, on the other hand, shall each pay 50% of the Stamp Duty payable on the
transfer of the Shares to Purchaser; provided, that the Sellers’ portion of such Stamp Duty shall be deducted in calculating the Aggregate Principal Amount of the Sellers Promissory Notes on the Closing Date. Purchaser shall file all
necessary documentation and Tax Returns with respect to payment of such Stamp Duty. 
  

 46 

 EXECUTION COPY 
  

 6.11 Corporation Tax Returns 
 (a) The Company shall prepare the Company’s corporation tax returns for the periods ended on or prior to Closing and deal with all matters and
correspondence relating thereto. All such returns shall be submitted in draft form to the Shareholders’ Representative or his duly authorised agent for comments. The Shareholders’ Representative shall comment within a reasonable period of
time of such submission and the Company shall adopt any reasonable comments and include them in the return(s). 
 (b) The Company shall
liaise with the Shareholders’ Representative in the event of an enquiry which may be raised in respect of the said returns, and reflect the Shareholders’ Representative’s reasonable comments in any correspondence, negotiations or
other contact with the Taxation Authority in respect of such enquiry. 
 6.12 Minority Shareholder SPA. During the Pre-Closing Period,
the Company shall use all reasonable endeavors to ensure that each Remaining Shareholder duly execute and deliver the Minority Shareholder SPA prior to the Closing. 
 ARTICLE 7. 
 CLOSING CONDITIONS 
 7.1 Conditions to Obligation of Each Party to Effect the Transactions. The respective obligations of each party to effect the transactions
contemplated by this Agreement shall be subject to the satisfaction at or prior to the Closing Date that, there is no temporary restraining order, preliminary or permanent injunction, or other order issued by any court of competent jurisdiction or
other legal restraint or prohibition preventing the consummation of the Sale contemplated hereby in effect, and no litigation by any Governmental Body seeking any of the foregoing shall have been commenced and be pending. There shall not be any
action taken, or any statute, rule, regulation, or order enacted, entered, enforced, or deemed applicable to the Transactions that makes the consummation of the Transactions illegal. 
 7.2 Additional Conditions to Obligations of Purchaser. The obligations of Purchaser to effect the Transactions are also subject to the following
conditions: 
 (a) Warranties of the Company; Performance of Obligations. 
 (i) Each of the warranties of the Company set forth herein shall be true, correct and complete in all material respects (except for any such warranties
which are qualified by their terms by a reference to materiality or Company Material Adverse Effect, which warranties as so qualified shall be true and correct in all respects) as of the date hereof and as of the Closing Date, with the same effect
as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case, as of such date); 
 (ii) each
of the terms, covenants, agreements and conditions set forth herein to be performed, complied with or satisfied by the Company on or prior to the Closing Date shall have been duly performed, complied with or satisfied in all material respects; and

  

 47 

 EXECUTION COPY 
  

 (iii) a certificate to the foregoing dated as of the Closing Date and signed by the Chief Executive
Officer of the Company shall have been delivered to Purchaser. 
 (b) Warranties of the Selling Shareholders; Performance of
Obligations. 
 (i) Each of the warranties of the Selling Shareholders set forth herein shall be true, correct and complete in all
material respects (except for any such warranties which are qualified by their terms by a reference to materiality, which warranties as so qualified shall be true and correct in all respects) as of the date hereof and as of the Closing Date, with
the same effect as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case as of such date); and 
 (ii) each of the terms, covenants, agreements and conditions set forth in this Agreement to be performed, complied with or satisfied by the Selling Shareholders on or prior to the Closing Date shall have been duly performed, complied with
or satisfied in all material respects. 
 (c) Officer’s Certificate. Purchaser shall have received a certificate, executed by
the Chief Executive Officer of the Company, which shall (i) certify to and attach a copy of the then-current Certificate of Incorporation of the Company, issued by the Registrar of Companies for England and Wales and certified by a director of
the Company, (ii) certify to and attach a copy of the resolutions of the Board and/or the members of the Company, as applicable, evidencing the adoption and approval of this Agreement and the Transactions, (iii) certify to and attach a
copy of the then-current Memorandum of Association of the Company, (iv) certify to and attach a copy of the then-current Articles of Association of the Company, and (v) attach a certificate of good standing issued by the Registrar of
Companies for England and Wales as of a date not more than five calendar days prior to the Closing Date. 
 (d) Claims Regarding Share
Ownership. There must not have been made or threatened by any Person (other than a Seller) any claim (other than claims that have been validly withdrawn or waived in writing with full and final release of the Company in respect of any liability
associated with such claim) asserting that such Person (i) is the holder or the beneficial owner of, or has the right to acquire or obtain beneficial ownership of, any stock of, or any other voting equity, or ownership interest in, the Company
or (ii) is entitled to all or any portion of the consideration payable for the Shares. 
 (e) Closing Documentation. Purchaser
shall have received (i) the Estimated Balance Sheet, (ii) the Estimated Closing Indebtedness, (iii) the Schedule of Company Transaction Costs and (iv) the Closing Certificate, and the assignment agreements referenced in
Section 1.5 shall remain in full force and effect. 
 (f) Shareholder List. The Company shall have delivered to Purchaser
for review a detailed spreadsheet, in such form as may be reasonably requested by the Purchaser, setting forth (i) the name and address of each Seller, as well as the number of Company Ordinary Shares held of record by each such Seller, as of
immediately prior to the Closing Date, (ii) the percentage of the Note Payment Amount and the Contingent Consideration to which each such Seller is entitled to pursuant to Article 1 of this Agreement and (iii) wire transfer
instructions or other means and address of payment for each Seller. 
  

 48 

 EXECUTION COPY 
  

 (g) Consents Obtained. All consents, waivers, approvals, authorizations, or orders required
to be obtained, and all filings required to be made, by the Company as set forth on Schedule 7.2(g) of the Company Disclosure Schedule for the authorization, execution, and delivery of this Agreement and the consummation by it of the
Transactions shall have been obtained and made by the Company or by the Selling Shareholders and shall be in full force and effect. 
 (h)
Material Adverse Effect. Since the date of this Agreement, there shall not have been a Company Material Adverse Effect, and no event shall have occurred that will, or could reasonably be expected to, have a Company Material Adverse Effect;

 (i) Retention of Key Employees. Each of the employees listed on Exhibit F shall have agreed to an amendment of their
respective existing employment agreements effective upon the Closing Date and shall not have indicated their intent to the Company to discontinue their employment with the Company following the Closing Date. 
 (j) Company Option Plan. The Company Option Plan shall have been terminated. 
 (k) Director and Officer Resignations. Purchaser shall have received a written resignation from each director and officer of the Company, in a
form reasonably acceptable to the Purchaser, effective as of the Closing Date. Each director of the Company shall have executed and delivered to the Purchaser the appropriate resignation forms to be filed with the Companies House in the UK.

 (l) Absence of Intellectual Property Claims. There shall not be pending or threatened any legal proceeding in which the scope,
validity or enforceability of any material Company Intellectual Property or material Intellectual Property Right has been contested or challenged or alleging infringement or misappropriation of any third party’s Intellectual Property Rights by
the Company. 
 (m) Termination of Engagement Letters. The Company shall have terminated that certain Engagement Letter, dated
December 4, 2007, between the Company and KBC Peel Hunt Ltd. (“KBC”), as amended by that certain Letter Agreement, dated July 18, 2008, between the Company and KBC, and that certain Engagement Letter, dated May 22,
2008, between the Company and the Financial Advisor, and received a payoff letter from each of KBC and the Financial Advisor in form and substance reasonably acceptable to Purchaser. 
 (n) Absence of Liabilities. The sum of the Company’s outstanding Indebtedness (other than Closing Indebtedness to be assigned to the
Purchaser at the Closing pursuant to Section 1.5 and real property lease obligations that are not past due), unpaid Transaction Costs and accounts payable and accrued expenses (other than those accounts payable and accrued expenses set
forth on Part 1.6(a) of the Company Disclosure Schedule, not to exceed £219,000), in each case, converted into U.S. dollars, if necessary, based upon the Agreed Rate, shall not exceed $250,000 in the aggregate. 
  

 49 

 EXECUTION COPY 
  

 (o) Termination of Company Rights. All options, warrants and other rights to purchase share
capital of the Company shall have been cancelled and terminated without liability to the Purchaser, the Company or any of their respective Affiliates following the Closing, and Purchaser shall have received a termination and release agreement
reasonably satisfactory to the Purchaser from (i) each Selling Shareholder holding a Company Right as of immediately prior to the Closing and (ii) each holder of a Company Right as of immediately prior to the Closing that does not
terminate automatically, in accordance with its terms, upon the Closing. 
 (p) Receipt Stock Transfer Forms. Purchaser shall have
received duly executed stock transfer forms, in such form as is reasonably satisfactory to the Purchaser, transferring ownership in the Shares to the Purchaser. 
 (q) Receipt of Legal Payoff Letters. Purchaser shall have received a payoff letter from each of Wilson Sonsini Goodrich & Rosati, P.C. and Burges Salmon in form and substance reasonably acceptable to
Purchaser. 
 (r) Execution of Minority Shareholder SPA. The Minority Shareholder SPA shall be duly executed by Remaining
Shareholders holding such number of Shares that when added to the Selling Shareholder Shares constitute at least 90% of the total Shares. 
 7.3 Additional Conditions to Obligation of the Selling Shareholders and the Company. The obligation of the Selling Shareholders and the Company to effect the Transactions is also subject to the following conditions: 
 (a) Warranties; Performance of Obligations. 
 (i) Each of the warranties of the Purchaser and Parent set forth herein shall be true, correct and complete in all material respects (except for any such warranties which are qualified by their terms by a reference to materiality, which
warranties as so qualified shall be true and correct in all respects) as of the date hereof and as of the Closing Date, with the same effect as if made at and as of such time (except to the extent expressly made as of an earlier date, in which case
as of such date); 
 (ii) each of the terms, covenants, agreements and conditions of this Agreement to be performed, complied with or
satisfied by the Purchaser or Parent on or prior to the Closing Date shall have been duly performed, complied with or satisfied; and 
 (iii) a certificate to the foregoing dated as of the Closing Date and signed by an officer of Parent shall have been delivered to the Company. 
 ARTICLE 8. 
 TERMINATION 
 8.1 Termination. This Agreement may be terminated at any time prior to the Closing Date: 
 (a) by the mutual written consent of Purchaser and the Shareholders’ Representative; 
  

 50 

 EXECUTION COPY 
  

 (b) by Purchaser, if Purchaser is not in material breach of any of its obligations under this
Agreement and there shall have been a material breach of any warranty, covenant or agreement by the Company or any of the Selling Shareholders set forth in this Agreement such that the conditions set forth in Section 7.2(a)(i),
Section 7.2(a)(ii), Section 7.2(b)(i) or Section 7.2(b)(ii) would not be satisfied on the date of such breach and such breach has not been cured within five (5) Business Days after written notice has been
provided to the Shareholders’ Representative; 
 (c) by the Shareholders’ Representative, if the Selling Shareholders or the
Company are not in material breach of any of their obligations under this Agreement and there shall have been a material breach of any warranty, covenant or agreement by Purchaser set forth in this Agreement such that the conditions set forth in
Section 7.3(a)(i) or Section 7.3(a)(ii) would not be satisfied on the date of such breach and such breach has not been cured within five (5) Business Days after written notice has been provided to Purchaser; or

 (d) by Purchaser or the Shareholders’ Representative if the Closing shall not have occurred by January 5, 2009;
provided, that the right to terminate this Agreement under this Section 8.1(d) shall not be available to any party if such party’s failure to fulfill any obligation under this Agreement has been the sole cause of, or solely
resulted in, the failure of the Closing to occur on or before such date; provided, further, that a party wishing to terminate pursuant to this Section 8.1(d) must provide the other parties hereto with two (2) Business
Days’ prior written notice of its intent to terminate this Agreement pursuant to this Section 8.1(d). 
 8.2 Procedure
and Effect of Termination. In the event of the termination of this Agreement pursuant to Section 8.1 hereof, written notice thereof shall forthwith be given to the other party to this Agreement and this Agreement shall terminate
without any further action by any of the parties hereto. If this Agreement is terminated as provided herein, no party hereto shall have any liability or further obligation to any other party to this Agreement resulting from such termination,
provided that each party hereto shall remain liable for any willful or intentional breaches of this Agreement that occurred prior to its termination. 
 ARTICLE 9. 
 RECOURSE FOR DAMAGES 
 9.1 Survival. All of the warranties (including those warranties set forth in Article 2, Article 3 and Article 4) and
covenants contained herein or in any instrument or document delivered or to be delivered pursuant to this Agreement, and the rights of the Sellers, the Company and the Purchaser to recover for damages incurred by them, as set forth in this
Article 9, shall survive the execution of this Agreement and the Closing Date notwithstanding any investigation heretofore or hereafter made by or on behalf of any party hereto or any Knowledge of facts determined or determinable by any party
hereto and shall continue until, and all claims with respect thereto shall be made on or prior to, the first anniversary of the date hereof, except for (a) the warranties set forth in (i) Section 2.3 (Capitalization) and
Section 3.3 (Ownership and 

  

 51 

 EXECUTION COPY 
  

 
Transfer of Shares), which shall survive indefinitely, (ii) Section 2.12 (Intellectual Property) and Section 2.17 (Tax Matters),
which shall survive until the second anniversary of the Closing Date; (b) warranties, covenants and other matters for which notice of a claim for recovery has been given in accordance with this Agreement as of the end of the applicable period
referred to above, in which event such warranties, covenants and other matters that serve as the basis for such claim shall survive until the final disposition of such claim; and (c) covenants to be performed after the Closing Date, which shall
survive until performed in accordance with their respective terms. 
 9.2 Recovery by Purchaser Parties. 
 (a) In the event a Purchaser Party directly or indirectly suffers or incurs or otherwise becomes subject to any Damages (regardless of whether such
Damages relate to any third-party claim) which arise from or as a result of or are, directly or indirectly, related to or in connection with: 
 (i) any inaccuracy in or breach of any warranty of the Company set forth in this Agreement (including in Article 2 of this Agreement) or contained in any Schedule or Exhibit to this Agreement or any certificate or instrument
delivered hereunder by the Company without regard to any “Company Material Adverse Effect,” materiality, or similar qualifications contained in such warranties; 
 (ii) any breach of any covenant or obligation of the Company contained in this Agreement; 
 (iii) any unpaid Transaction Costs, past due real property lease obligations as of the Closing Date, and other accounts payable or accrued liabilities
of the Company (excluding those accounts payable and accrued liabilities set forth on Part 1.6(a) of the Company Disclosure Schedule that in the aggregate do not exceed £219,000), without duplication, that were not deducted in
calculating the Aggregate Principal Amount of the Sellers Promissory Notes on the Closing Date; 
 (iv) any Closing Indebtedness (excluding
any capital lease payment obligations that are not past due) that remains outstanding after the Closing, other than any past due capital lease obligations that were deducted in calculating the Aggregate Principal Amount of the Sellers Promissory
Notes on the Closing Date; 
 (v) Company Rights which were not terminated or cancelled prior to the Closing; 
 (vi) any Taxes of the Company attributable to any period prior to the Closing that were not deducted in calculating the Aggregate Principal Amount of
the Sellers Promissory Notes on the Closing Date, and the Sellers’ portion of any transfer Taxes arising out of or in connection with the transactions effected pursuant to this Agreement (if and to the extent the Sellers’ portion of any
transfer Taxes, as set forth in Section 6.10, was not deducted in calculating the Aggregate Principal Amount of the Sellers Promissory Notes on the Closing Date); and 
  

 52 

 EXECUTION COPY 
  

 (vii) all demands, assessments, judgments, costs and reasonable legal and other expenses arising
from, or in connection with, any action, suit, proceeding or claim incident to any of the foregoing, 
 such Purchaser Party shall set off
the determined amount of such Damages, on a dollar for dollar basis, in the manner set forth in Section 9.4 (but subject always to the limitations set forth in Section 9.3). 
 (b) In the event a Purchaser Party directly or indirectly suffers or incurs or otherwise becomes subject to any Damages (regardless of whether such
Damages relate to any third-party claim) which arise from or as a result of or are, directly or indirectly, related to or in connection with: 
 (i) any inaccuracy in or breach of any warranty of a Selling Shareholder set forth in this Agreement (including in Article 3 of this Agreement) or contained in any Schedule or Exhibit to this Agreement or any certificate or
instrument delivered hereunder by such Selling Shareholder; and 
 (ii) any breach of any covenant or obligation of a Selling Shareholder
contained in this Agreement, 
 such Purchaser Party shall set off the determined amount of such Damages from such Selling Shareholder, on a
dollar for dollar basis, in the manner set forth in Section 9.4 (but subject always to the limitations set forth in Section 9.3). 
 9.3 Basket; Limitation on Liability. 
 (a) The Purchaser Parties shall not be entitled to set off for
Damages arising under Section 9.2(a)(i) or Section 9.2(b)(i) until the aggregate amount of all Damages suffered by the Purchaser Parties exceeds US$100,000 (the “Basket”), in which case the applicable parties
shall be entitled to recover for the aggregate amount of all Damages suffered in excess of the Basket. For the purpose of determining whether the aggregate amount of Damages suffered by the Purchaser Parties has exceeded the Basket, individual
claims shall only be considered if made pursuant to Section 9.5 and if totaling in amount at least US$2,500. From and after such time as the amount of the Basket has been exceeded, there shall be no such limitation on the size of
individual claims. For the avoidance of doubt, Damages suffered by the Purchaser Parties pursuant to Sections 9.2(a)(ii) through (vii) and Section 9.2(b)(ii) shall not be subject to the Basket or any limitation on the size of
individual claims, and the Purchaser Parties shall be entitled to recover for the aggregate amount of such Damages. 
 (b) Notwithstanding
anything contained in this Agreement to the contrary, (i) the maximum amount that the Purchaser Parties shall be entitled to set off in respect of Damages under this Agreement (including this Article 9), the Related Agreements and under
all other theories of liability, shall not exceed (A) in the case of any Damages which arise from or as a result of or are, directly or indirectly, related to or in connection with Section 9.2(a)(i) or Section 9.2(b)(i)
(excluding any inaccuracy in or breach of a warranty set forth in Section 2.12 (Intellectual Property) or Section 2.17 (Tax Matters)), an aggregate amount equal to the Recourse Amount and (B) in the case of any Damages
which arise from or as a result of or are, 

  

 53 

 EXECUTION COPY 
  

 
directly or indirectly, related to or in connection with any inaccuracy in or breach of a warranty set forth in Section 2.12 (Intellectual
Property) or Section 2.17 (Tax Matters), the aggregate of the total principal and accrued interest outstanding under the Seller Promissory Notes and any Contingent Consideration that becomes payable pursuant to Section 1.7 of
this Agreement, and (ii) any recovery of Damages to which the Purchaser Parties may be entitled under this Agreement, the Related Agreements and under any other theory of liability, shall be pursuant to this Article 9 and shall be
satisfied solely by recourse to the total principal and accrued interest outstanding under the Sellers Promissory Notes or the Contingent Consideration, as applicable, as provided in Section 9.4, pro rated between the Sellers in
accordance with their relative interests in the Sellers Promissory Notes and Contingent Consideration, except to the extent the Purchaser Parties’ right to recover arises pursuant to Section 9.2(b), in which case, such set off shall
be made solely from the principal and accrued interest outstanding under the Selling Shareholders Promissory Note held by the Selling Shareholder whose breach gave rise to such recovery or such Selling Shareholder’s proportional interest in any
Contingent Consideration, as applicable. For the avoidance of doubt, in no event shall a Seller be liable under this Agreement, any Related Agreement or any other theory of liability for any amount which exceeds such Seller’s interest in the
total principal and accrued interest outstanding under the Sellers Promissory Notes or the Contingent Consideration, if any; provided, that this Section 9.3(b) shall not limit the amount that the Purchaser Parties shall be
entitled to recover from a Selling Shareholder in respect of Damages under this Agreement or any Related Agreement for fraud by such Selling Shareholder, willful and intentional misconduct by such Selling Shareholder and willful and intentional
misrepresentation by such Selling Shareholder. 
 9.4 Offset Against Sellers Promissory Notes and Contingent Consideration. In the
event a Purchaser Party shall suffer any Damages for which such Purchaser Party is entitled to recovery under this Article 9, such Purchaser Party shall set off an amount equal to such Damages first by offsetting an amount equal to the
aggregate amount of such Damages (converted into U.S. dollars as set forth below, if necessary) against the total principal and accrued interest outstanding under the Sellers Promissory Notes, and second from any Contingent Consideration that
becomes payable pursuant to Section 1.7(d). A Purchaser Party shall not be entitled to set off more than once for the same Damages, and, for the avoidance of doubt, a Purchaser Party shall not be entitled to set off pursuant to this
Article 9 for those amounts already deducted in calculating the Aggregate Principal Amount of the Sellers Promissory Notes on the Closing Date pursuant to Section 1.6(a). To the extent the Purchaser Party’s right to recover
pursuant to this Article 9 arises pursuant to Section 9.2(a), any such offset shall be from each Seller, in the same proportion as such Seller’s proportionate interest in the principal and accrued interest outstanding under
the Sellers Promissory Notes or the Contingent Consideration, as applicable. To the extent the Purchaser Party’s right to recover arises pursuant to Section 9.2(b), any such offset shall be made solely from the principal and accrued
interest outstanding under the Selling Shareholder Promissory Note held by the Selling Shareholder whose breach gave rise to such recovery or such Selling Shareholder’s proportional interest in any Contingent Consideration, as applicable.
Damages to be offset against the outstanding balances under the Sellers Promissory Notes or any Contingent Consideration pursuant to Section 1.6(b), Section 1.7(d) and/or this Section 9.4 shall be converted into
U.S. dollars, if necessary, based on the average of the daily average Interbank currency exchange rates for British pounds sterling being converted into U.S. dollars at the close of business on each of the five Business Days prior to (a) the
date the amount of such Damages was finally determined 

  

 54 

 EXECUTION COPY 
  

 
pursuant to this Agreement or (b) if such Damages relate to a pending claim for recovery of Damages and have not been finally determined pursuant to
this Agreement, the date on which final payment under the Sellers Promissory Notes is due or the relevant Installment Due Date, as applicable, in each case as reported in the Wall Street Journal. 
 9.5 Procedure for Recovery of Damages. 
 (a) If a Purchaser Party has or claims to have incurred or suffered Damages for which it is or may be entitled to recovery under this Agreement, Parent or the Purchaser, on behalf of such Purchaser Party, or such Purchaser Party shall
promptly deliver a written claim notice (a “Claim Notice”) to the Shareholders’ Representative. Each Claim Notice shall state (i) that such Purchaser Party believes that there is or has been a breach of a warranty or
covenant contained in this Agreement or that such Purchaser Party is otherwise entitled to recovery of Damages pursuant to this Article 9, (ii) a reasonably detailed description of the circumstances supporting the basis for such
Purchaser Party’s belief that there is or has been such a breach or the basis for which such Purchaser Party is so entitled to recovery of Damages under this Article 9, and (iii) the estimated amount of Damages such Purchaser Party
claims to have so incurred or suffered (the “Claimed Amount”). The Shareholders’ Representative shall be the sole party authorized, on behalf of the Sellers, to dispute, adjudicate, negotiate and enter into settlements and
compromises of claims made pursuant to this Section 9.5. 
 (b) Within thirty (30) days after receipt by the
Shareholders’ Representative of a Claim Notice, the Shareholders’ Representative may deliver to Purchaser a written response (the “Response Notice”) in which the Shareholders’ Representative: (i) agrees that an
amount equal to the full Claimed Amount may be offset against the outstanding balance under the Sellers Promissory Notes, pursuant to Section 1.6(b) and Section 9.4 of this Agreement, or any Contingent Consideration payable,
in accordance with Section 1.7(d) and Section 9.4 of this Agreement, as applicable; (ii) agrees that an amount equal to part, but not all, of the Claimed Amount (the “Agreed Amount”) may be offset
against the outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable; or (iii) indicates that no offset may be made from the outstanding balance under the Sellers Promissory Notes or any
Contingent Consideration payable, as applicable. Any part of the Claimed Amount that is not agreed to be offset pursuant to the Response Notice shall be the “Contested Amount.” If a Response Notice is not received by the Purchaser
within such 30-day period, then the Shareholders’ Representative shall be conclusively deemed to have agreed that an amount equal to the full Claimed Amount may be offset against the outstanding balance under the Sellers Promissory Notes or any
Contingent Consideration payable, as applicable. 
 (c) If the Shareholders’ Representative delivers a Response Notice agreeing that an
amount equal to the full Claimed Amount may be offset against the outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable, or if the Shareholders’ Representative does not deliver a Response
Notice on a timely basis in accordance with Section 9.5(b), the full Claimed Amount shall be offset against the outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable, and such
offset shall be deemed to be made in full and final satisfaction of the claim described in such Claim Notice. 
  

 55 

 EXECUTION COPY 
  

 (d) If the Shareholders’ Representative delivers a Response Notice agreeing that an amount
equal to less than the full Claimed Amount may be offset against the outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable, an amount equal to the Agreed Amount shall be offset against the
outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable. 
 (e) If the
Shareholders’ Representative delivers a Response Notice indicating that there is a Contested Amount, the Shareholders’ Representative and the Purchaser Party shall attempt in good faith to resolve the dispute related to the Contested
Amount. If the Purchaser Party and the Shareholders’ Representative resolve such dispute, such resolution shall be binding on all of the Sellers and such Purchaser Party, and a joint written instruction shall be signed by Purchaser and the
Shareholders’ Representative (regarding such resolution) (the “Joint Written Instruction”) and such amount as may be set forth in such Joint Written Instruction, if any, shall be offset against the outstanding balance under the
Sellers Promissory Notes or any Contingent Consideration payable, as applicable, and such offset shall be deemed to be made in full and final satisfaction of the claim described in such Claim Notice. 
 (f) If the Shareholders’ Representative and the Purchaser Party are unable to resolve the dispute related to the Contested Amount within sixty
(60) days after delivery of the Response Notice, either the Shareholders’ Representative or the Purchaser Party may demand arbitration of the matter unless the amount of the Damages is at issue in pending litigation with a third party, in
which event arbitration shall not be commenced until such amount is ascertained or both parties agree to arbitration. In the event such dispute is submitted to arbitration as provided above, then such dispute shall be settled by arbitration
conducted by one arbitrator mutually agreeable to the Shareholders’ Representative and the Purchaser Party. In the event that, within thirty (30) days after submission of any dispute related to a Contested Amount to arbitration, the
Shareholders’ Representative and the Purchaser Party cannot mutually agree on one arbitrator, then, within fifteen (15) days after the end of such thirty (30) day period, the Shareholders’ Representative, on the one hand, and the
Purchaser Party, on the other hand, shall each select one arbitrator. The two arbitrators so selected shall select a third arbitrator. Any such arbitration shall be conducted in the English language and held in London, England, under the rules then
in effect of the Chartered Institute of Arbitrators. 
 (g) The arbitrator shall (i) determine how all expenses relating to the
arbitration shall be paid, including without limitation, the fees of each arbitrator and the administrative fee of the Chartered Institute of Arbitrators, (ii) set a limited time period and establish procedures designed to reduce the cost and
time for discovery while allowing the parties an opportunity (adequate in the sole judgment of the arbitrator) to discover relevant information about the subject matter of the dispute, (iii) rule upon motions to compel or limit discovery, and
(iv) have the authority to impose sanctions, including attorneys’ fees and costs, to the same extent as a competent court of law or equity, should the arbitrator determine that discovery was sought without substantial justification or that
discovery was refused or objected to without substantial justification. The decision of the arbitrator shall be final, binding, and conclusive. Such amount as may be set forth in the final arbitration decision, if any, shall be offset against the
outstanding balance under the Sellers Promissory Notes or any Contingent Consideration payable, as applicable, and such offset shall be deemed to be made in full satisfaction of the claim described in such Claim Notice. 
  

 56 

 EXECUTION COPY 
  

 9.6 Third Party Claims. Except as otherwise provided in this Agreement, the following
procedures shall be applicable with respect to recovery for claims made by third parties (“Third Party Claims”). Promptly after receipt by a Purchaser Party of notice of the commencement of any (a) Tax audit or proceeding for
the assessment of Tax by any Taxation Authority or any other proceeding likely to result in the imposition of a Tax liability or obligation or (b) any action or the assertion of any Legal Proceeding, liability or obligation by a third party
(whether by legal process or otherwise), against which Legal Proceeding, liability or obligation the Purchaser is entitled to recover from Sellers under this Agreement, the Purchaser will (i) use commercially reasonable efforts to obtain
insurance coverage under existing policies covering the Purchaser Party with respect to such Third Party Claim and (ii) promptly notify the Shareholders’ Representative in writing of the commencement or assertion thereof and give the
Shareholders’ Representative a copy of such Third Party Claim, process and all legal pleadings; provided, however, that any failure by the Purchaser to so notify the Shareholders’ Representative shall not limit any of the
Purchaser Parties’ rights to recover Damages under this Article 9 (except to the extent such failure actually prejudices the defence of such Third Party Claim). The Shareholders’ Representative shall be the sole party authorized, on
behalf of the Sellers, to assume or participate in the defence of and negotiate and enter into settlements and compromises of claims made pursuant to this Section 9.6. The Shareholders’ Representative shall have the right,
exercisable upon written notice within 10 Business Days after receipt of such notice, to assume the defence of such action with counsel of reputable standing unless in such action injunctive or equitable remedies have been sought therein in respect
of the Purchaser Party(ies), the Purchaser or the Company or such action involves Intellectual Property (in which event Purchaser and Parent shall have the sole right to defend such claim). The Shareholders’ Representative and the Purchaser
Party(ies) shall reasonably cooperate in the defence of such claims. If the Shareholders’ Representative shall assume or participate in the defence of such audit, assessment or other proceeding as provided herein, the Purchaser Party(ies) shall
make available to the Shareholders’ Representative all relevant records and take such other action and sign such documents as are necessary to defend such audit, assessment or other proceeding in a timely manner. If the Purchaser Party(ies)
shall be required by judgment or a settlement agreement to pay any amount in respect of any obligation or liability against which the Purchaser Party(ies) are entitled to recover from Sellers under this Agreement, such amount, net of any insurance
proceeds actually recovered (less any amounts reasonably incurred by the Purchaser Parties in order to secure such recoveries, including any applicable insurance deductibles), shall be offset against the outstanding balance under the Seller
Promissory Notes or any Contingent Consideration payable, as applicable. No Seller, in the defence of any such Third Party Claim, shall, except with the written consent of the Purchaser Party(ies) (which consent shall not be unreasonably withheld or
delayed), consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Purchaser Party(ies) of a release from all liability with respect to such
claim or litigation. In the event that the Shareholders’ Representative does not assume the defence of any matter for which it is entitled to assume such defence as provided above, the Purchaser Party(ies) shall have the full right to defend
against any such claim or demand, and shall be entitled to in good faith settle or agree to pay in full such claim or demand, in its sole discretion; provided, that the Purchaser Party(ies) may, at its or their option, seek the consent of the
Shareholders’ 

  

 57 

 EXECUTION COPY 
  

 
Representative to such settlement or payment (which consent shall not be unreasonably withheld or delayed), and, if such consent is given, such settlement
shall be finally determined to have been made by the Purchaser Party(ies) in good faith. With respect to any matter as to which the Shareholders’ Representative is not entitled to assume the defence pursuant to this Section 9.6, the
Purchaser Party(ies) shall not enter into any settlement for which a claim for recovery of Damages will be made hereunder without the written consent of the Shareholders’ Representative (which consent shall not be unreasonably withheld or
delayed). 
 If the Shareholders’ Representative shall have assumed the defence of an action pursuant to this Section 9.6, a
Purchaser Party shall have the right to participate in the defence of such action with its own counsel, but the fees and expenses of such counsel shall be at the expense of the Purchaser Party unless (a) the employment of such counsel shall
have been authorized in writing by the Shareholders’ Representative in connection with the defence of such action or claim, (b) the Shareholders’ Representative shall not have employed counsel in the defence of such action or claim,
or (c) such Purchaser Party shall have reasonably concluded on the advice of its counsel that there may be defences available to it which are contrary to, or inconsistent with, those available to the Sellers, thus preventing the Sellers’
counsel from adequately representing the Sellers and the Purchaser Party, in any of which events such fees and expenses of not more than one additional counsel for the Purchaser Party(ies) shall be borne by the Sellers. 
 9.7 Characterization of Recovery. The parties agree to treat any recovery of Damages received by the Purchaser Parties under this Agreement as an
adjustment to the purchase price for Tax purposes, unless otherwise required by applicable law. 
 9.8 No Contribution. The Sellers
shall not have and shall not exercise or assert (or attempt to exercise or assert), any right of contribution, right of recovery or other right or remedy against the Company or any of its officers or directors in connection with any reimbursement
obligation or any other liability to which such Sellers may become subject under or in connection with this Agreement. 
 ARTICLE 10. 

 MISCELLANEOUS PROVISIONS 
 10.1 Shareholders’ Representative. 
 (a) The Selling Shareholders hereby appoint Michael Powell to serve as their
Shareholders’ Representative and to act as their agent and attorney-in-fact for purposes of Article 1, Article 5, Article 8, Article 9 and Section 10.4 of this Agreement, and consent to the taking by
the Shareholders’ Representative of any and all actions and the making of any decisions required or permitted to be taken by him pursuant to such provisions of this Agreement. The Shareholders’ Representative hereby agrees to negotiate,
enter into settlements and compromises of claims, including third-party claims, to comply with orders of courts and awards of arbitrators with respect to such claims, resolve any claim made pursuant to Article 9 of this Agreement, take
all actions necessary in his judgment for the accomplishment of the foregoing and hereby accepts his appointment as the Shareholders’ Representative for purposes of Article 1, Article 5, Article 8, Article 9 and
Section 10.4 of this Agreement and for purposes of any claims under the 

  

 58 

 EXECUTION COPY 
  

 
Remaining Shareholder Promissory Note and the Contingent Consideration Note. Parent and Purchaser shall be entitled to deal exclusively with the
Shareholders’ Representative on all matters relating to Article 1, Article 5, Article 8, Article 9 and Section 10.4 of this Agreement, and shall be entitled to rely conclusively (without further
evidence of any kind whatsoever) on any document executed or purported to be executed on behalf of any Seller by the Shareholders’ Representative, and on any other action taken or purported to be taken on behalf of any Seller by the
Shareholders’ Representative, as fully binding upon such Seller. 
 (b) If the Shareholders’ Representative shall die, become
disabled or otherwise be unable or declare himself unwilling to fulfill his responsibilities as agent of the Sellers, then the Selling Shareholders who held a majority of the Shares prior to the Closing collectively shall, within ten days after such
time, appoint a successor representative reasonably satisfactory to Purchaser. The Shareholders’ Representative may be removed at any time, with or without cause, by the Selling Shareholders who held a majority of the Shares prior to the
Closing; provided, that within ten days after such time, such Selling Shareholders shall appoint a successor representative reasonably satisfactory to Purchaser. Any such successor shall become the “Shareholders’
Representative” for purposes of Article 1, Article 5, Article 8, Article 9 and Section 10.4 of this Agreement and this Section 10.1. 
 (c) A Shareholders’ Representative shall not be liable for any act done or omitted hereunder as Shareholders’ Representative while acting in
good faith and in the exercise of reasonable judgment. The Selling Shareholders shall severally and proportionate between themselves indemnify each Shareholders’ Representative and hold each Shareholders’ Representative harmless against
any loss, liability, cost or expense incurred without gross negligence, bad faith or willful misconduct on the part of such Shareholders’ Representative and arising out of or in connection with the acceptance or administration of such
Shareholders’ Representative’s duties pursuant to the terms of this Agreement, including the reasonable fees and expenses of any legal counsel retained by such Shareholders’ Representative. 
 (d) The Shareholders’ Representative shall be entitled to rely upon any order, judgment, certificate, demand, notice, instrument or other writing
delivered to him hereunder without being required to investigate the validity, accuracy or content thereof nor shall the Shareholders’ Representative be responsible for the validity or sufficiency of this Agreement. In all questions arising
under this Agreement, the Shareholders’ Representative may rely on the advice of counsel, and for anything done, omitted or suffered in good faith by the Shareholders’ Representative based on such advice, the Shareholders’
Representative shall not be liable to anyone. 
 10.2 Further Assurances. Each party hereto shall execute and cause to be delivered to
each other party hereto such instruments and other documents, and shall take such other actions, as such other party may reasonably request (on or after the Closing Date) for the purpose of carrying out or evidencing any of the transactions
contemplated by this Agreement, any of the Related Agreements or any of the other documents, certificates, etc. executed or delivered in connection therewith. 
  

 59 

 EXECUTION COPY 
  

 10.3 Fees and Expenses. Each party to this Agreement shall bear and pay all fees, costs and
expenses (including legal fees and accounting fees) that have been incurred or that are incurred by such party in connection with the transactions contemplated by this Agreement, including all fees, costs and expenses incurred by such party in
connection with or by virtue of (a) the investigation and review conducted by Purchaser and its Representatives with respect to the Company’s business (and the furnishing of information to Purchaser and its Representatives in connection
with such investigation and review), (b) the negotiation, preparation and review of this Agreement (including the Company Disclosure Schedule), the Related Agreements and all agreements, certificates, opinions and other instruments and
documents delivered or to be delivered in connection with the transactions contemplated by this Agreement or the Related Agreements, (c) the preparation and submission of any filing or notice required to be made or given in connection with any
of the transactions contemplated by this Agreement or the Related Agreements, and the obtaining of any Consent required to be obtained in connection with any of such transactions, and (d) the consummation of the Transactions; provided,
that any Transaction Costs that have not been paid prior to the Closing Date and which shall remain obligations on the Company after the Closing Date shall be taken into account in calculating the Aggregate Principal Amount of the Sellers Promissory
Notes; provided, further, that the Sellers shall be responsible in the manner set forth in Article 9 for any Transaction Costs that were not paid prior to the Closing Date and were not taken into account in determining the
Aggregate Principal Amount of the Sellers Promissory Notes. 
 10.4 Amendment. The Selling Shareholders hereby consent to the
Shareholders’ Representative proposing, negotiating and agreeing (as applicable) to any variation to this Agreement on behalf of the Selling Shareholders; provided, that any such variation shall not be to the detriment of any one or more
of the Sellers. This Agreement may be amended only by an instrument in writing signed by the Company, Purchaser and the Selling Shareholders or the Shareholders’ Representative at any time. 
 10.5 Attorneys’ Fees. In any action or proceeding relating to this Agreement or the enforcement of any provision of this Agreement is brought
against any party hereto, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled). 
 10.6 Waiver; Remedies Cumulative. The rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither any failure
nor any delay by any party in exercising any right, power or privilege under this Agreement, any of the Related Agreements or any of the documents referred to in this Agreement will operate as a waiver of such right, power or privilege and no single
or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable Legal
Requirements, (i) no claim or right arising out of this Agreement, any of the Related Agreements or any of the documents referred to in this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim
or right unless in writing signed by the other party; (ii) no waiver that may be given by a party will be applicable except in the specific instance for which it is given; and (iii) no notice to or demand on one party will be deemed to be
a waiver of any obligation of that party or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement or the documents referred to in this Agreement. 
  

 60 

 EXECUTION COPY 
  

 10.7 Entire Agreement. This Agreement, the Related Agreements and the Minority Shareholder SPA
constitute the entire agreement among the parties to this Agreement and supersedes all other prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof.

 10.8 Execution of Agreement; Counterparts; Electronic Signatures. 
 (a) This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same
instrument, and shall become effective when counterparts have been signed by each of the parties and delivered to the other parties; it being understood that all parties need not sign the same counterparts. 
 (b) The exchange of copies of this Agreement and of signature pages by facsimile transmission (whether directly from one facsimile device to another by
means of a dial-up connection or whether mediated by the worldwide web), by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, or by combination of such means, shall constitute effective execution and delivery of this Agreement as to the parties and may be used in lieu of the original Agreement for all purposes. Signatures of the parties
transmitted by facsimile shall be deemed to be their original signatures for all purposes. 
 10.9 Governing Law and Submission to
Jurisdiction; Appointment of Process Agent. Except as otherwise set forth in Article 9 of this Agreement: 
 (a) This Agreement
shall be governed by and construed in accordance with the laws of England and Wales. 
 (b) The parties irrevocably agree that the courts of
England are to have exclusive jurisdiction to settle any dispute that may arise out of or in connection with this Agreement and that any proceedings arising out of or in connection with this Agreement shall be brought in such courts. Each of the
parties hereto irrevocably submits to the exclusive jurisdiction (both subject matter and personal jurisdiction) of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that proceedings have
been brought in an inconvenient forum. 
 (c) The Purchaser hereby irrevocably appoints the Company, Unit R, Trecenydd Business Park,
Caerphilly, CF83 2RZ. UK, as its agent to accept service of process in England in any legal action or proceedings arising out of this Agreement following the Closing, service upon whom shall be deemed completed whether or not forwarded to or
received by the Purchaser. 
 (d) If such process agent ceases to be able to act as such or to have an address in England, each party
irrevocably agrees to appoint a new process agent in England acceptable to the other party and to deliver to the other party within 14 days a copy of a written acceptance of appointment by the process agent. 
  

 61 

 EXECUTION COPY 
  

 10.10 Assignment and Successors. No party may assign any of its rights or delegate any of its
obligations under this Agreement without the prior written consent of the other parties, except that Purchaser may assign any of its rights and delegate any of its obligations under this Agreement to any Affiliate of Purchaser (it being agreed
acknowledged that Parent will continue to guarantee the performance of such Affiliate pursuant to the terms of Article 5 hereof). Subject to the preceding sentence, this Agreement will apply to, be binding in all respects upon and inure to
the benefit of the successors and permitted assigns of the parties. 
 10.11 Parties in Interest. Except for the provisions of
Section 1.1, Article 9 and Section 10.1, none of the provisions of this Agreement is intended to provide any rights or remedies to any Person other than the parties hereto and their respective successors and assigns (if any), except
for the provisions of Section 5.1 with respect to the Remaining Shareholders. 
 10.12 Notices. All notices and other
communications required or permitted hereunder shall be in writing and shall be deemed to have been duly given (a) upon actual receipt, when delivered by hand, (b) upon receipt of transmission confirmation, when sent by facsimile,
(c) three Business Days after mailing by prepaid registered or certified mail within the United States, (d) one Business Day after sending by overnight courier (with postage prepaid and confirmation requested) within the United States or
(e) two Business Days after sending by international courier (with postage prepaid and confirmation requested): 
 if to
Purchaser: 
 Multi-Fineline Electronix, Inc. 
 3140 E. Coronado Street 
 Anaheim, CA 92806 
 Fax No.: (714) 238-1487 
 Attention: General Counsel 
 with a copy to (which copy shall not constitute notice): 
 Paul, Hastings,
Janofsky & Walker LLP 
 4747 Executive Drive, 12th Floor 
 San Diego, CA 92121 
 Attention: Carl Sanchez 
 Fax No.: (858) 458-3005 
 if to the Company: 
 Pelikon Limited 
 Unit R 
 Trecenydd Business Park 
 Caerphilly, CF83 2RZ. UK 
 Fax: +44 (0)2920 855211 
 Attention: President 
  

 62 

 EXECUTION COPY 
  

 with a copy to (which copy shall not constitute notice): 
 Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attn: Steven V. Bernard 
 Fax No.: (650) 439-6811 
 Burges Salmon 
 Narrow Quay House 
 Narrow Quay 
 Bristol 
 BS1 4AH 
 Attn: Richard Spink 
 Fax: 0117 902 4400 
 if to the Shareholders’ Representative or the Sellers: 
 Mr. M A Powell 
 87 Ranelagh Road 
 London 
 W5 5RP 
 with
a copy to (which copy shall not constitute notice): 
 Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Attn: Steven V. Bernard 
 Fax No.: (650) 439-6811 
 Burges Salmon 
 Narrow Quay House 
 Narrow Quay 
 Bristol 
 BS1 4AH 
 Attn: Richard Spink 
 Fax: 0117 902 4400 
 If to one or more Selling Shareholders individually, to the address set forth for such Selling Shareholder on such Selling Shareholder’s signature
page hereto. 
 10.13 Construction; Usage. 
 (a) Interpretation. In this Agreement, unless a clear contrary intention appears: 
 (i) the singular
number includes the plural number and vice versa; 
  

 63 

 EXECUTION COPY 
  

 (ii) reference to any Person includes such Person’s successors and assigns but, if applicable,
only if such successors and assigns are not prohibited by this Agreement, and reference to a Person in a particular capacity excludes such Person in any other capacity or individually; 
 (iii) reference to any gender includes each other gender; 
 (iv) reference to any agreement, document or instrument means such agreement, document or instrument as amended or modified and in effect from time to time in accordance with the terms thereof; 
 (v) reference to any Legal Requirement means such Legal Requirement as amended, modified, codified, replaced or reenacted, in whole or in part, and in
effect from time to time, including rules and regulations promulgated thereunder, and reference to any section or other provision of any Legal Requirement means that provision of such Legal Requirement from time to time in effect and constituting
the substantive amendment, modification, codification, replacement or reenactment of such section or other provision; 
 (vi)
“hereunder,” “hereof,” “hereto,” and words of similar import shall be deemed references to this Agreement as a whole and not to any particular Article, Section or other provision hereof; 
 (vii) “including” means including without limiting the generality of any description preceding such term; and 
 (viii) references to documents, instruments or agreements shall be deemed to refer as well to all addenda, exhibits, schedules or amendments thereto.

 (b) Legal Representation of the Parties. This Agreement was negotiated by the parties with the benefit of legal representation and
any rule of construction or interpretation otherwise requiring this Agreement to be construed or interpreted against any party shall not apply to any construction or interpretation hereof. 
 (c) Headings. The headings contained in this Agreement are for the convenience of reference only, shall not be deemed to be a part of this
Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. 
 10.14 Enforcement of
Agreement. The parties acknowledge and agree that each of them would be irreparably damaged if any of the provisions of this Agreement are not performed in accordance with their specific terms and that any breach of this Agreement could not be
adequately compensated in all cases by monetary damages alone. Accordingly, in addition to any other right or remedy to which any party may be entitled, at law or in equity, it shall be entitled to enforce any provision of this Agreement by a decree
of specific performance and temporary, preliminary and permanent injunctive relief to prevent breaches or threatened breaches of any of the provisions of this Agreement, without posting any bond or other undertaking. 
  

 64 

 EXECUTION COPY 
  

 10.15 Severability. If any provision of this Agreement is held invalid or unenforceable by any
court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not
held invalid or unenforceable. 
  

 65 

 EXECUTION COPY 
  

 The parties hereto have caused this Agreement to be executed and delivered as a deed as of the date
first set forth above. 
  

							
		 		 	PURCHASER
			
		 		 	Multi-Fineline Electronix Singapore Pte. Ltd.
				
		 		 	By:	 	 /s/    Reza Meshgin

		 		 	Name:	 	Reza Meshgin
		 	Title:	 	President
			
	 COMPANY
	 		 	
			
	SIGNED as a DEED by Mike Powell	 	)	 	 /s/    Mike Powell

	PELIKON LIMITED acting by a director	 	)	 	Name: Mike Powell
	in the presence of	 		 	)	 	Director
				
	Witness Signature	 	 /s/    B. Schubert
	 		 	
	Witness Full Name	 	B. Schubert	 		 	
	Witness Address	 	106 Rushdene Crescent	 		 	
		 	Northolt Middx	 		 	
		 	UB5. 6NH	 		 	
	Witness Occupation	 	  
	 		 	
			
		 		 	 PARENT

			
		 		 	 Multi-Fineline Electronix, Inc.

				
		 		 	By:	 	 /s/    Reza Meshgin

		 		 	Name:	 	Reza Meshgin
		 		 	Title:	 	President

  

 1 

 EXECUTION COPY 
  

							
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Peter Wright

	as a DEED by FINANCE WALES	 	)	 	Investment Director
	INVESTMENTS LIMITED acting by	 	)	 	
	a director in the presence of:	 	)	 	
			
	Witness Signature	  	 /s/    Kathryn Barker
	 	
	Witness Full Name	  	Kathryn Barker	 	
	Witness Address	  	Finance Wales	 	
		  	Cardiff	 	
	Witness Occupation	  	Executive Assistant	 	
	Address	  	Finance Wales	 	
		  	Cardiff	 	
			
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Reese E. Schroeder

	as a DEED by MOTOROLA INC	 	)	 	Name: Reese E. Schroeder
	who is in accordance with the laws of the	 	)	 	Managing Director of Motorola Ventures
	territory in which MOTOROLA INC is	 	)	 	Authorized signatory
	incorporated is acting under the authority of	 	)	 	
	MOTOROLA INC	 	)	 	
		
	Address	  	1303 E. Algonquin Road, Schaumburg, IL 60196, U.S.A., Attn: Managing Director, Motorola Ventures
		  	Copy to: 1303 E. Algonquin Road, Schaumburg, IL 60196, U.S.A., Attn: General Counsel

  

 2 

 EXECUTION COPY 
  

							
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Jake Leavesley

	as a DEED by RAB CAPITAL PLC	 	)	 	Name: Jake Leavesley
	for and on behalf of RAB SPECIAL	 	)	 	Authorised signatory
	SITUATIONS (MASTER) FUND LIMITED	 	)	 	
	acting by its authorised signatories	 	)	 	 /s/    Benjamin Hill

		 		 		 	Name: Benjamin Hill
		 		 		 	Authorised signatory
			
	Address	 	 c/o RAB Capital Plc, 1 Adam Street
	 	
		 	 London, WCLN 6LE, UK
	 	
			
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Mark Murray

	as a DEED by ARTEMIS INVESTMENT	 	)	 	Name: Mark Murray
	MANAGEMENT LIMITED as manager for	 	)	 	Fund Manager/Authorised signatory
	and on behalf of ARTEMIS AIM VCT 2	 	)	 	
	PLC acting by its authorised signatory	 	)	 	
			
	Address	 	42 Melville Street	 	
		 	Edinburgh EH3 7HA	 	
			
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Trelawny Williams

	as a DEED by FIL INVESTMENTS	 	)	 	Name: Trelawny Williams
	INTERNATIONAL (for and on behalf of	 	)	 	Director/Authorized Signatory
	Fidelity Funds – European Smaller Companies	 	)	 	
	Fund) acting by	 	)	 	
			
	Witness Signature	 	 /s/ Margaret Rowe
	 	
	Witness Full Name	 	Margaret Rowe	 	

  

 3 

 EXECUTION COPY 
  

									
	EXECUTED and unconditionally delivered	 	)	 		 	 /s/    Trelawny Williams

	as a DEED by FIL INVESTMENT	 	)	 		 	Name: Trelawny Williams
	SERVICES LIMITED (for and on behalf of	 	)	 		 	Director/Authorized Signatory
	Fidelity European Opportunities Fund)	 	)	 		 	
	acting by	 	)	 		 	
					
	Witness Signature	  	 /s/    Margaret Rowe
	 		 		 	
	Witness Full Name	  	Margaret Rowe	 	
				
	EXECUTED and unconditionally delivered	 	)	 		 	 /s/    Sergio Levi

	as a DEED by SPARK VCT Plc	 	)	 		 	Name: Sergio Levi
	acting by its manager	 	)	 		 	Director
	SPARK VENTURE MANAGEMENT	 	)	 		 	
	LIMITED	 		 		 	
					
		  		 		 		 	 /s/    Nghi Tran

		  		 		 		 	Name: Nghi Tran
		  		 		 		 	Secretary
		
	Address	  	33 Glasshouse Street
		  	London WIB SDG
				
	EXECUTED and unconditionally delivered	 	)	 		 	 /s/    Sergio Levi

	as a DEED by SPARK VCT 2 Plc	 	)	 		 	Name: Sergio Levi
	acting by its manager	 	)	 		 	Director
	SPARK VENTURE MANAGEMENT	 	)	 		 	
	LIMITED	 		 		 	
					
		  		 		 		 	 /s/    Nghi Tran

		  		 		 		 	Name: Nghi Tran
		  		 		 		 	Secretary
					
	Address	  	33 Glasshouse Street	 		 		 	
		  	London WIB SDG	 		 		 	

  

 4 

 EXECUTION COPY 
  

							
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Sergio Levi

	as a DEED by SPARK VCT 3 Plc	 	)	 	Name: Sergio Levi
	acting by its manager	 	)	 	Director
	SPARK VENTURE MANAGEMENT	 	)	 	
	LIMITED	 		 	
				
		 		 		 	 /s/    Nghi Tran

		 		 		 	Name: Nghi Tran
		 		 		 	Secretary
	Address	 	33 Glasshouse Street	 		 	
		 	London WIB SDG	 		 	
			
	EXECUTED and unconditionally delivered	 	)	 	 /s/    Simon Chambers

	as a DEED by KBC PEEL HUNT	 	)	 	Name: Simon Chambers
	LIMITED acting by Simon Chambers	 	)	 	Director
	a director in the presence of:	 	)	 	
				
	Witness Signature	 	 /s/    Kelly Louise Morgan
	 		 	
	Witness Full Name	 	Kelly Louise Morgan	 		 	
	Witness Address	 	93 Princes Road	 		 	
		 	Ramford	 		 	
		 	RM1 2SP	 		 	
	Witness Occupation	 	Assistant Compliance Officer
	Address	 	  
	 		 	
		 	  
	 		 	

  

 5 

 EXECUTION COPY 
  

					
	EXECUTED as a DEED by	  	)	 	 /s/    Michael Powell

	MICHAEL POWELL	  	)
	in the presence of:-	  	)
		
	Signature of witness	  	 /s/    B. Schubert

	Name (in BLOCK CAPITALS)	  	B. SCHUBERT
	Address	  	106 Rushdene Crescent
		  	Northolt Middx
		  	UB5 6NH
			
	EXECUTED as a DEED by	  	)	 	 /s/    Colin Alexander Garrett

	COLIN ALEXANDER GARRETT	  	)	 
	in the presence of:-	  	)
		
	Signature of witness	  	 /s/    J.C. Wright

	Name (in BLOCK CAPITALS)	  	J.C. WRIGHT
	Address	  	810, Warick Road
		  	Southill
		  	W-MIDS
			
	EXECUTED as a DEED by	  	)	 	 /s/    Christopher Fryer

	CHRISTOPHER FRYER	  	)
	in the presence of:-	  	)
		
	Signature of witness	  	 /s/    C.M. Evans

	Name (in BLOCK CAPITALS)	  	C.M. EVANS
	Address	  	16 Ash Gree
		  	Great Chesterford CBIOIQR

  

 6 

 EXECUTION COPY 
  

 EXHIBIT A 
 CERTAIN DEFINITIONS 
 For purposes of the Agreement (including this Exhibit A): 
 “2008 R&D Tax Credit” shall mean that certain R&D Tax Credit related to calendar year 2008 that is expected by the Company to be
paid to the Company by the appropriate Tax Authority during calendar year 2009. 
 “Accounting Referee” shall have the
meaning specified in Section 1.7(e)(ii). 
 “Accounts” shall mean the Estimated Balance Sheet, Estimated Closing
Indebtedness, Schedule of Company Transaction Costs and the Closing Certificate. 
 “Acquisition Proposal” shall have the
meaning specified in Section 6.3(a). 
 “Acquisition Transaction” shall mean any transaction or series of
transactions involving: 
 (a) any merger, consolidation, share exchange, share purchase, business combination, issuance of securities,
direct or indirect acquisition of securities, recapitalization, tender offer, exchange offer or other similar transaction in which (i) the Company is a constituent corporation or is otherwise involved, (ii) a Person or “group”
(as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 5% of the outstanding securities of any class of voting securities
of any of the Company or (iii) the Company issues securities representing more than 5% of the outstanding securities of any class of voting securities of the Company; 
 (b) any direct or indirect sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or of assets or rights that
constitute or account for 10% or more of the consolidated net revenues, net income or assets of the Company; or 
 (c) any liquidation or
dissolution of any of the Company. 
 “Affiliate” shall mean, with respect to any Person, any other Person, directly or
indirectly, controlling, controlled by or under common control with such Person. 
 “Aggregate Principal Amount” shall have
the meaning specified in Section 1.6(a). 
 “Agreed Amount” shall have the meaning specified in
Section 9.5(b). 
 “Agreed Rate” shall mean the average of the daily average Interbank currency exchange rates
for British pounds sterling being converted into U.S. dollars at the close of business on each of the five Business Days prior to the Closing Date as reported in the Wall Street Journal. 
 “Agreement” shall have the meaning specified in the introductory paragraph to this Agreement. 
  

 7 

 EXECUTION COPY 
  

 “Agreement Date” shall have the meaning specified in the introductory paragraph to
this Agreement. 
 “Balance Sheet” shall have the meaning specified in Section 2.6(a)(i). 
 “Balance Sheet Date” shall have the meaning specified in Section 2.6(a)(ii). 
 “Basket” shall have the meaning specified in Section 9.3(a). 
 “Board” shall have the meaning specified in Section 2.1(d). 
 “Business Day” shall mean any day, other than a Saturday, Sunday or legal holiday in the State of California or in England, on which
banks are open for substantially all their banking business in Los Angeles and London. 
 “CAA 2001” shall mean the Capital
Allowances Act 2001. 
 “Capital Lease Obligations” shall mean those lease obligations that are required to be capitalized
by the lessee pursuant to GAAP. 
 “Claim Notice” shall have the meaning specified in Section 9.5(a).

 “Claimed Amount” shall have the meaning specified in Section 9.5(a). 
 “Closing” shall have the meaning specified in Section 1.2. 
 “Closing Certificate” shall have the meaning specified in Section 1.4. 
 “Closing Date” shall have the meaning specified in Section 1.2. 
 “Closing Indebtedness” shall mean all Indebtedness of the Company outstanding immediately prior to the Closing. 
 “Company” shall have the meaning specified in the introductory paragraph to this Agreement. 
 “Company Audited Financial Statements” shall have the meaning specified in Section 2.6(a)(i). 
 “Company Constituent Documents” shall have the meaning specified in Section 2.2. 
 “Company Contract” shall mean any Contract, including any amendment or supplement thereto, (a) to which the Company is a party;
(b) by which the Company or any of its assets is bound or under which the Company has any obligation or (c) under which Company has any right or interest. 
 “Company Disclosure Schedule” shall mean the schedule (dated as of the date of the Agreement) delivered to Purchaser on behalf of the Company on the date of this Agreement and, to the extent updated
and provided pursuant to Section 6.7 hereof and subject to the limitations of such Section 6.7, such schedule as updated. 
  

 8 

 EXECUTION COPY 
  

 “Company Employee Plan” shall mean (i) any employee pension benefit plan, any
employee welfare benefit plan, and any other plan, agreement or arrangement, written or oral, involving compensation or benefits, including insurance coverage, severance benefits, disability benefits, deferred compensation, bonuses, stock options,
stock-based or stock related awards, stock purchase, phantom stock, stock appreciation or other forms of fringe benefits, perquisites, incentive compensation or post-retirement compensation or post-employment compensation; and (ii) all
employment, management, consulting, relocation, repatriation, expatriation, visa, work permit, change in control, severance or similar agreements or contracts, written or oral, maintained, or contributed to or required to be contributed to during
the last six (6) years by the Company, and in the case of clauses (i) and (ii) above, established for the benefit of, or relating to, any current or former employee, officer, director or consultant who provided services to the Company
for which such individual received compensation. 
 “Company Financial Statements” shall have the meaning specified in
Section 2.6(a). 
 “Company Intellectual Property” shall mean any and all Intellectual Property and Intellectual
Property Rights that are owned by, or claimed to be owned by, licensed to, or filed in the name of the Company. 
 “Company Material
Adverse Effect” An event, violation, inaccuracy, circumstance or other matter will be deemed to have a “Material Adverse Effect” on the Company if, individually or in the aggregate, such event, violation, inaccuracy, circumstance
or other matter had or could reasonably be expected to have a material adverse effect on the business, assets, liabilities, operations, or condition (financial or otherwise) of the Company; provided, however, that Company Material
Adverse Effect shall not include any material adverse change, effect, event, occurrence, state of facts or development (i) relating to or resulting from the industry in which the Company operates generally or the U.S. or European economy in
general, only to the extent such adverse change, effect, occurrence, state of fact or development does not affect the Company more adversely than comparable Entities or (ii) resulting from any worldwide, national or local crisis (political,
economic, financial or regulatory), including, without limitation, an outbreak or escalation of war, armed hostilities, acts of terrorism, political instability or other national or international calamity, crisis or emergency occurring within or
outside the United States or Europe. 
 “Company Option Plan” shall mean the EMI Scheme. 
 “Company Ordinary Shares” shall have the meaning specified in the Recitals to this Agreement. 
 “Company Products” shall mean all products, technologies and services developed (including products, technologies and services under
development), owned, made, distributed, or sold by the Company. 
 “Company Rights” shall have the meaning specified in
Section 2.3(c). 
  

 9 

 EXECUTION COPY 
  

 “Company Software” shall have the meaning specified in Section 2.12(m).

 “Confidentiality Agreement” shall have the meaning specified in Section 6.8. 
 “Consent” shall mean any approval, consent, ratification, permission, waiver or authorization (including any Governmental
Authorization). 
 “Contested Amount” shall have the meaning specified in Section 9.5(b). 
 “Contingent Consideration” shall have the meaning specified in Section 1.7(b). 
 “Contingent Consideration Note” shall have the meaning specified in Section 1.7(a). 
 “Contract” shall mean any written agreement, oral or other agreement, contract, subcontract, lease, understanding, instrument, note,
warranty, license, sublicense, insurance policy, benefit plan or legally binding commitment or undertaking of any nature, whether express or implied. 
 “Damages” shall include any loss, damage, injury, liability, claim, demand, settlement, judgment, award, fine, penalty, Tax, fee (including reasonable attorneys’ fees), charge, cost (including
costs of investigation) or expense of any nature. 
 “Defaulting Shares” shall have the meaning specified in
Section 6.5. 
 “Drag-Along Right” shall have the meaning specified in the Recitals to this Agreement.

 “EMI Scheme” shall have the meaning specified in Section 2.18(f). 
 “Employee” shall have the meaning specified in Section 2.18(a). 
 “Encumbrance” shall mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, infringement,
interference, option, right of first refusal, preemptive right, community property interest or restriction of any nature affecting property, real or personal, tangible or intangible, including any restriction on the voting of any security, any
restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset, any restriction on the possession, exercise or transfer of any other attribute
of ownership of any asset, any lease in the nature thereof and any filing of or agreement to give any financing statement under the Uniform Commercial Code (or equivalent statute of any jurisdiction). 
 “Entity” shall mean any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited liability company), firm or other enterprise, association, organization or entity. 
 “Environmental Law” means any federal, state, local or foreign Legal Requirement relating to pollution or protection of human health or the environment (including ambient air, surface water, ground
water, land surface or subsurface strata), including any law or regulation 
  

 10 

 EXECUTION COPY 
  

 relating to emissions, discharges, releases or threatened releases of Materials of Environmental Concern, or
otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern. 
 “Estimated Balance Sheet” shall have the meaning specified in Section 1.4. 
 “Estimated Closing Indebtedness” shall have the meaning specified in Section 1.4. 
 “Estimated
Remaining Return Amount” shall mean an amount equal to (a) US$0.30, multiplied by (b) (i) (A) the total number of pSel Hybrid Display units sold and delivered to third parties by the Selling Parties during the
period commencing on March 1, 2010 and ending on December 31, 2010, multiplied by (B) the average return rate (expressed as a percentage) experienced by Purchaser, the Company and/or any of their respective Affiliates or
licensees on pSel Hybrid Display units sold and delivered to third parties by the Selling Parties during the six month period commencing on September 1, 2009 and ending on February 28, 2010, minus (ii) the total number of pSel
Hybrid Display units returned prior to February 28, 2011 which were initially sold and delivered to third parties by the Selling Parties during the period commencing on March 1, 2010 and ending on December 31, 2010. 
 “Excess Warranty Holdback Amount” shall be equal to an amount determined by subtracting (a) the Purchaser Actual Return Amount from
(b) the Estimated Remaining Return Amount. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended
and, the rules and regulations promulgated thereunder. 
 “Final Objection Notice” shall have the meaning specified in
Section 1.7(e)(ii). 
 “Final Response Period” shall have the meaning specified in
Section 1.7(e)(ii). 
 “Financial Advisor” shall mean Woodside Capital Partners International LLC. 

“Financial Advisor Commission” shall have the meaning specified in Section 1.1(b)(i). 
 “Fully Diluted Company Ordinary Shares” shall have the meaning specified in Section 1.1(b)(ii). 
 “GAAP” shall have the meaning specified in Section 1.4. 
 “Governmental Authorization” shall mean any: (a) approval, permit, license, certificate, franchise, permission, clearance,
registration, qualification or other authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal Requirement; or (b) right under any Contract with any Governmental
Body. 
 “Governmental Body” shall mean any: (a) nation, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign, supranational or other government or (c) governmental, self-regulatory or quasi-governmental authority of any nature (including any
governmental division, department, agency, commission, instrumentality, official, organization, unit, body or Entity and any court or other tribunal). 
  

 11 

 EXECUTION COPY 
  

 “Guaranteed Obligations” shall have the meaning specified in
Section 5.1. 
 “Guaranteed Party” shall have the meaning specified in Section 5.1. 
 “ICTA 1988” means the Income and Corporation Taxes Act 1988. 
 “IHTA 1984” means the Inheritance Tax Act 1984. 
 “In-Licenses” shall mean all agreements pursuant to which a third party has licensed any Intellectual Property or Intellectual Property Rights to the Company. 
 “Indebtedness” shall mean all outstanding indebtedness of the Company for borrowed money and any accrued interest thereon, including,
without limitation, any short and long-term debt to any creditors, including members and Affiliates of the Company, and capital lease payment obligations. 
 “Initial Objection Notice” shall have the meaning specified in Section 1.7(e)(ii). 
 “Initial Response Period” shall have the meaning specified in Section 1.7(e)(ii). 
 “Installment Due Date” shall have the meaning specified in Section 1.7(d). 
 “Intellectual
Property” shall mean and includes all algorithms, APIs, apparatus, databases and data collections, diagrams, inventions (whether or not patentable), know-how, logos, marks (including brand names, product names, logos, and slogans), methods,
network configurations and architectures, processes, proprietary information, protocols, schematics, specifications, software, software code (in any form including source code and executable or object code), subroutines, user interfaces, techniques,
URLs, web sites, works of authorship and other forms of technology (whether or not embodied in any tangible form and including all tangible embodiments of the foregoing such as instruction manuals, prototypes, samples, studies, and summaries).

 “Intellectual Property Rights” shall mean and includes all past, present, and future rights of the following types, which
may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights and moral rights; (b) trademark and trade name rights and similar
rights; (c) trade secret rights; (d) patents and industrial property rights; (e) other proprietary rights in Intellectual Property of every kind and nature; and (f) all registrations, renewals, extensions, combinations,
divisions, or reissues of, and applications for, any of the rights referred to in clauses (a) through (e) above. 
 “IP
Contracts” shall mean In-Licenses and Out-Licenses, collectively. 
 “Joint Written Instruction” shall have the
meaning specified in Section 9.5(e). 
  

 12 

 EXECUTION COPY 
  

 “KBC” shall have the meaning specified in Section 7.2(m). 
 “Knowledge” An individual shall be deemed to have “knowledge” of a particular fact or other matter if: 
 (a) such individual is actually aware of such fact or other matter; or 
 (b) such individual would have had knowledge of such fact following a reasonable investigation, if under the circumstances a reasonable
person would have determined such investigation was required or appropriate in the normal course of fulfillment of such individual’s duties. 
 The Company shall be deemed to have “knowledge” of a particular fact or other matter if any Person listed on Part A of the Company Disclosure Schedule has Knowledge of such fact or other matter. 
 “Lease” shall have the meaning specified in Section 2.11(a). 
 “Legal Proceeding” shall mean any ongoing or threatened action, suit, litigation, arbitration, proceeding (including any civil,
criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any
arbitrator or arbitration panel. 
 “Legal Requirement” shall mean any federal, state, local, municipal, foreign or
international, multinational or other law, statute, constitution, principle of common law, resolution, ordinance, legally binding code, edict, decree, rule, regulation, ruling or legally binding requirement issued, enacted, adopted, promulgated,
implemented or otherwise put into effect by or under the authority of any Governmental Body. 
 “Lender Promissory Notes”
shall have the meaning specified in Section 1.5. 
 “Material Contracts” shall have the meaning specified in
Section 2.13(a). 
 “Materials of Environmental Concern” means any chemicals, pollutants, contaminants, wastes,
toxic substances, petroleum and petroleum products and any other substance that is regulated under any applicable Environmental Law. 
 “Measurement Period” shall have the meaning specified in Section 1.7(d). 
 “Minority
Shareholder SPA” shall mean that certain agreement for the sale and purchase of Company Ordinary Shares held by the Remaining Shareholders to be entered into between each Remaining Shareholder, the Purchaser and the Shareholders’
Representative following the date of this Agreement. 
 “New Articles of Association” shall mean the New Articles of
Association of Pelikon Limited, as adopted by Special Resolution passed on February 19, 2008. 
  

 13 

 EXECUTION COPY 
  

 “Note Payment Amount” shall have the meaning specified in
Section 1.6(a). 
 “Notice Date” shall have the meaning specified in Section 6.5. 
 “NVF I” shall have the meaning specified in Section 6.6. 
 “NVF II” shall have the meaning specified in Section 6.6. 
 “Order” shall mean any decree, permanent injunction, stipulation, order or similar action. 
 “Out-Licenses” shall mean all agreements pursuant to which the Company has granted to any third party any rights or licenses to
Intellectual Property or Company Products. 
 “Parent” shall have the meaning specified in the introductory paragraph to
this Agreement. 
 “Permitted Encumbrances” shall mean (i) liens for taxes or other governmental charges not at the
time delinquent or thereafter payable without penalty or being contested in good faith; (ii) liens of carriers, warehousemen, mechanics, materialmen, vendors, and landlords incurred in the ordinary course of business for sums not overdue,
payable without penalty or being contested in good faith; (iii) easements, reservations, rights of way, restrictions, minor defects or irregularities in title and other similar charges or encumbrances affecting real property in a manner not
affecting the value or use of such property; (iv) liens securing obligations under a capital lease or securing the purchase price of equipment if such liens do not extend to property other than the property leased under such capital lease or so
purchased, and any accessions, replacements, substitutions and proceeds (including insurance proceeds) thereof or thereto. 
 “pSel
Hybrid Display” shall mean any product containing a polymer dispersed liquid crystal coated substrate which such product’s application is for a morphing keypad display or LCD display window cover. 
 “Per Share Contingent Consideration” shall have the meaning specified in Section 1.1(b)(iii). 
 “Per Share Note Payment Amount” shall have the meaning specified in Section 1.1(b)(iv). 
 “Person” shall mean any individual, Entity or Governmental Body. 
 “Plans” shall have the meaning specified in Section 2.18(a). 
 “Policies” shall have the meaning specified in Section 2.20(a). 
 “Pre-Closing Period” shall have the meaning specified in Section 6.1(a). 
 “Purchase Commitments” shall have the meaning specified in Section 2.14(a). 
 “Purchaser” shall have the meaning specified in the introductory paragraph to this Agreement. 
  

 14 

 EXECUTION COPY 
  

 “Purchaser Actual Return Amount” shall be equal to (a) US$0.30 multiplied
by (b) the actual number of pSel Hybrid Display units returned (including returns for warranty claims) to the Selling Parties during the period commencing on March 1, 2011 and ending on August 31, 2011 related to pSel Hybrid
Display units sold and delivered to third parties by the Selling Parties during calendar year 2010. 
 “Purchaser Party”
shall mean any of the following Persons: (a) Purchaser; (b) Purchaser’s current and future Affiliates (including the Company following the Closing Date); (c) the respective officers, directors or employees of the Persons referred
to in clauses (a) and (b) of this paragraph and (d) the respective successors and assigns of the Persons referred to in clauses (a), (b) and (c) of this paragraph. 
 “Real Property” shall have the meaning specified in Section 2.11(b). 
 “Recourse Amount” shall equal, in aggregate, the sum of US$2,000,000 and any Contingent Consideration payable pursuant to
Section 1.7 of this Agreement. 
 “Registered IP” means all Intellectual Property Rights that are registered,
filed or issued under the authority of any Governmental Body, including all patents, registered copyrights, and registered trademarks and all applications for any of the foregoing. 
 “Related Agreements” shall mean the Seller Promissory Notes, the Contingent Consideration Note and the Lender Promissory Notes.

 “Related Party” shall mean (a) each individual who is a corporate officer or director of the Company; (b) each
member of the immediate family of each of the individuals referred to in clause (a) above; and (c) any trust or other Entity (other than the Company) in which any one of the individuals referred to in clauses (a) and (b) above
holds (or in which more than one of such individuals collectively hold), beneficially or otherwise, a controlling interest. 
 “Remaining Shareholder Promissory Note” shall have the meaning specified in Section 1.6(a). 
 “Remaining Shareholder Shares” shall have the meaning specified in the Recitals to this Agreement. 
 “Remaining Shareholders” shall have the meaning specified in the Recitals to this Agreement. 
 “Representatives” shall mean officers, directors, employees, agents, attorneys, accountants, advisors and representatives. 
 “Response Notice” shall have the meaning specified in Section 9.5(b). 
 “Sale” shall mean the purchase and sale of the Shares pursuant to this Agreement. 
 “Sales
Statement” shall have the meaning specified in Section 1.7(c)(i). 
  

 15 

 EXECUTION COPY 
  

 “Schedule of Company Transaction Costs” shall have the meaning specified in
Section 1.4. 
 “Sellers” shall have the meaning specified in the Recitals to this Agreement. 
 “Sellers Promissory Notes” shall have the meaning specified in Section 1.6(a). 
 “Selling Parties” shall have the meaning specified in Section 1.7(b). 
 “Selling Shareholder Promissory Note” shall have the meaning specified in Section 1.6(a). 
 “Selling Shareholder Shares” shall have the meaning specified in the Recitals to this Agreement. 
 “Selling Shareholders” shall have the meaning specified in the introductory paragraph to this Agreement. 
 “Shares” shall have the meaning specified in the Recitals to this Agreement. 
 “Shareholders’ Representative” shall have the meaning specified in the introductory paragraph to this Agreement. 
 “Subsidiary” any Entity shall be deemed to be a “Subsidiary” of another Person if such Person directly or indirectly
(a) has the power to direct the management or policies of such Entity or (b) owns, beneficially or of record, (i) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at
least a majority of the members of such Entity’s board of directors or other governing body or (ii) at least 50% of the outstanding equity or financial interests of such Entity. 
 “Taxation” or “Tax” means any form of taxation, withholding, duty, impost, levy or tariff in each case in the nature of
taxation, anywhere in the world, whenever and wherever imposed including, without limitation, income tax, corporation tax, capital gains tax, value added tax, import or export duties, stamp duty, stamp duty reserve tax, national insurance and social
security contributions, and including any fines, penalties, surcharge, interest or other imposition relating to any such tax, withholding, duty, impost or levy. 
 “Tax Authority” or “Taxation Authority” means any authority or body, anywhere in the world and whether national or otherwise, having the power or authority or other function in
relation to Tax. 
 “Tax Return” shall mean any return (including any information return), report, statement, declaration,
estimate, schedule, notice, notification, form, election, certificate or other document or information filed with or submitted to, or required to be filed with or submitted to, any Taxation Authority in connection with the determination, assessment,
collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Legal Requirement relating to any Tax. 
  

 16 

 EXECUTION COPY 
  

 “Tax Statute” means any primary or secondary statute, instrument, enactment, order,
law, by-law or regulation in any jurisdiction making any provision for or in relation to Tax. 
 “Tax Warranties” shall mean
the warranties set out at Section 2.17 of this Agreement. 
 “TCGA 1992” means the Taxation of Capital Gains Act
1992. 
 “Third Party Claims” shall have the meaning specified in Section 9.6. 
 “Transaction Costs” shall mean all fees, costs and expenses incurred by the Sellers or by the Company for its account or for the account
of any of the Sellers at any time in connection with pursuing, negotiating or consummating the Letter of Intent, this Agreement, the Related Agreements and/or the transactions contemplated hereby or thereby, including, without limitation, legal,
investment banking and other professional fees and expenses, including, without limitation, any fees payable to the Financial Advisor in connection therewith (other than fees payable to the Financial Advisor in accordance with
Section 1.7(f), if any), the amount of all bonuses, accelerated payments or other similar amounts that may become payable by the Company to any directors, officers or employees of the Company or to other Persons in connection with or as
a result of the consummation of the transactions contemplated by this Agreement and the Related Agreements, including, without limitation, any Taxes or other amounts payable by the Company in connection therewith, the amount of any Taxes payable by
the Company with respect to the cancellation and termination of Company Rights, fees and expenses for any appraisal or other valuation of the Company performed by the Company or the Sellers, travel and overhead expenses of representatives of the
Sellers or the Company incurred in connection with pursuing, negotiating or consummating this Agreement, the Related Agreements or the transactions contemplated hereby or thereby and one-half of any filing fees associated with obtaining any domestic
or foreign antitrust, anti-competition or other necessary Governmental Authorization required for the consummation of the transactions contemplated by this Agreement. 
 “Transactions” shall mean the Sale and the other transactions contemplated by this Agreement and the Related Agreements. 
 “Unaudited Interim Financial Statements” shall have the meaning specified in Section 2.6(a)(ii). 
 “VAT” means value added tax or any similar sales tax in any jurisdiction. 
 “VATA
1994” means the Value Added Tax Act 1994. 
  

 17Master Development and Supply Agreement

 Exhibit 10.47 
  ̈ 
 APPLE COMPUTER, INC. 
 MASTER DEVELOPMENT AND SUPPLY AGREEMENT 
 #C56-06-00844 
 THIS MASTER DEVELOPMENT AND SUPPLY AGREEMENT is entered into by and between Apple Computer, Inc., a
California corporation having its principal place of business at 1 Infinite Loop, Cupertino, California 95014, United States and Apple Computer International, an Irish Corporation having its principal place of business at Holly Hill
Industrial Estate, Cork City, Ireland (collectively, “Apple”), and Multi-Fineline Electronix, Inc. (aka M-FLEX), a Delaware corporation, having its principal place of business at 3140-A Coronado Street, Anaheim, CA
92806 (“Company”), effective as of June 22, 2006 (the “Effective Date”). 
 PURPOSE

 Apple desires to engage Company and its affiliates to provide services in connection with the development and supply of components for
use in Apple products. This Master Development and Supply Agreement contains the general terms and conditions governing the relationship of the parties. The parties may sign statements of work that reference this Master Development and Supply
Agreement to set forth terms and conditions specific to particular goods and services. However, if the parties have not yet signed a statement of work for particular goods and services to be provided, then, unless the provision of such goods and
services is governed by a separate written agreement, the terms and conditions of this Master Development and Supply Agreement will apply. 
 AGREEMENT 
 Capitalized terms not defined herein, have the meanings set forth in Schedule 1, attached hereto
and incorporated herein by reference. 
  

	1.	Development 

 1.1. Deliverables. At the beginning of a
project, Apple and Supplier will meet to agree upon a Project Schedule that sets forth the dates Supplier will provide Development Deliverables agreed upon by Apple and Supplier. 
 1.2. Delivery. Supplier will deliver Development Deliverables to Authorized Purchasers in accordance with the Project Schedule with written notice of the delivery. Payment of invoices will not
[CONFIDENTIAL TREATMENT REQUESTED] of Development Deliverables, but rather Development Deliverables delivered will [CONFIDENTIAL TREATMENT REQUESTED] the Authorized Purchaser. Upon delivery of a Development Deliverable, the Authorized Purchaser will
[CONFIDENTIAL TREATMENT REQUESTED] the Development Deliverable, [CONFIDENTIAL TREATMENT REQUESTED] in the event that, in [CONFIDENTIAL TREATMENT REQUESTED], the Development Deliverable [CONFIDENTIAL TREATMENT REQUESTED], including the Project
Schedule [CONFIDENTIAL TREATMENT REQUESTED] Development Deliverable. If an Authorized Purchaser requests, Supplier will assist the Authorized Purchaser with testing the Development Deliverables [CONFIDENTIAL TREATMENT REQUESTED]. Upon [CONFIDENTIAL
TREATMENT REQUESTED] Development Deliverable, Supplier will promptly [CONFIDENTIAL 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 1

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
TREATMENT REQUESTED] with the Specifications [CONFIDENTIAL TREATMENT REQUESTED] the Development Deliverable to Authorized Purchasers as soon as is
practicable, or such other time period agreed upon by the Authorized Purchaser in writing. The Authorized Purchaser will [CONFIDENTIAL TREATMENT REQUESTED] in accordance with the foregoing procedure, which procedure will [CONFIDENTIAL TREATMENT
REQUESTED] the Authorized Purchaser [CONFIDENTIAL TREATMENT REQUESTED] the Development Deliverable [CONFIDENTIAL TREATMENT REQUESTED] the Development Deliverable. 
 1.3. Re-scheduling. If Supplier is unable to provide the Development Deliverables or related services in accordance with the Project Schedule for any reason, including Apple’s or any Authorized Purchaser’s failure to
provide timely delivery of required information, Supplier will promptly notify Apple, specifying the reason for such failure to comply with the Project Schedule. 
 1.4. Cancellation. An Authorized Purchaser may cancel all or any part of a Purchase Order issued by such Authorized Purchaser for Development Deliverables and related services [CONFIDENTIAL TREATMENT REQUESTED]. Upon any such
cancellation, Supplier will, to the extent and at the times specified by the Authorized Purchaser, stop all work on the Purchase Order (or designated portions thereof) so cancelled, incur no further costs, and protect all property in which the
Authorized Purchaser has or may acquire an interest. Supplier will do so promptly [CONFIDENTIAL TREATMENT REQUESTED]. Except as may be set forth in the applicable SOW, the Authorized Purchaser will [CONFIDENTIAL TREATMENT REQUESTED] in connection
with the cancelled Purchase Order except for [CONFIDENTIAL TREATMENT REQUESTED] performed [CONFIDENTIAL TREATMENT REQUESTED] in accordance with this Section 1 [CONFIDENTIAL TREATMENT REQUESTED], provided, however, [CONFIDENTIAL TREATMENT
REQUESTED] (1) the EOL Date, (2) expiration or termination of the applicable SOW, or (3) termination of this Agreement, [CONFIDENTIAL TREATMENT REQUESTED] (a) undelivered Development Deliverables completed in accordance with the
Specifications, (b) work-in progress prepared in accordance with the Specifications and the Forecast, and (c) the excess Long Lead Time Materials, if any, at [CONFIDENTIAL TREATMENT REQUESTED] for such materials, [CONFIDENTIAL TREATMENT
REQUESTED] (i) were purchased no earlier than required by applicable Lead-Times to fulfill the requirements of the then current (at the time of purchase by Supplier) Forecast, (ii) meet all applicable Specifications, and
(iii) [CONFIDENTIAL TREATMENT REQUESTED]. Supplier will scrap any such materials [CONFIDENTIAL TREATMENT REQUESTED] upon Apple’s request, provided [CONFIDENTIAL TREATMENT REQUESTED] to scrap such materials. 
 1.5. No Obligation. Provision by Supplier of any Development Deliverables or related services does not obligate Apple or any other Authorized Purchaser to
purchase any Goods from Supplier. 
 1.6. Costs. Except for amounts due pursuant to a Purchase Order or SOW or as otherwise agreed in writing
by the parties, Authorized Purchasers will not be responsible for any costs in connection with the Development Deliverables or related services. 
 1.7. Taxes. The Development Deliverables in their tangible form have no intrinsic value. As such, no value added, sales, or use taxes have been assessed or are anticipated to be required as a result of the services provided
under this Agreement. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL
THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

					
		 	Apple Confidential	 	Page 2

	2.	Production and Order Fulfillment 

 2.1. Production.
Supplier will manufacture, test, package, and deliver Goods in accordance with all applicable Specifications pursuant to Purchase Orders issued by Authorized Purchasers and the requirements set forth, if any, in the applicable SOW, as more fully set
forth below. 
 2.2. Forecasts 
 (a) Delivery. Apple will provide Supplier with a Forecast on at least [CONFIDENTIAL TREATMENT REQUESTED] until the EOL Date. 
 (b) Confirmation. Within [CONFIDENTIAL TREATMENT REQUESTED] of receipt of a Forecast, Supplier will respond [CONFIDENTIAL TREATMENT REQUESTED] supply of the Goods [CONFIDENTIAL TREATMENT REQUESTED] the Forecast. Supplier
agrees to [CONFIDENTIAL TREATMENT REQUESTED] subsequent Forecasts with respect to each [CONFIDENTIAL TREATMENT REQUESTED] of the Forecast to the extent that: (i) the subsequent Forecast does not exceed the previous Forecast for the
[CONFIDENTIAL TREATMENT REQUESTED] by more than [CONFIDENTIAL TREATMENT REQUESTED] if any, in the applicable SOW; or (ii) if no previous Forecast exists for a [CONFIDENTIAL TREATMENT REQUESTED], the subsequent Forecast does not exceed the
[CONFIDENTIAL TREATMENT REQUESTED] forecasted in a Forecast by more than [CONFIDENTIAL TREATMENT REQUESTED], if any, in the applicable SOW. 
 If the
applicable SOW does not contain a Flexibility Schedule, Supplier will respond in the same manner as with the initial Forecast set forth above. 
 (c) Supply Constraint. If Supplier’s ability to supply any Goods in accordance with the then current Forecast is constrained for any reason, Supplier agrees that Supplier [CONFIDENTIAL TREATMENT REQUESTED] will
immediately escalate the issue to both parties’ management for the purpose of resolving the supply constraint. 
 (d)
Disclaimer. APPLE MAKES NO WARRANTIES REGARDING THE QUANTITY OF GOODS THAT IT OR ANY OTHER AUTHORIZED PURCHASERS WILL ORDER OR PURCHASE, IF ANY. SUBJECT TO SECTION 2.4(D) BELOW WITH RESPECT TO QUANTITIES CITED IN A PURCHASE ORDER, ALL
QUANTITIES CITED IN THIS AGREEMENT OR IN DISCUSSIONS ARE NON-BINDING. 
 2.3. Hubs. If requested by an Authorized Purchaser, Supplier will
store Goods in Hubs before their delivery date to support just-in-time delivery of the Goods required pursuant to the then current Forecast. Supplier will: (i) [CONFIDENTIAL TREATMENT REQUESTED] associated with warehousing Goods in Hubs;
(ii) maintain a sufficient inventory of Goods in the Hubs to satisfy the requirements of the then current Forecast; (iii) ensure that the Authorized Purchaser or its carrier(s) may withdraw Goods from the Hubs as needed; (iv) retain
title to Goods until they are withdrawn by the Authorized Purchaser or its carrier from the Hubs; (v) fully insure or require the Hub operator to fully insure all Goods in transit to or stored at a Hub against all risk of loss or damage until
such time as the Authorized Purchaser takes title to them; and (vi) require that the Hub operator take all steps necessary to protect all Goods in a Hub consistent with good commercial warehousing practice. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 3

 2.4. Purchase Orders 
 (a) Orders. An Authorized Purchaser may purchase Goods by issuing Supplier a Purchase Order. During the period covered by a Forecast confirmed by Supplier in accordance with Section 2.2(b) above,
Supplier may [CONFIDENTIAL TREATMENT REQUESTED] a Purchase Order for Goods issued by an Authorized Purchaser [CONFIDENTIAL TREATMENT REQUESTED] of Goods ordered [CONFIDENTIAL TREATMENT REQUESTED] in the then current Forecast [CONFIDENTIAL TREATMENT
REQUESTED], if any, in the applicable SOW, or if the Purchase Order does not conform with the terms of this Agreement. Supplier will fulfill orders for Goods using the electronic order processing protocols identified in the document(s), if any,
referenced in the Apple Requirements Document. 
 (b) [CONFIDENTIAL TREATMENT REQUESTED]. The price of Goods will be set forth
in the applicable SOW or other written agreement among the parties, or if none, in the applicable Purchase Order. Except as set forth in the applicable Purchase Order or SOW or as otherwise agreed in writing, prices include all duties and taxes
assessable upon the Goods prior to delivery to an Authorized Purchaser in accordance with this Agreement. Supplier represents and warrants that the prices for Goods [CONFIDENTIAL TREATMENT REQUESTED]. If previously agreed upon pricing [CONFIDENTIAL
TREATMENT REQUESTED], then Supplier will [CONFIDENTIAL TREATMENT REQUESTED] to Authorized Purchasers [CONFIDENTIAL TREATMENT REQUESTED]. 
 (c) Adjustments. Authorized Purchasers may reschedule the shipment date of any undelivered Goods [CONFIDENTIAL TREATMENT REQUESTED]. An Authorized Purchaser may increase the number of units of Goods ordered pursuant to a
particular Purchase Order [CONFIDENTIAL TREATMENT REQUESTED] in accordance with the Flexibility Schedule, if any, in the applicable SOW. An Authorized Purchaser may redirect shipments of any Goods under any Purchase Order to alternate locations
[CONFIDENTIAL TREATMENT REQUESTED]. 
 (d) Cancellation. An Authorized Purchaser may cancel all or any part of a Purchase Order
issued by such Authorized Purchaser at any time. Upon any such cancellation, Supplier will, to the extent and at the times specified by the Authorized Purchaser, stop all work on the Purchase Order (or designated portions thereof) so cancelled,
incur no further costs, and protect all property in which the Authorized Purchaser has or may acquire an interest. Supplier will do so promptly [CONFIDENTIAL TREATMENT REQUESTED]. Except as may be set forth in the applicable SOW, an Authorized
Purchaser will [CONFIDENTIAL TREATMENT REQUESTED] in connection with the cancellation of a Purchase Order for Goods to be delivered during the Production Period. For Goods to be delivered outside of the Production Period, an Authorized Purchaser
will [CONFIDENTIAL TREATMENT REQUESTED] in connection with the cancellation of a Purchase Order if the cancelled Purchase Order is cancelled more than the applicable Lead-Time prior to the requested delivery date. If an Authorized Purchaser cancels
a Purchase Order for Goods to be delivered outside of the Production Period less than or equal to the applicable Lead-Time prior to the requested delivery date, the Authorized Purchaser will [CONFIDENTIAL TREATMENT REQUESTED] to fulfill the
cancelled Purchase Order that [CONFIDENTIAL TREATMENT REQUESTED]. 
 (e) Excess Materials. Upon the earlier of (1) the EOL
Date, (2) expiration or termination of the applicable SOW, or (3) termination of this Agreement, the [CONFIDENTIAL TREATMENT REQUESTED] (a) undelivered Goods completed in accordance with the Specifications, (b) work-in progress
prepared in accordance with the Specifications and the Forecast, and (c) the excess Long Lead 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 4

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
Time Materials, if any, held by Supplier, [CONFIDENTIAL TREATMENT REQUESTED] (i) were purchased no earlier than required by applicable Lead-Times to
fulfill the requirements of the then current (at the time of purchase by Supplier) Forecast, (ii) meet all applicable Specifications, and (iii) [CONFIDENTIAL TREATMENT REQUESTED]. Supplier will scrap any such materials so purchased upon
Apple’s request, provided [CONFIDENTIAL TREATMENT REQUESTED]. 
 2.5. Delivery 
 (a) On-Time Delivery. TIME IS OF THE ESSENCE as to the provision of the Goods under this Agreement. If Supplier cannot meet the
requirements of the then current Forecast or of the delivery date specified in a Purchase Order, Supplier will promptly notify the Authorized Purchaser and propose a revised delivery date, and the Authorized Purchaser may [CONFIDENTIAL TREATMENT
REQUESTED] (i) [CONFIDENTIAL TREATMENT REQUESTED] the Purchase Order [CONFIDENTIAL TREATMENT REQUESTED]; or (ii) require Supplier to [CONFIDENTIAL TREATMENT REQUESTED]. If neither the remedy in clause (i) or (ii) is sufficient,
after reasonable efforts to resolve the delay in delivery between senior management of both parties, the Authorized Purchaser may [CONFIDENTIAL TREATMENT REQUESTED] and hold [CONFIDENTIAL TREATMENT REQUESTED] for the [CONFIDENTIAL TREATMENT
REQUESTED] Authorized Purchasers for [CONFIDENTIAL TREATMENT REQUESTED] including [CONFIDENTIAL TREATMENT REQUESTED], and may exercise all other remedies provided at law, in equity and in this Agreement. If after a reasonable effort [CONFIDENTIAL
TREATMENT REQUESTED] the Authorized Purchaser is unable to do so, or if circumstances reasonably indicate that such effort will be unavailing, the Authorized Purchaser will have [CONFIDENTIAL TREATMENT REQUESTED]. No Authorized Purchaser is
obligated to accept [CONFIDENTIAL TREATMENT REQUESTED]. Unless an Authorized Purchaser has otherwise agreed in writing, Supplier must [CONFIDENTIAL TREATMENT REQUESTED] in the applicable Purchase Order. Authorized Purchasers reserve the right to
[CONFIDENTIAL TREATMENT REQUESTED] and to [CONFIDENTIAL TREATMENT REQUESTED]. 
 (b) [CONFIDENTIAL TREATMENT REQUESTED]. Payment of
invoices will [CONFIDENTIAL TREATMENT REQUESTED]. The Authorized Purchaser may [CONFIDENTIAL TREATMENT REQUESTED] that do not [CONFIDENTIAL TREATMENT REQUESTED] with the [CONFIDENTIAL TREATMENT REQUESTED] applicable Purchase Order or this Agreement.
At the Authorized Purchaser’s option, and pursuant to the Authorized Purchaser’s written instructions, Supplier will promptly: (i) [CONFIDENTIAL TREATMENT REQUESTED] plus any [CONFIDENTIAL TREATMENT REQUESTED] or
(ii) [CONFIDENTIAL TREATMENT REQUESTED] such items. 
 (c) Terms of Sale. Except as provided in Section 3.2 below,
all Goods will be delivered by [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that if Goods are delivered via Hubs in accordance with Section 2.3 above, Supplier will retain title and risk of loss with respect to Goods delivered to a
Hub until [CONFIDENTIAL TREATMENT REQUESTED]. 
 2.6. Costs. Except for amounts due pursuant to a Purchase Order or SOW, Authorized Purchasers
will not be responsible for any costs in connection with the ordering and purchase of any Goods. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 5

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  

	3.	Support Services and Service Units 

 3.1. Service Unit
Inventory. Supplier will, at Supplier’s expense, provide an inventory of Service Units to Apple in accordance with the Service Unit inventory requirements set forth in document(s), if any, referenced in the Apple Requirements Document or
applicable SOW. In absence of such requirements and upon Apple’s request, Supplier will (i) deliver an Initial Service Unit Inventory to entities designated by Apple, [CONFIDENTIAL TREATMENT REQUESTED] Apple first ships the applicable
Apple Product. 
 3.2. Terms of Sale. Supplier will deliver all Service Units [CONFIDENTIAL TREATMENT REQUESTED] and title will transfer
[CONFIDENTIAL TREATMENT REQUESTED] of the Service Units at [CONFIDENTIAL TREATMENT REQUESTED]; provided, however, that whenever Service Units are delivered to Apple Computer International or Apple Computer Limited, Cork Branch in the Asia-Pacific
region, Goods will be delivered [CONFIDENTIAL TREATMENT REQUESTED] and title will transfer at [CONFIDENTIAL TREATMENT REQUESTED]. 
 3.3.
Costs. Except for amounts due pursuant to a Purchase Order or SOW, Authorized Purchasers will not be responsible for any costs in connection with Supplier’s obligations in this Section 3. 
  

	4.	Modifications 

 4.1. By Supplier. Supplier will not
modify any Specifications without obtaining Apple’s prior consent via the Project Management System. 
 4.2. By Apple. Apple may modify
any Specifications via the Project Management System. Supplier will acknowledge the modification via the Project Management System in accordance with applicable procedures. The terms and conditions of this Agreement will be amended by such
modification upon Supplier’s acknowledgement thereof or, if within [CONFIDENTIAL TREATMENT REQUESTED] of receipt of notice of such modification, if Supplier has not given Apple notice of its acknowledgement. In the event the modification
results in [CONFIDENTIAL TREATMENT REQUESTED] performance of Supplier’s obligations under this Agreement, Apple will [CONFIDENTIAL TREATMENT REQUESTED] Supplier’s reports [CONFIDENTIAL TREATMENT REQUESTED] to Apple within [CONFIDENTIAL
TREATMENT REQUESTED] of the receipt of the notice and obtains Apple’s prior written consent to proceed with the modification. 
  

	5.	Quality and Safety Requirements 

 5.1. Requirements and
Qualifications. Supplier will comply with the quality, safety and regulatory requirements as set forth in the document(s), if any, referenced in the Apple Requirements Document and as set forth in the applicable SOW, or in the absence of such
requirements, with good commercial practice and applicable law. 
 5.2. Testing Requirements. Supplier will test the Development Deliverables
and the Goods in accordance with the testing requirements set forth in the document(s), if any, referenced in the Apple Requirements Document and as set forth in the applicable SOW, or in the absence of such testing requirements, in a manner
sufficient to confirm conformance with all applicable Specifications. Upon 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 6

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
Apple’s request, Supplier will provide and ship Development Deliverables and Goods to Apple to be used for testing. 
 5.3. Environmental Compliance. Supplier will, with respect to the provision of Development Deliverables and Goods, and all related processes and materials
used in connection therewith, including packaging, comply with: (i) all applicable laws and regulations governing the use, declaration, preparation and marketing of hazardous substances and energy consumption efficiency; and (ii) any
requirements with respect to the same set forth in the document(s), if any, referenced in the Apple Requirements Document and in the applicable SOW. 
 5.4. Failures and Safety Risks. 
 (a) Generally. Supplier must notify Apple immediately if it has
reason to believe that the Goods provided under this Agreement may (i) produce an Excessive Failure; (ii) produce an Environmental Compliance Failure; or (iii) present a Safety Risk. 
 (b) Remedies. If there is an Excessive Failure, an Environmental Compliance Failure, or the Goods present a Safety Risk, [CONFIDENTIAL
TREATMENT REQUESTED] (i) reimburse Authorized Purchasers for [CONFIDENTIAL TREATMENT REQUESTED] (ii) if [CONFIDENTIAL TREATMENT REQUESTED] affected Goods; and (iii) [CONFIDENTIAL TREATMENT REQUESTED], promptly provide [CONFIDENTIAL
TREATMENT REQUESTED]. For Multiple-Cause Excessive Failures, these remedies will apply only to [CONFIDENTIAL TREATMENT REQUESTED]. For Single-Cause Excessive Failures, these remedies will apply to [CONFIDENTIAL TREATMENT REQUESTED]. 
 (c) Exceptions. Supplier will not be liable under this Section 5.4 for an Excessive Failure or a Safety Risk to the extent
(i) [CONFIDENTIAL TREATMENT REQUESTED] the Excessive Failure or the Safety Risk; or (ii) the Goods were [CONFIDENTIAL TREATMENT REQUESTED] to the Authorized Purchaser. [CONFIDENTIAL TREATMENT REQUESTED]. 
 (d) Tracking. Supplier must track the date Goods are produced and make such information available to Apple upon Apple’s request during
the term of this Agreement and for [CONFIDENTIAL TREATMENT REQUESTED] after the Goods are delivered. 
 5.5. Costs. Except for amounts due
pursuant to a Purchase Order or SOW, Authorized Purchasers will not be responsible for any costs in connection with Supplier’s obligations in this Section 5. 
  

	6.	Resource Requirements 

 6.1. Human Resources

 (a) Management. Supplier is solely responsible for managing Supplier Personnel, including hiring, firing, where and when
Supplier Personnel perform their work, work assignments, practices, policies and procedures, and compliance with all applicable laws and regulations. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN
FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 7

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 (b) Apple Premises. Upon Apple’s request, Supplier will
provide Supplier Personnel [CONFIDENTIAL TREATMENT REQUESTED]. Such Supplier personnel may be required to sign a written agreement with Apple acknowledging and agreeing to comply with Apple’s security and confidentiality requirements. Apple
reserves the right to prohibit specific Supplier Personnel from entering Apple’s premises at Apple’s sole discretion. 
 (c)
Written Agreements. Supplier represents that Supplier has written agreements in place with each Supplier Personnel sufficient to enable Supplier to comply with all provisions of this Agreement. 
 (d) Costs. Except for amounts due pursuant to a Purchase Order or SOW, Authorized Purchasers will not be responsible for any costs
associated with Supplier Personnel. 
 6.2. Equipment 
 (a) Supplier will secure all Equipment necessary to provide the Development Deliverables and the Goods, including the Equipment specified in the applicable SOW and the document(s), if any, referenced in the
Apple Requirements Document. Supplier will purchase, lease or borrow the Equipment in a timely manner to ensure that the Equipment is delivered in time to meet the requirements of the Project Schedule, the then current Forecast, or any Purchase
Order, as applicable. 
 (b) Upon Apple’s and Supplier’s mutual agreement, Supplier will obtain certain items of Equipment
from Apple or purchase or lease Equipment on Apple’s behalf (collectively, “Apple Equipment”). 
 (c) As
applicable, Supplier will place purchase orders for or lease the Apple Equipment only upon prior written approval by Apple with respect to the specifications and price of each item of Apple Equipment. Upon request, Supplier will provide Apple
[CONFIDENTIAL TREATMENT REQUESTED] for each item. 
 (d) Supplier will hold the Apple Equipment as a bailee only and will not permit
any lien or other encumbrance to be placed against it when in Supplier’s care, custody and control. Apple owns all Apple Equipment obtained from Apple. With respect to Apple Equipment purchased on Apple’s behalf, Supplier agrees that title
to such Apple Equipment will transfer to Apple upon payment for the Apple Equipment by Apple. Supplier will execute any documents necessary to document or perfect Apple’s ownership of the Apple Equipment. With respect to Apple Equipment leased
on Apple’s behalf, Supplier will assign Supplier’s rights and obligations under the lease to Apple upon Apple’s request. 
 (e) Supplier will apply Apple asset tags provided by Apple to all Apple Equipment in accordance with the requirements set forth in the documents, if any, referenced in the Apple Requirements Document. Under no circumstances will
Supplier move Apple Equipment from the location designated by Apple, without Apple’s prior written consent, or deny Apple, its agents or contractors access to the Equipment. 
 (f) Immediately upon Apple’s request or termination of this Agreement, Supplier will deliver the Apple Equipment [CONFIDENTIAL TREATMENT
REQUESTED] provided Apple has paid for any 
  
 [CONFIDENTIAL TREATMENT REQUESTED]
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 8

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
Apple Equipment purchased or leased by Supplier on Apple’s behalf. Supplier agrees to return the Apple Equipment to Apple in the same condition as it
was provided to Supplier, except for normal wear and tear. Supplier will be responsible for physical loss of or damage to the Apple Equipment while in the possession or control of Supplier. 
 (g) Supplier agrees to use Apple Equipment and any other Equipment specifically designed to manufacture or test Goods that are unique to Apple
(“Custom Equipment”) solely for Apple’s benefit. Supplier will not use Apple Equipment or Custom Equipment for any other purpose or permit a third party to use the Apple Equipment or Customer Equipment except as set
forth in this Agreement. 
 (h) The Apple Equipment provided by Apple is provided to Supplier “as is” and Apple disclaims
all warranties, express or implied, including the implied warranties of merchantability and fitness for a particular purpose. 
 (i)
Supplier is solely responsible for installing, testing, and maintaining the Equipment in its control in good working condition in compliance with applicable manufacturing specifications, for purchasing and maintaining spare parts to repair such
Equipment with a minimum of downtime, and for any risk of loss in connection with the Equipment. 
 (j) Apple reserves the right to
inspect any Apple Equipment in Supplier’s control at any time, provided it gives Supplier at least 24 hours advance notice. 
 (k) Except for amounts due pursuant to a Purchase Order or SOW, Authorized Purchasers will not be responsible for any costs associated with the Equipment. 
 6.3. Materials 
 (a) Procurement. Supplier will secure all materials in
accordance with applicable Specifications to provide the Development Deliverables and Goods necessary to meet the requirements of the Project Schedule, the then current Forecast and Purchase Orders. 
 (b) [CONFIDENTIAL TREATMENT REQUESTED]. Upon Apple’s request, Supplier will [CONFIDENTIAL TREATMENT REQUESTED] set forth in the applicable
SOW and document(s), if any, referenced in the Apple Requirements Document, or in the absence of such requirements, will provide Apple (i) [CONFIDENTIAL TREATMENT REQUESTED] reports by part number specifying [CONFIDENTIAL TREATMENT REQUESTED]
for the immediately following [CONFIDENTIAL TREATMENT REQUESTED] period; (ii) [CONFIDENTIAL TREATMENT REQUESTED] Purchase Orders for materials required for at least [CONFIDENTIAL TREATMENT REQUESTED] period; and (iii) [CONFIDENTIAL
TREATMENT REQUESTED] receipt logs of any such materials. 
 (c) Bill of Materials. Before placing orders for or purchasing any
materials for use in Goods that are comprised of multiple components, Supplier will provide Apple, for Apple’s review and approval, a complete BOM for such Goods, as applicable, listing the supplier(s), part number(s), lead time(s), and cost(s)
of each material therein, as applicable. 
  
 [CONFIDENTIAL TREATMENT REQUESTED]
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 9

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 (d) Costs. Except for amounts due pursuant to a Letter of
Authorization, the applicable SOW or Purchase Order, Apple will not be responsible for any costs associated with the materials, including any financing charges. 
  

	7.	Documentation, Reports and Reviews 

 7.1.
Documentation. Supplier will, at Supplier’s expense, provide Documentation in English for the Development Deliverables and the Goods upon request by Apple, including the Documentation identified in the applicable SOW and the document(s),
if any, referenced in the Apple Requirements Document, in the format and frequency set forth therein. 
 7.2. Reports. Supplier will, at
Supplier’s expense, provide Apple (i) reports requested by Apple, including reports regarding the Development Deliverables, Goods, Purchase Orders, Hubs, and Defective Goods; and (ii) the reports described in the document(s), if any,
referenced in the Apple Requirements Document, in the format and frequency set forth therein. 
 7.3. Audits. During the term of this Agreement
and for [CONFIDENTIAL TREATMENT REQUESTED], Apple may, at any time during Business Days, [CONFIDENTIAL TREATMENT REQUESTED] to verify that Supplier and Supplier Affiliates have complied with their obligations under this Agreement. Supplier will
provide Apple any information and documentation Apple may reasonably request in connection with such inspection and audit regarding the Goods ordered or purchased by any Authorized Purchasers. Supplier will provide such information and documentation
in the format requested. Supplier agrees to maintain all records, contracts and accounts relating to such Development Deliverables and Goods, or otherwise related to this Agreement, during the term of this Agreement and for [CONFIDENTIAL TREATMENT
REQUESTED]. Supplier will ensure that Supplier Personnel who are knowledgeable of the relevant records and business practices are available to facilitate any audit, and that any information or materials requested in preparation for or during such
audit are provided to Apple without delay. Supplier will [CONFIDENTIAL TREATMENT REQUESTED] the audit is completed for [CONFIDENTIAL TREATMENT REQUESTED] by Authorized Purchasers [CONFIDENTIAL TREATMENT REQUESTED]. Supplier will be responsible for
[CONFIDENTIAL TREATMENT REQUESTED] if the audit reveals [CONFIDENTIAL TREATMENT REQUESTED] by Authorized Purchasers during the period of time subject to the audit. 
 7.4. Inspections. Upon reasonable advance notice, Supplier will allow Apple, during Business Days to visit Supplier’s facilities used in connection with the provision of the Development Deliverables or Goods to ensure
compliance with the terms and conditions of this Agreement, including inspection of Development Deliverables in progress or completed, Goods in progress or completed, and development and manufacturing processes. Supplier will ensure that Supplier
Personnel who are knowledgeable of the relevant facilities attend such inspections. 
 7.5. Disclaimer. Any reports provided or audits or
inspections performed in accordance with this Section 7 will not relieve Supplier of any of its obligations under this Agreement. 
 7.6.
Costs. Except for amounts due pursuant to a Purchase Order or SOW, Authorized Purchasers will not be responsible for any costs in connection with Supplier’s obligations in this Section 7. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 10

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  

	8.	Purchase and Payment Terms 

 8.1. Purchase Orders.

 (a) Orders. An Authorized Purchaser will have no obligation to purchase or pay for any Development Deliverables, Goods, or
related services except pursuant to a Purchase Order issued by that Authorized Purchaser and accepted in accordance with the terms of this Agreement. 
 (b) Acceptance. Supplier’s acknowledgment of an order, delivery of Development Deliverables and/or Goods or performance of services will constitute acceptance of a Purchase Order. 
 (c) Terms. All Purchase Orders placed during the term of this Agreement will be subject to and governed by the terms and conditions of this
Agreement, regardless of whether they reference this Agreement or whether the parties have executed an SOW specific to the Development Deliverables or Goods ordered, unless there is another signed, written agreement in place between the parties with
respect to the Development Deliverables, Goods, or related services being purchased. Subject to the terms of Section 16.17 below, any different or additional terms or conditions in any proposal, acknowledgment form or any other document will be
of no force or effect and will not become part of the agreement between the parties. 
 8.2. Invoices 
 (a) Terms. Supplier will invoice Authorized Purchasers for any amounts owed by Authorized Purchasers. Except as provided elsewhere in this
Agreement, payment terms of any invoices issued under this Agreement will be at least [CONFIDENTIAL TREATMENT REQUESTED] from the date of invoice. With respect to Goods, Supplier will not issue an invoice before title to Goods transfers to the
Authorized Purchaser. With respect to Development Deliverables and services, Supplier will not issue an invoice until payment is due in accordance with the Purchase Order or the applicable SOW. 
 (b) Disputed Invoices. Supplier must provide supporting documentation to the Authorized Purchaser for any disputed invoice [CONFIDENTIAL
TREATMENT REQUESTED] after receiving any such notice. If a correction is warranted, the Authorized Purchaser will pay the corrected amount [CONFIDENTIAL TREATMENT REQUESTED] after receipt of the corrected invoice, or if the correction is reflected
on the next regular invoice, [CONFIDENTIAL TREATMENT REQUESTED] after the date of that invoice. While the parties work to resolve good-faith disputes under this section, neither party will be deemed to be in breach of this Agreement. 
 (c) Written Claims. Supplier must submit invoices to Authorized Purchasers for cancellation charges, [CONFIDENTIAL TREATMENT REQUESTED]
after the charges arise, together with such reasonable evidence as the Authorized Purchaser may request supporting such claim. Failure to submit a claim within the foregoing specified period will constitute a waiver of the claim and a release of the
Authorized Purchaser from all liability arising out of the cancellation. 
 (d) Method of Payment. Any payments due under this
Agreement will be made by wire transfer to a bank account, designated by the receiving party by Notice, and in accordance with the requirements set forth in the document(s), if any, referenced in the Apple Requirements Document. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 11

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 (e) Currency. All amounts payable will be specified and paid in
United States Dollars. 
 8.3. Right [CONFIDENTIAL TREATMENT REQUESTED]. Apple may, from time to time, [CONFIDENTIAL TREATMENT REQUESTED] Apple
[CONFIDENTIAL TREATMENT REQUESTED] and [CONFIDENTIAL TREATMENT REQUESTED] to Supplier against any [CONFIDENTIAL TREATMENT REQUESTED] Supplier to Apple (regardless whether [CONFIDENTIAL TREATMENT REQUESTED] this Agreement). Apple must give Supplier
notice at least [CONFIDENTIAL TREATMENT REQUESTED] any such [CONFIDENTIAL TREATMENT REQUESTED]. Supplier agrees that notice given will be effective even if a receiver, custodian, trustee, examiner, liquidator or similar official has been appointed
for Supplier or any substantial portion of its assets. As used in this Section 8.3: (i) the terms “Apple” and “Supplier” include, in addition to the definition of these terms above, any individual, corporation,
partnership, limited liability company, joint venture, association, trust, unincorporated organization or other business entity that controls, is controlled by, or is under common control with such party, provided, however, that the term
“Supplier” shall not include WBL Corporation Limited, a Singapore company (“WBL”) and the entities, other than Supplier and its subsidiaries, controlled by WBL; and (ii) “control” means that the entity possesses,
directly or indirectly, the power to direct or cause the direction of the management policies of the other entity, whether through ownership of voting securities, an interest in registered capital, by contract, or otherwise. The rights described in
this Section 8.3 are in addition to any other rights and remedies available under this Agreement or applicable law, [CONFIDENTIAL TREATMENT REQUESTED]. 
 8.4. Other Financial Requirements. Supplier will comply with the financial requirements set forth in the document(s), if any, referenced in the Apple Requirements Document. 
  

	9.	Logistics 

 9.1. Labeling. Supplier will label the
Goods in accordance with applicable Specifications. Upon Apple’s request, Supplier [CONFIDENTIAL TREATMENT REQUESTED]. If Apple requires use of Apple Trademarks on the Goods, Supplier must reproduce such Apple Trademarks on each unit of Goods
in accordance with the most current version of the Apple trademark guidelines, available upon request. Upon termination of this Agreement, Supplier must destroy or deliver to Apple all finished or unfinished Goods in its possession or control
bearing any Apple Trademark, or must remove the Apple Trademark from such Goods in accordance with Apple’s instructions. Apple will provide Supplier with any Apple Trademark artwork as necessary. Upon request, Supplier shall provide Apple with
samples of the labeled Goods to verify compliance with this Section 9.1. 
 9.2. Packaging. All orders will be packaged and delivered in
accordance with the applicable packaging requirements set forth in the applicable Purchase Order or SOW and in the document(s), if any, referenced in the Apple Requirements Document, or, in the absence of such requirements, the best method possible
in accordance with good commercial practice and applicable regulations and laws. 
 9.3. Carriers. Supplier will use the freight carriers
identified in the document(s), if any, referenced in the Apple Requirements Document, and in accordance with the requirements set forth therein, or in the absence of such documents, the providers selected by Supplier and approved by Apple via the
Project Management System. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES
MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	Apple Confidential	 	Page 12

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 9.4. Importer of Record. When an Authorized Purchaser is the “Importer of
Record” as specified in the applicable Purchase Order or SOW, Supplier will, at no charge, promptly forward to the Authorized Purchaser any documents the Authorized Purchaser may reasonably require to allow the Authorized Purchaser to clear the
Development Deliverables or Goods through customs and/or obtain possession of the Development Deliverables or Goods at the port of entry. 
 10.
Intellectual Property Rights 
 10.1. Apple Intellectual Property 
 (a) [CONFIDENTIAL TREATMENT REQUESTED]. As between the parties, [CONFIDENTIAL TREATMENT REQUESTED]. Supplier hereby [CONFIDENTIAL TREATMENT
REQUESTED] to Apple, without reservation, [CONFIDENTIAL TREATMENT REQUESTED] rights, title and interest, including [CONFIDENTIAL TREATMENT REQUESTED], it may have in and to [CONFIDENTIAL TREATMENT REQUESTED]. Supplier agrees to execute any documents
reasonably requested by Apple to enable Apple to secure, register or enforce any [CONFIDENTIAL TREATMENT REQUESTED]. Apple may file for patent rights or take other action to protect its proprietary rights in [CONFIDENTIAL TREATMENT REQUESTED]
anywhere in the world. Subject to Sections 10.1(b) and 10.1(c) below, Apple hereby grants to Supplier [CONFIDENTIAL TREATMENT REQUESTED] to the extent necessary for Supplier to perform its obligations under this Agreement. Supplier agrees that it
will not engage in, nor will it authorize others to engage in, the reverse engineering, disassembly or the decompilation of [CONFIDENTIAL TREATMENT REQUESTED] except as required to perform its obligations under this Agreement. 
 (b) Apple Software. In the event Apple and Supplier mutually agreed to use any Apple Software not subject to the terms and conditions of a
written license agreement between Apple and Supplier with respect to such software, the following additional terms and conditions will apply to the use of the Apple Software: 
 (i) Supplier may make copies of the Apple Software only if reasonably necessary for performing Supplier’s obligations under this Agreement,
including testing or installing the Apple Software. The license granted hereunder is not a license to incorporate the Apple Software into any product, board, module, integrated circuit, core or other assembly or device other than Development
Deliverables and Goods, as applicable, or a license, expressly or by implication, estoppel, exhaustion or otherwise, under any Apple patents. 
 (ii) Supplier must retain and reproduce in all copies of the Apple Software the Apple copyright and other proprietary notices and disclaimers as they appear in the Apple Software, and keep intact all notices in the Apple Software that refer
to the license granted hereunder. 
 (iii) [CONFIDENTIAL TREATMENT REQUESTED]. Supplier hereby grants to Apple and its subsidiaries
[CONFIDENTIAL TREATMENT REQUESTED], in any form, through multiple tiers of distribution. 
 (iv) Upon Apple’s request, Supplier agrees
to provide Apple with test results obtained through use of the Apple Software. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 13

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 (v) THE APPLE SOFTWARE IS PROVIDED “AS IS” AND WITHOUT WARRANTY,
UPGRADES OR SUPPORT OF ANY KIND AND APPLE EXPRESSLY DISCLAIMS ALL WARRANTIES AND/OR CONDITIONS, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES AND/OR CONDITIONS OF MERCHANTABILITY, OF SATISFACTORY QUALITY, OF FITNESS FOR A
PARTICULAR PURPOSE, OF ACCURACY, OF QUIET ENJOYMENT, AND NONINFRINGEMENT OF THIRD PARTY RIGHTS. APPLE DOES NOT WARRANT THAT THE FUNCTIONS CONTAINED IN THE APPLE SOFTWARE WILL MEET SUPPLIER’S REQUIREMENTS, THAT THE OPERATION OF THE APPLE
SOFTWARE WILL BE UNINTERRUPTED OR ERROR-FREE, OR THAT DEFECTS IN THE APPLE SOFTWARE WILL BE CORRECTED. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY APPLE SHALL CREATE A WARRANTY.  
 (c) Apple Trademarks. Supplier will not use any Apple Trademarks for any purpose except to comply with its obligations under this Agreement
or with Apple’s prior written consent. The goodwill derived from Supplier’s use of any Apple Trademarks inures exclusively to the benefit of and belongs to Apple. Supplier acknowledges Apple’s ownership of the Apple Trademarks and
agrees not do anything inconsistent with Apple’s ownership of the Apple Trademarks, such as filing any trademark application for an identical or similar mark anywhere in the world. Any such trademark registrations that Supplier seeks to obtain
will be deemed to be obtained for the benefit of Apple. APPLE LICENSES THE APPLE TRADEMARKS ON AN “AS-IS” BASIS AND EXPRESSLY DISCLAIMS ALL WARRANTIES EXPRESS OR IMPLIED, INCLUDING THE WARRANTY OF NON-INFRINGEMENT. 
 10.2. Supplier Intellectual Property. 
 (a) [CONFIDENTIAL TREATMENT REQUESTED]. As between the parties, [CONFIDENTIAL TREATMENT REQUESTED]. 
 (b)
License. Supplier grants to Apple a [CONFIDENTIAL TREATMENT REQUESTED] worldwide license under all Intellectual Property Rights and other proprietary rights of Supplier necessary to permit Apple and others authorized by Apple to [CONFIDENTIAL
TREATMENT REQUESTED] Development Deliverables, and to [CONFIDENTIAL TREATMENT REQUESTED] the Goods and derivatives thereof in connection with Apple products. 
  

	11.	Confidentiality 

 11.1. Definitions. For purposes of
this Agreement, “Confidential Information” is defined as all information disclosed by one party (the “Discloser”) to the other (the “Recipient”) in connection with this
Agreement, including the negotiation of this Agreement, its existence and the terms and conditions hereof, and information learned by Recipient from Discloser’s employees or agents, or through inspection of documents or other property in
connection with this Agreement, whether disclosed by Discloser or accessed by Recipient from Discloser’s Information Systems. In addition, Confidential Information of Apple includes requests for information, proposals or quotations in
connection with any future Development Deliverables or Goods, related documents, and the terms and conditions thereof, and the existence of any Development Deliverables or Goods, any information discerned from the inspection thereof, including their
form, features and functionality. Notwithstanding anything to the contrary in the 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 14

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
foregoing, “Confidential Information” of the Discloser does not include information that: (i) is now or subsequently becomes generally
available to the public through no fault or breach on the part of Recipient; (ii) Recipient can demonstrate to have had rightfully in its possession prior to disclosure to Recipient by Discloser; (iii) is independently developed by
Recipient without the use of any Confidential Information of Discloser; or (iv) Recipient rightfully obtains from a third party who has the right to transfer or disclose it to Recipient without limitation. 
 11.2. Non-Disclosure. During the period from the disclosure of any Confidential Information of Discloser until [CONFIDENTIAL TREATMENT REQUESTED],
Recipient agrees: (i) to protect the Confidential Information of Discloser, using at least the same degree of care that it uses to protect its own confidential and proprietary information of similar importance, but no less than a reasonable
degree of care; (ii) to use the Confidential Information of Discloser solely for the purpose of performing its obligations under this Agreement, and not to use the Confidential Information for any other purpose or for its own or any third
party’s benefit without the express prior written consent of an authorized representative of Discloser in each instance; and (iii) not to disclose, publish, or disseminate Confidential Information of Discloser to anyone other than its
Personnel who have a need to know the Confidential Information and who are bound by written agreement that prohibits unauthorized disclosure or use of the Confidential Information that is at least as protective of the Confidential Information as
Recipient’s obligations hereunder. Recipient may disclose Confidential Information of Discloser to the extent required by law, provided that Recipient shall make reasonable efforts to give Discloser notice of such requirement prior to any such
disclosure and shall take reasonable steps to obtain protective treatment of the Confidential Information. Within three Business Days of receipt of Discloser’s written request, and at Discloser’s option, Recipient will either return to
Discloser all tangible Confidential Information of Discloser, including but not limited to all electronic files, documentation, notes, plans, drawings, and copies thereof, or will provide Discloser with written certification that all such tangible
Confidential Information has been destroyed. 
  

	12.	Warranties 

 12.1. General Warranties. Supplier
represents and warrants that: (i) it has the right to enter into this Agreement and its performance of this Agreement will be free and clear of liens and encumbrances; (ii) entering into this Agreement will not cause Supplier to breach any
other written agreements to which it is a party; (iii) the Development Deliverables or Goods including any portion thereof or any intended combination with other hardware or software, or the sale, offer for sale, use, or importation thereof,
does not infringe any patent, copyright, trademark, trade secret, or other proprietary right of a third party; (iv) all Specifications and Documentation provided by Supplier in connection with this Agreement will be complete and accurate; and
(v) the Development Deliverables and Goods will not be misbranded or falsely labeled, advertised, or invoiced. 
 12.2. Product
Warranties. Supplier warrants that all Goods will: (i) be new and comprised of new materials when delivered (not including Service Units); (ii) be safe for any use that is consistent with applicable Specifications or that is reasonably
foreseeable; (iii) [CONFIDENTIAL TREATMENT REQUESTED] to all applicable Specifications; (iv) [CONFIDENTIAL TREATMENT REQUESTED] when delivered; (v) comply with all applicable requirements pursuant to Sections 5.1, 5.2, and 5.3 above.

  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 15

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  

	13.	Indemnification 

 13.1. Indemnification. At
Apple’s request, Supplier will defend any claims or allegations against Apple, Apple Affiliates or Apple Personnel that: (i) the Development Deliverables or Goods, or any portion thereof, on their own or in combination with other goods and
services, infringe any third-party’s patent, copyright, trademark, trade secret, mask work right or other intellectual property right; or (ii) the Development Deliverables, Goods, or Apple Equipment (in Supplier’s possession) caused
injury or damages; or (iii) arise or are alleged to have arisen as a result of negligent and/or intentional acts or omissions of Supplier or Supplier Personnel or breach by Supplier of any term of the Agreement. Supplier will indemnify and hold
Apple, Apple Affiliates and Apple Personnel harmless from and against any costs, damages and fees (including attorney and other professional fees) attributable to any such claims or allegations, provided that Apple: (a) notifies Supplier
promptly in writing of any such claims or allegations; (b) permits Supplier to answer and defend the claim using counsel of Supplier’s choice; and (c) provides information and assistance reasonably necessary to enable Supplier to
defend the claim (at Supplier’s expense). [CONFIDENTIAL TREATMENT REQUESTED]. If Supplier does not agree that the claim or suit is fully covered by this indemnity provision, then the parties agree to negotiate in good faith an equitable
arrangement regarding the control of defense of the claim or suit and any settlement thereof consistent with Supplier’s obligations hereunder. 
 13.2. Exceptions. Supplier will have no obligation to indemnify Apple, Apple Affiliates, or Apple Personnel against any claims pursuant to clause (i) in Section 13.1 above or to perform any actions pursuant to
Section 13.3 below if and to the extent that: (a) the claim is directly attributable to [CONFIDENTIAL TREATMENT REQUESTED] or (b) the infringement is directly attributable to [CONFIDENTIAL TREATMENT REQUESTED]. 
 13.3. Duty to Correct. If a third party claims that the Development Deliverables or Goods infringe an intellectual property right, Supplier will, in
addition to its obligations under Section 13.1 above, promptly notify Apple in writing and [CONFIDENTIAL TREATMENT REQUESTED] remedies that is practicable: (i) obtain for Apple from such third party rights with respect to the Development
Deliverables and Goods consistent with the rights granted to Apple by Supplier under this Agreement; (ii) modify the Development Deliverables and Goods so they are non-infringing and in compliance with this Agreement; (iii) replace the
Development Deliverables and Goods with non-infringing versions that comply with the requirements of this Agreement; or (iv) [CONFIDENTIAL TREATMENT REQUESTED] of infringing Development Deliverables and Goods [CONFIDENTIAL TREATMENT REQUESTED].

  

	14.	Limitation of Liability 

 EXCEPT FOR SUPPLIER’S OBLIGATIONS
UNDER SECTION [CONFIDENTIAL TREATMENT REQUESTED], SECTION [CONFIDENTIAL TREATMENT REQUESTED], AND SECTION [CONFIDENTIAL TREATMENT REQUESTED], AND FOR BREACHES OF SECTION [CONFIDENTIAL TREATMENT REQUESTED], IN NO EVENT
WILL [CONFIDENTIAL TREATMENT REQUESTED] BE ENTITLED TO INCIDENTAL, INDIRECT, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS, LOST REVENUES OR BUSINESS INTERRUPTION BASED ON ANY BREACH OR DEFAULT OF THE OTHER
PARTY. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 16

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  

	15.	Term and Termination 

 15.1. Term. This Agreement will
commence on the Effective Date and continue until terminated. 
 15.2. Termination 
 (a) Termination of this Agreement. Any party may terminate this Agreement for Cause. Such termination will be effective upon [CONFIDENTIAL
TREATMENT REQUESTED] advance Notice if the Cause remains uncured, or, in the event of an incurable Cause such as breach of confidentiality obligations, immediately upon written Notice. Upon any termination, unless otherwise provided in Apple’s
written direction, Supplier will immediately: (i) cease work in connection with this Agreement; (ii) prepare and submit to Apple an itemization of all completed and partially completed Development Deliverables and Goods in connection with
this Agreement; (iii) deliver upon request any work in process in connection with this Agreement; and (iv) deliver upon request any Apple Equipment. Subject to the terms of Section 2.4(e) above, in the event Apple terminates this
Agreement for Cause, neither Apple nor any other Authorized Purchaser [CONFIDENTIAL TREATMENT REQUESTED]. 
 (b) Termination of an
SOW. Any party to an SOW may terminate the SOW for Cause. Such termination will be effective upon [CONFIDENTIAL TREATMENT REQUESTED] advance Notice. Such termination will be effective upon [CONFIDENTIAL TREATMENT REQUESTED] Notice if the Cause
remains uncured, or, in the event of an incurable Cause, immediately upon Notice. [CONFIDENTIAL TREATMENT REQUESTED] any SOW without Cause upon [CONFIDENTIAL TREATMENT REQUESTED] advance Notice. Upon any termination, unless otherwise provided in
Apple’s written direction, Supplier will immediately: (i) cease work in connection with the applicable SOW; (ii) prepare and submit to Apple an itemization of all completed and partially completed Development Deliverables and Goods in
connection with the applicable SOW; (iii) deliver upon request any work in process in connection with the applicable SOW; and (iv) deliver upon request any Apple Equipment associated with the applicable SOW. In the event Apple terminates
any SOW with Cause, neither Apple nor any other Authorized Purchaser will [CONFIDENTIAL TREATMENT REQUESTED]. 
 15.3. Survival. Provisions in
this Agreement, which by their nature, should remain in effect beyond termination of the Master Development and Supply Agreement will survive until fulfilled, including Sections 5, 6.2 (c) through (g), 7.3, 8, 9, 10, 11, 12, 13, 14, 15, and 16.

  

	16.	Miscellaneous 

 16.1. Press Releases and Publicity.
Neither Apple nor Supplier will issue press releases or other publicity regarding this Agreement or its subject matter without the prior written approval of the other. 
 16.2. Compliance with Laws. 
 (a) Supplier agrees that it will fully comply with all
applicable laws and regulations in performing its obligations under this Agreement, including all applicable employment, tax, export control and environmental laws and regulations. Without limiting this requirement Supplier agrees that it will not
export, re-export, sell, resell or transfer any customer data or any export-controlled commodity, technical data or software (i) in violation of any law, regulation, order, policy or other limitation imposed 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 17

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
by the United States (including the United States Export Administration regulations) or any other government authority with jurisdiction; or (ii) to any
country for which an export license or other governmental approval is required at the time of export, without first obtaining all necessary licenses or equivalent. 
 (b) To the extent that Goods will be transported into the United States, Supplier represents that either (a) it is C-TPAT-certified by U.S. Customs & Border Protection, and will maintain that
certification throughout the term of this Agreement, or (b) it will comply with the C-TPAT (Customs-Trade Partnership Against Terrorism) security procedures that may be found on the Customs website at www.cbp.gov <http://www.cbp.gov> (or
such other website that the C-TPAT security procedures may be moved to by the U.S. Government). Supplier must fairly compensate its employees by providing wages and benefits that are in compliance with applicable law, or with prevailing local
standards if such standards are higher than applicable law, and must ensure that any subcontractors supplying goods and services or materials for goods and services do the same. 
 16.3. No Forced or Child Labor. Supplier must ensure that neither the goods and services nor any materials procured by Supplier are produced or manufactured, in whole or in part, by convict or forced
labor or by any child under the age of sixteen or the minimum age permitted by applicable law, whichever age is higher. 
 16.4. Small Business
Contracting and Socio-Economic Requirements. 
 (a) Utilization of Small Business Concerns. As a federal contractor, Apple
is subject to federal laws and regulations governing subcontracting with small businesses. As required by federal regulation and its federal contract(s), Apple incorporates by reference FAR 52.219-8, “Utilization of Small Business
Concerns” in this contract to the extent that this contract offers further subcontracting opportunities. Unless Supplier is a small business or further subcontracting is not practicable, Supplier must utilize small business concerns (as that
term is defined in FAR 52.219-8) to the maximum extent practicable. 
 (b) Socio-Economic Requirements. As a federal
contractor, Apple also is subject to federal laws, executive orders, and regulations governing certain socio-economic requirements such as Equal Opportunity and Affirmative Action. As required by federal regulation and its federal contract(s), Apple
incorporates by reference in this contract the following clauses: FAR 52.222-26, Equal Opportunity, FAR 52.222-35, Affirmative Action for Special Disabled and Vietnam Era Veterans, and FAR 52.222-36, Affirmative Action for Workers with Disabilities.

 16.5. Insurance and Loss Prevention. 
 (a) Supplier will [CONFIDENTIAL TREATMENT REQUESTED] maintain the following minimum insurance in full force and effect throughout the term of this Agreement: (i) commercial or comprehensive general liability, public liability or
local equivalent, including products/completed operations, and fire legal liability, with coverage of not less than the equivalent of [CONFIDENTIAL TREATMENT REQUESTED] combined single limit per occurrence and [CONFIDENTIAL TREATMENT REQUESTED]
annual aggregate. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT
HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

					
		 	Apple Confidential	 	Page 18

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 (b) Supplier will deliver to Apple’s Procurement Department (1
Infinite Loop, M/S 35-PO, Cupertino, California 95014) one or more certificates of insurance, or comparable documents, showing evidence of the coverage required above. Supplier shall endeavor to comply with the insurance and loss prevention
requirements set forth in the document(s), if any, referenced in the Apple Requirements Document. Apple reserves the right to perform risk evaluations of Supplier’s facilities and Supplier agrees to work with Apple to upgrade any facility that
does not comply with such requirements. 
 16.6. Independent Efforts and Similar Goods. Provided there is no infringement of the other
party’s intellectual property rights or breach of the provisions in Section 11 above, nothing in this Agreement will impair either party’s right to develop, manufacture, purchase, use or market, directly or indirectly, alone or with
others, products or services competitive with those offered by the other. 
 16.7. Relationship of Parties. Apple and Supplier are independent
contractors. Nothing in this Agreement creates a joint venture, partnership, franchise, employment or agency relationship or fiduciary duty of any kind. Neither party will have the power, and will not hold itself out as having the power, to act for
or in the name of or to bind the other party. Except as expressly provided, this Agreement is not for the benefit of any third parties. 
 16.8.
Assignment. No party hereto or to any SOW may assign or delegate its rights or obligations under this Agreement without the other’s prior written consent; provided, however, that either party may assign all of its rights and obligations
under this Agreement in connection with a merger or the sale of all or substantially all of its assets relating to its subject matter without the consent of the other party. This Agreement shall be binding upon, and inure to the benefit of, the
successors, representatives, and administrators of the parties. 
 16.9. Force Majeure. No party hereto or to any SOW will be liable for delay
or failure to fulfill its obligations under this Agreement due to acts of God beyond its reasonable control, provided it promptly notifies the other party and uses reasonable efforts to correct such failure or delay in its performance. 

16.10. No Waiver. No delay or failure to act in the event of a breach of this Agreement will be deemed a waiver of that or any subsequent breach of any
provision of this Agreement. Any remedies at law or equity not specifically disclaimed or modified by this Agreement remain available to both parties. 
 16.11. Governing Law. This Agreement and the rights and obligations of the parties will be governed by and construed and enforced in accordance with the laws of the State of California as applied to agreements entered into and
to be performed entirely within California between California residents, without regard to conflicts of law principles. The parties expressly agree that the provisions of the United Nations Convention on Contracts for the International Sale of Goods
will not apply to this Agreement or to their relationship. 
 16.12. Dispute Resolution, Jurisdiction and Venue. If there is a dispute between
the parties, the parties agree that they will first attempt to resolve the dispute through one senior management member of each party named as a representative of the party to resolve the dispute. If they are unable to do so within 60 days after the
complaining party’s written notice to the other party, the parties will then seek to resolve the dispute through non-binding mediation conducted in Santa Clara County or San Francisco County, California. Each party must bear its own expenses in
connection with the mediation and must share 
  
 [CONFIDENTIAL TREATMENT
REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 19

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
equally the fees and expenses of the mediator. If the parties are unable to resolve the dispute within 60 days after commencing mediation, either party may
commence litigation in the state or federal courts in Santa Clara County, California. The parties irrevocably submit to the exclusive jurisdiction of those courts and agree that final judgment in any action or proceeding brought in such courts will
be conclusive and may be enforced in any other jurisdiction by suit on the judgment (a certified copy of which will be conclusive evidence of the judgment) or in any other manner provided by law. Process served personally or by registered or
certified mail, return receipt requested, will constitute adequate service of process in any such action, suit or proceeding. Each party irrevocably waives to the fullest extent permitted by applicable law (i) any objection it may have to the
laying of venue in any court referred to above; (ii) any claim that any such action or proceeding has been brought in an inconvenient forum; and (iii) any immunity that it or its assets may have from any suit, execution, attachment
(whether provisional or final, in aid of execution, before judgment or otherwise) or other legal process. The terms of this Section apply whether or not the dispute arises out of or relates to this Agreement, unless the dispute is governed by a
separate written agreement. 
 16.13. Equitable Relief. Notwithstanding anything to the contrary in Section 16.12 above, either party may
seek equitable relief in order to protect its Confidential Information or Intellectual Property Rights at any time, [CONFIDENTIAL TREATMENT REQUESTED]. The parties hereby [CONFIDENTIAL TREATMENT REQUESTED]. The confidentiality provisions of this
Agreement will be enforceable under the provisions of the California Uniform Trade Secrets Act, California Civil Code Section 3426, as amended. 
 16.14. Construction. The section headings in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement. References to sections, schedules, exhibits, and SOWs are
references to sections of, and exhibits, schedules and SOWs to, this Agreement, and the word “herein” and words of similar meaning refer to this Agreement in its entirety and not to any particular section or provision. The word
“party” means a party to this Agreement and the phrase “third party” means any person, partnership, corporation or other entity not a party to this Agreement. The words “will” and “shall” are used in a
mandatory, not a permissive, sense, and the word “including” is intended to be exemplary, not exhaustive, and will be deemed followed by “without limitation. Any requirement to obtain a party’s consent is a requirement to obtain
such consent in each instance. 
 16.15. Severability. If a court of competent jurisdiction finds any provision of this Agreement unlawful or
unenforceable, that provision will be enforced to the maximum extent permissible so as to effect the intent of the parties, and the remainder of this Agreement will continue in full force and effect. 
 16.16. Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but which collectively will
constitute one and the same instrument. 
  
 [CONFIDENTIAL TREATMENT REQUESTED]
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 20

 16.17. Related Documents; Precedence. The terms and conditions of any SOW, Purchase Order, and the terms
and conditions of any schedules, exhibits, attachments and other documents referenced herein or therein are incorporated into the terms and conditions of this Agreement. In the event of any conflict in the documents which constitute this Agreement,
the order of precedence will be (i) the quantity, price, payment and delivery terms of the applicable Purchase Order; (ii) the applicable SOW; (iii) this Master Development and Supply Agreement; and (iv) any other schedules,
exhibits, attachments and other documents referenced and incorporated herein and therein. Notwithstanding the foregoing, Supplier agrees that the price, payment and delivery terms on any Purchase Order will be at least as favorable to Authorized
Purchasers as such terms are set forth in this Agreement, and that in any case the price, payment and delivery terms on any Purchase Order are less favorable to Authorized Purchasers than those in this Agreement, then the terms of such Purchase
Order will be deemed to be consistent with this Agreement regarding such terms. If there is a conflict between Section 11 above and any other agreement governing the use of Confidential Information disclosed by any party in connection with this
Agreement, the terms and conditions of Section 11 will govern to the extent that such terms and conditions are more restrictive with respect to the use and disclosure of such Confidential Information. 
 16.18. Complete Agreement. The parties agree that this Agreement constitutes the complete and exclusive agreement between them superseding all
contemporaneous and prior agreements (written and oral) and all other communications between them relating to its subject matter, excluding any confidentiality agreements. Except as expressly provided herein, this Agreement may not be amended or
modified except by a written amendment signed by authorized signatories of both parties. The parties expressly acknowledge that they have received and are in possession of a copy of any referenced item not physically attached to this Agreement and
any such item will be treated as if attached. 
  
 [CONFIDENTIAL TREATMENT
REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 21

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 By signing below, each party agrees to be bound by the terms and conditions
of this Agreement. 
  

			
	Apple Computer, Inc.	  	Multi-Fineline Electronix, Inc.
		
	 By /s/ Tony Blevins
	  	By /s/ Reza Meshgin
		
	 Name Tony Blevins
	  	Name Reza Meshgin
		
	 Title Sr. Director, Operations
	  	Title President/COO
		
	 Date 8/26/06
	  	Date 8/16/06
		
	Apple Computer International	  	
		
	 By /s/ Jae Allen
	  	
		
	 Name Jae Allen
	  	
		
	 Title Director
	  	
		
	 Date 1 September 2006
	  	

  
 [CONFIDENTIAL TREATMENT REQUESTED]
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

					
		 	Apple Confidential	 	Page 22

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 SCHEDULE 1 
 Definitions 
 “Agreement” means this Master Development and
Supply Agreement and all SOWs, Purchase Orders, schedules, exhibits, attachments, and other documents incorporated in or permitted by this Master Development and Supply Agreement. 
 “Apple” is defined in the preamble of the Agreement. 
 “Apple Affiliate”
means any entity authorized by Apple to procure Development Deliverables or Goods under the Agreement, including those entities listed as Apple Affiliates in the document(s), if any, referenced in the Apple Requirements Document. 
 “Apple Equipment” is defined in Section 6.2(b) of the Agreement. 
 “Apple Modification” means a modification of Specifications requested by Apple and approved by Supplier in accordance with Section 4.2 of the Agreement. 
 “Apple Product” means a finished good manufactured by or for Apple that incorporates the Goods. 
 “Apple Requirements Document” means the document attached to the Agreement as Schedule 2, as amended from time-to-time. 
 “Apple Software” means the Apple software provided to Supplier in connection with the performance of Supplier’s obligations under the
Agreement, including the Apple software identified in the document(s), if any, in the Apple Requirement Document. 
 [CONFIDENTIAL TREATMENT REQUESTED].

 “Apple Trademarks” means any Apple trademarks, service marks, trade names, logos or other Apple commercial or product
designations. 
 “Apple Unique Materials” means those materials, if any, identified in an SOW as “Apple Unique Materials”.

 “Authorized Purchaser” means Apple or Apple Affiliate, as applicable. 
 “Authorized Vendor” means a supplier of materials that has been approved by Apple for the purpose of providing such materials as set forth in the
applicable BOM or SOW or as set forth in the document(s), if any, referenced in the Apple Requirements Document. 
 “BOM” means the
engineering bill of materials for the Development Deliverables or Goods created and approved by Apple via the Project Management System. 
 “Business Day” means any day Monday through Saturday. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 “Cause” means a material breach of the Agreement by another party, or
the event of a party becoming insolvent, making an assignment for the benefit of creditors, or filing or being the subject of a petition in bankruptcy. 
 “Company” is defined in the preamble of the Agreement. 
 “Confidential Information” is defined in
Section 11.1 of the Agreement. 
 “Custom Equipment” is defined in Section 6.2(g) of the Agreement. 
 [CONFIDENTIAL TREATMENT REQUESTED]. 
 [CONFIDENTIAL TREATMENT REQUESTED].

 “Defective Goods” means Goods that (i) failed [CONFIDENTIAL TREATMENT REQUESTED] to conform with or operate according to
applicable Specifications [CONFIDENTIAL TREATMENT REQUESTED]; or (ii) are the subject of an Environmental Compliance Failure or a Safety Risk. 
 “Development Deliverables” means the tangible results of services performed by Supplier to be delivered to Authorized Purchasers in connection with the development of Goods for use in Apple products, including the
items to be delivered that are identified in an SOW, and any other such items not identified in an SOW that are offered by Supplier to Authorized Purchasers to the extent that such items are not covered under the terms and conditions of a separate
written agreement signed by the parties to the Agreement, not including Goods. 
 “Discloser” is defined in Section 11.1 of the
Agreement. 
 “Documentation” means documents, in English and in hard copy and electronic format, containing instructions,
specifications, schematics, drawings, reports, or other descriptions in connection with the Development Deliverables and/or Goods. 
 “Effective
Date” is defined in the preamble of the Agreement. 
 “End User” means a purchaser who acquires an Apple product (into
which a unit of Goods has been incorporated) for personal use rather than for distribution or resale. 
 “Environmental Compliance
Failure” means the failure by Supplier to comply with the environmental requirements set forth in Section 5.3 of the Agreement. 
 “EOL Date” means the date that new Goods (not including Service Units) are last required. 
 “Equipment” means fixtures, tooling, test equipment and any other equipment used in connection with the development, manufacturing, testing, packaging, delivery or servicing of the Development Deliverables or Goods,
including Apple Equipment and Custom Equipment. 
 “Error Corrections” is defined in Section 10.1(b)(iii) of the Agreement.

  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED
AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 “Excessive Failure Threshold” means the excessive failure threshold
in the SOW, or if no excessive failure threshold is specified in the SOW, [CONFIDENTIAL TREATMENT REQUESTED] for a Single Cause Excessive Failure and [CONFIDENTIAL TREATMENT REQUESTED] for a Multiple-Cause Excessive Failure. 
 “Excessive Failure” means the Failure Rate exceeds the Excessive Failure Threshold. 
 “Ex Works” has the meaning defined by the International Chamber of Commerce in its publication, Incoterms 2000; ICC Official Rules for the
Interpretation of Trade Terms. 
 “Failure Rate” means the rate calculated using the following formula: 
 Failure rate    =    [CONFIDENTIAL TREATMENT REQUESTED] where: 
 A    =    the [CONFIDENTIAL TREATMENT REQUESTED] in a [CONFIDENTIAL TREATMENT REQUESTED] that failed
[CONFIDENTIAL TREATMENT REQUESTED] to conform with or operate according to applicable Specifications [CONFIDENTIAL TREATMENT REQUESTED] within [CONFIDENTIAL TREATMENT REQUESTED] after they were manufactured; and 
 B    =    the [CONFIDENTIAL TREATMENT REQUESTED] in that [CONFIDENTIAL TREATMENT REQUESTED]. 
 “Flexibility Schedule” means a schedule that sets forth the maximum percentage increase in units forecasted or ordered, based on when notice of
such increase is given. 
 “Forecast” means a written estimate of the Goods required per week for production of Apple Products.

 “Goods” means components and related Service Units identified in an SOW, and any components and related Service Units not
identified in an SOW but offered by Supplier to Authorized Purchasers to the extent that such goods and related Service Units are not covered under the terms and conditions of a separate written agreement signed by the parties to the Master
Development and Supply Agreement. 
 “Hub” means an Apple-approved warehouse located at or near Apple-specified manufacturing or
distribution facilities, or other Apple-specified location. 
 “Information Systems” means computer hardware and software systems,
including the Project Management System. 
 “Initial Service Unit Inventory” means the number of Service Units calculated using the
following formula: 
 Initial Service Unit Inventory    =    [CONFIDENTIAL TREATMENT REQUESTED],
where: 
 A    =    the [CONFIDENTIAL TREATMENT REQUESTED] (as determined [CONFIDENTIAL TREATMENT
REQUESTED]) of the Goods. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES
MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  

					
		 	Apple Confidential	 	

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 B    =    the [CONFIDENTIAL TREATMENT
REQUESTED] in the then current Forecast for the first [CONFIDENTIAL TREATMENT REQUESTED] of production. 
 “Intellectual Property
Rights” means all current and future rights in copyrights, trade secrets, trademarks, mask works, patents, and other intellectual property rights, including, in each case whether unregistered, registered or comprising an application for
registration, and all rights and forms of protection of a similar nature or having equivalent or similar effect to any of the foregoing that may exist anywhere in the world. 
 “Lead-Time” means the minimum amount of time in advance of the date Goods are required in accordance with Forecasts or Purchase Orders that Supplier must begin production of the Goods.

 “Long Lead-Time Materials” means those materials, if any, identified in an SOW as “Long Lead-Time Materials”.

 [CONFIDENTIAL TREATMENT REQUESTED]. 
 “Multiple
Causes” means any defect or defects (e.g. multiple, unrelated Single Causes). 
 “Multiple-Cause Excessive Failure”
means an Excessive Failure due to Multiple Causes. 
 “Notice” means a written notification addressed to the authorized
representative(s) of the a party, which notification will be deemed given: (i) when delivered personally; (ii) when sent by confirmed facsimile; (iii) one day after having been sent by commercial overnight carrier specifying next-day
delivery with written verification of receipt; or (iv) three days after having been sent by first class or certified mail postage prepaid. A copy of any notice sent to Apple must also be sent simultaneously to Apple’s General Counsel at
Apple Computer, Inc., 1 Infinite Loop, Cupertino, CA 95014, United States, or by fax to (408) 974-8530. 
 “Personnel” means
officers, directors, agents, consultants, contractors, and employees. 
 “Production Period” means the period during which Goods are
produced by Supplier to meet the requirements of the Forecasts provided by Apple in accordance with Section of 2.2(a) the Agreement. 
 “Project
Management System” means an Information System identified by Apple and accessible to Supplier that is used to, among other things, (i) obtain approval for changes to Specifications; and (ii) maintain electronic versions of
Specifications and to provide notification of and to track modifications to such Specifications, used in accordance with the procedures set forth in the document(s), if any, referenced in the Apple Requirements Document, or in the absence of such
procedures, as mutually agreed by Apple and Supplier. 
 “Project Schedule” means the most current version of schedule(s) provided by
Apple that set(s) forth when the Development Deliverables must be delivered, and when production of the Goods is to begin. 
 “Purchase
Order” or “PO” means a written or electronically transmitted purchase order from an Authorized Purchaser to Supplier for Development Deliverables, Goods or related services that includes a description of the
Development Deliverables, Goods or related services ordered, and a requested delivery 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406
PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 
or performance date and location, as applicable; provided, however, that the delivery or performance date and location may be provided separately in a
subsequent ship order. 
 “Recipient” is defined in Section 11.1 of the Agreement. 
 “Repair Facilities” means the facilities provided by Supplier at which Supplier is able to perform its obligations under Section 3 of the
Agreement. 
 “Safety Risk” means a risk of bodily injury or property damage. 
 “Service Units” means replacements, spare parts and service modules for Goods. 
 “Single Cause” means the same or substantially the same defect (e.g. related to the same component, material, design, manufacturing process, or test procedure). 
 “Single-Cause Excessive Failure” means an Excessive Failure due to a Single Cause. 
 “SOW” means a written statement of work or plan of record, signed by Apple and Supplier, that references this Master Development and Supply Agreement and that describes the terms and conditions
specific to Development Deliverable, Goods and/or related services. 
 “Specifications” means the most current version of all
applicable specifications and requirements provided by Apple, including the Project Schedule, the specifications and requirements set forth in the documents referenced in the Agreement, including any documents referenced in any BOM, SOW, and any
relevant specifications, drawings, samples or other descriptions provided by Supplier and approved by Apple in writing. 
 “Supplier”
means Company and Supplier Affiliates. 
 “Supplier Affiliate” means any entity authorized by Apple to provide Development
Deliverables and/or Goods under the Agreement. 
 “Supplier Modification” means a modification of Specifications requested by
Supplier and approved by Apple in accordance with Section 4.1 of the Agreement. 
 [CONFIDENTIAL TREATMENT REQUESTED]. 
  
 [CONFIDENTIAL TREATMENT REQUESTED] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

					
		 	Apple Confidential	 	

 Apple-M-FLEX 
 Master Development and Supply Agreement 
 #C56-06-00844 
  
 SCHEDULE 2 
 Apple Requirements Document 
  

			
	P/N	  	Title
		
	069-0135	  	Specification, Regulated Substances
	069-1111	  	Apple RoHS Compliance Specification
	080-2153	  	RoHS Declaration of Conformity Procedure
	080-2503	  	Apple Supplier Code of Conduct

  
 [CONFIDENTIAL TREATMENT REQUESTED]
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

					
		 	Apple Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]